<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE html><html xmlns="http://www.w3.org/1999/xhtml" xmlns:art="http://www.rsc.org/schema/rscart38" xmlns:epub="http://www.idpf.org/2007/ops" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:rsc="urn:rsc.org" xml:lang="en" lang="en"><head><!--Google Tag Manager--><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&amp;l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-56FZ7G');</script><!--End Google Tag Manager--><title>The role of porphyrin chemistry in tumor imaging and photodynamic therapy  - Chemical Society Reviews (RSC Publishing) DOI:10.1039/B915149B</title><link rel="canonical" href="https://pubs.rsc.org/en/content/articlehtml/2011/cs/b915149b"/><meta http-equiv="content-type" content="application/xhtml+xml; charset=utf-8"/><script type="text/javascript">window.NREUM||(NREUM={});NREUM.info = {"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"NRJS-aaa897feae8feeca979","applicationID":"1313546638","transactionName":"M1wANxQFCEcDVU0PWgoWLzUlSyVbDEJcCEEnVgwXFAsKWAdEFgdHEFABDwMMElkO","queueTime":0,"applicationTime":58,"agent":"","atts":""}</script><script type="text/javascript">(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"1386013924",accountID:"2851366",trustKey:"1029994",xpid:"Vg4CUFVVDhABV1BRAgUBUFcJ",licenseKey:"NRJS-aaa897feae8feeca979",applicationID:"1313546638"};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({1:[function(t,e,n){function r(t){try{s.console&&console.log(t)}catch(e){}}var o,i=t("ee"),a=t(31),s={};try{o=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(s.console=!0,o.indexOf("dev")!==-1&&(s.dev=!0),o.indexOf("nr_dev")!==-1&&(s.nrDev=!0))}catch(c){}s.nrDev&&i.on("internal-error",function(t){r(t.stack)}),s.dev&&i.on("fn-err",function(t,e,n){r(n.stack)}),s.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(s,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,s){try{l?l-=1:o(s||new UncaughtException(t,e,n),!0)}catch(f){try{i("ierr",[f,c.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function o(t,e){var n=e?null:c.now();i("err",[t,n])}var i=t("handle"),a=t(32),s=t("ee"),c=t("loader"),f=t("gos"),u=window.onerror,d=!1,p="nr@seenError";if(!c.disabled){var l=0;c.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(14),t(13),"addEventListener"in window&&t(7),c.xhrWrappable&&t(15),d=!0)}s.on("fn-start",function(t,e,n){d&&(l+=1)}),s.on("fn-err",function(t,e,n){d&&!n[p]&&(f(n,p,function(){return!0}),this.thrown=!0,o(n))}),s.on("fn-end",function(){d&&!this.thrown&&l>0&&(l-=1)}),s.on("internal-error",function(t){i("ierr",[t,c.now(),!0])})}},{}],3:[function(t,e,n){var r=t("loader");r.disabled||(r.features.ins=!0)},{}],4:[function(t,e,n){function r(){U++,L=g.hash,this[u]=y.now()}function o(){U--,g.hash!==L&&i(0,!0);var t=y.now();this[h]=~~this[h]+t-this[u],this[d]=t}function i(t,e){E.emit("newURL",[""+g,e])}function a(t,e){t.on(e,function(){this[e]=y.now()})}var s="-start",c="-end",f="-body",u="fn"+s,d="fn"+c,p="cb"+s,l="cb"+c,h="jsTime",m="fetch",v="addEventListener",w=window,g=w.location,y=t("loader");if(w[v]&&y.xhrWrappable&&!y.disabled){var x=t(11),b=t(12),E=t(9),R=t(7),O=t(14),T=t(8),S=t(15),P=t(10),M=t("ee"),C=M.get("tracer"),N=t(23);t(17),y.features.spa=!0;var L,U=0;M.on(u,r),b.on(p,r),P.on(p,r),M.on(d,o),b.on(l,o),P.on(l,o),M.buffer([u,d,"xhr-resolved"]),R.buffer([u]),O.buffer(["setTimeout"+c,"clearTimeout"+s,u]),S.buffer([u,"new-xhr","send-xhr"+s]),T.buffer([m+s,m+"-done",m+f+s,m+f+c]),E.buffer(["newURL"]),x.buffer([u]),b.buffer(["propagate",p,l,"executor-err","resolve"+s]),C.buffer([u,"no-"+u]),P.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"]),a(T,m+s),a(T,m+"-done"),a(P,"new-jsonp"),a(P,"jsonp-end"),a(P,"cb-start"),E.on("pushState-end",i),E.on("replaceState-end",i),w[v]("hashchange",i,N(!0)),w[v]("load",i,N(!0)),w[v]("popstate",function(){i(0,U>1)},N(!0))}},{}],5:[function(t,e,n){function r(){var t=new PerformanceObserver(function(t,e){var n=t.getEntries();s(v,[n])});try{t.observe({entryTypes:["resource"]})}catch(e){}}function o(t){if(s(v,[window.performance.getEntriesByType(w)]),window.performance["c"+p])try{window.performance[h](m,o,!1)}catch(t){}else try{window.performance[h]("webkit"+m,o,!1)}catch(t){}}function i(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var a=t("ee"),s=t("handle"),c=t(14),f=t(13),u=t(6),d=t(23),p="learResourceTimings",l="addEventListener",h="removeEventListener",m="resourcetimingbufferfull",v="bstResource",w="resource",g="-start",y="-end",x="fn"+g,b="fn"+y,E="bstTimer",R="pushState",O=t("loader");if(!O.disabled){O.features.stn=!0,t(9),"addEventListener"in window&&t(7);var T=NREUM.o.EV;a.on(x,function(t,e){var n=t[0];n instanceof T&&(this.bstStart=O.now())}),a.on(b,function(t,e){var n=t[0];n instanceof T&&s("bst",[n,e,this.bstStart,O.now()])}),c.on(x,function(t,e,n){this.bstStart=O.now(),this.bstType=n}),c.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),this.bstType])}),f.on(x,function(){this.bstStart=O.now()}),f.on(b,function(t,e){s(E,[e,this.bstStart,O.now(),"requestAnimationFrame"])}),a.on(R+g,function(t){this.time=O.now(),this.startPath=location.pathname+location.hash}),a.on(R+y,function(t){s("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),u()?(s(v,[window.performance.getEntriesByType("resource")]),r()):l in window.performance&&(window.performance["c"+p]?window.performance[l](m,o,d(!1)):window.performance[l]("webkit"+m,o,d(!1))),document[l]("scroll",i,d(!1)),document[l]("keypress",i,d(!1)),document[l]("click",i,d(!1))}}},{}],6:[function(t,e,n){e.exports=function(){return"PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver}},{}],7:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&o(e)}function o(t){s.inPlace(t,[u,d],"-",i)}function i(t,e){return t[1]}var a=t("ee").get("events"),s=t("wrap-function")(a,!0),c=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var r=c(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?s(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],8:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=i(arguments),e={};o.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var s=r.apply(this,t);return o.emit(n+"start",[t,a],s),s.then(function(t){return o.emit(n+"end",[null,t],s),t},function(t){throw o.emit(n+"end",[t],s),t})})}var o=t("ee").get("fetch"),i=t(32),a=t(31);e.exports=o;var s=window,c="fetch-",f=c+"body-",u=["arrayBuffer","blob","json","text","formData"],d=s.Request,p=s.Response,l=s.fetch,h="prototype",m="nr@context";d&&p&&l&&(a(u,function(t,e){r(d[h],e,f),r(p[h],e,f)}),r(s,"fetch",c),o.on(c+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(c+"done",[null,e],n)}else o.emit(c+"done",[t],n)}))},{}],9:[function(t,e,n){var r=t("ee").get("history"),o=t("wrap-function")(r);e.exports=r;var i=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;i&&i.pushState&&i.replaceState&&(a=i),o.inPlace(a,["pushState","replaceState"],"-")},{}],10:[function(t,e,n){function r(t){function e(){f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}function n(){f.emit("jsonp-error",[],l),f.emit("jsonp-end",[],l),t.removeEventListener("load",e,c(!1)),t.removeEventListener("error",n,c(!1))}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var d=s(a),p="function"==typeof d.parent[d.key];if(p){var l={};u.inPlace(d.parent,[d.key],"cb-",l),t.addEventListener("load",e,c(!1)),t.addEventListener("error",n,c(!1)),f.emit("new-jsonp",[t.src],l)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(d);return e?e[1]:null}function a(t,e){var n=t.match(l),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function s(t){var e=t.match(p);return e&&e.length>=3?{key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var c=t(23),f=t("ee").get("jsonp"),u=t("wrap-function")(f);if(e.exports=f,o()){var d=/[?&](?:callback|cb)=([^&#]+)/,p=/(.*)\.([^.]+)/,l=/^(\w+)(\.|$)(.*)$/,h=["appendChild","insertBefore","replaceChild"];Node&&Node.prototype&&Node.prototype.appendChild?u.inPlace(Node.prototype,h,"dom-"):(u.inPlace(HTMLElement.prototype,h,"dom-"),u.inPlace(HTMLHeadElement.prototype,h,"dom-"),u.inPlace(HTMLBodyElement.prototype,h,"dom-")),f.on("dom-start",function(t){r(t[0])})}},{}],11:[function(t,e,n){var r=t("ee").get("mutation"),o=t("wrap-function")(r),i=NREUM.o.MO;e.exports=r,i&&(window.MutationObserver=function(t){return this instanceof i?new i(o(t,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype)},{}],12:[function(t,e,n){function r(t){var e=i.context(),n=s(t,"executor-",e,null,!1),r=new f(n);return i.context(r).getCtx=function(){return e},r}var o=t("wrap-function"),i=t("ee").get("promise"),a=t("ee").getOrSetContext,s=o(i),c=t(31),f=NREUM.o.PR;e.exports=i,f&&(window.Promise=r,["all","race"].forEach(function(t){var e=f[t];f[t]=function(n){function r(t){return function(){i.emit("propagate",[null,!o],a,!1,!1),o=o||!t}}var o=!1;c(n,function(e,n){Promise.resolve(n).then(r("all"===t),r(!1))});var a=e.apply(f,arguments),s=f.resolve(a);return s}}),["resolve","reject"].forEach(function(t){var e=f[t];f[t]=function(t){var n=e.apply(f,arguments);return t!==n&&i.emit("propagate",[t,!0],n,!1,!1),n}}),f.prototype["catch"]=function(t){return this.then(null,t)},f.prototype=Object.create(f.prototype,{constructor:{value:r}}),c(Object.getOwnPropertyNames(f),function(t,e){try{r[e]=f[e]}catch(n){}}),o.wrapInPlace(f.prototype,"then",function(t){return function(){var e=this,n=o.argsToArray.apply(this,arguments),r=a(e);r.promise=e,n[0]=s(n[0],"cb-",r,null,!1),n[1]=s(n[1],"cb-",r,null,!1);var c=t.apply(this,n);return r.nextPromise=c,i.emit("propagate",[e,!0],c,!1,!1),c}}),i.on("executor-start",function(t){t[0]=s(t[0],"resolve-",this,null,!1),t[1]=s(t[1],"resolve-",this,null,!1)}),i.on("executor-err",function(t,e,n){t[1](n)}),i.on("cb-end",function(t,e,n){i.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),i.on("propagate",function(t,e,n){this.getCtx&&!e||(this.getCtx=function(){if(t instanceof Promise)var e=i.context(t);return e&&e.getCtx?e.getCtx():this})}),r.toString=function(){return""+f})},{}],13:[function(t,e,n){var r=t("ee").get("raf"),o=t("wrap-function")(r),i="equestAnimationFrame";e.exports=r,o.inPlace(window,["r"+i,"mozR"+i,"webkitR"+i,"msR"+i],"raf-"),r.on("raf-start",function(t){t[0]=o(t[0],"fn-")})},{}],14:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function o(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var i=t("ee").get("timer"),a=t("wrap-function")(i),s="setTimeout",c="setInterval",f="clearTimeout",u="-start",d="-";e.exports=i,a.inPlace(window,[s,"setImmediate"],s+d),a.inPlace(window,[c],c+d),a.inPlace(window,[f,"clearImmediate"],f+d),i.on(c+u,r),i.on(s+u,o)},{}],15:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",s)}function o(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,y,"fn-",s)}function i(t){x.push(t),m&&(E?E.then(a):w?w(a):(R=-R,O.data=R))}function a(){for(var t=0;t<x.length;t++)r([],x[t]);x.length&&(x=[])}function s(t,e){return e}function c(t,e){for(var n in t)e[n]=t[n];return e}t(7);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),p=t(23),l=NREUM.o,h=l.XHR,m=l.MO,v=l.PR,w=l.SI,g="readystatechange",y=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],x=[];e.exports=u;var b=window.XMLHttpRequest=function(t){var e=new h(t);try{u.emit("new-xhr",[e],e),e.addEventListener(g,o,p(!1))}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(c(h,b),b.prototype=h.prototype,d.inPlace(b.prototype,["open","send"],"-xhr-",s),u.on("send-xhr-start",function(t,e){r(t,e),i(e)}),u.on("open-xhr-start",r),m){var E=v&&v.resolve();if(!w&&!v){var R=1,O=document.createTextNode(R);new m(a).observe(O,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===g||a()})},{}],16:[function(t,e,n){function r(t){if(!s(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=l.generateSpanId(),m=l.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||c(t)&&p())&&(w.traceContextParentHeader=o(h,m),w.traceContextStateHeader=i(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&c(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function o(t,e){return"00-"+e+"-"+t+"-01"}function i(t,e,n,r,o){var i=0,a="",s=1,c="",f="";return o+"@nr="+i+"-"+s+"-"+n+"-"+r+"-"+t+"-"+a+"-"+c+"-"+f+"-"+e}function a(t,e,n,r,o,i){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var s={v:[0,1],d:{ty:"Browser",ac:r,ap:o,id:t,tr:e,ti:n}};return i&&r!==i&&(s.d.tk=i),btoa(JSON.stringify(s))}function s(t){return f()&&c(t)}function c(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var o=h(n.allowed_origins[r]);if(t.hostname===o.hostname&&t.protocol===o.protocol&&t.port===o.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function p(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var l=t(28),h=t(18);e.exports={generateTracePayload:r,shouldGenerateTrace:s}},{}],17:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<p;r++)t.removeEventListener(d[r],this.listener,!1);return e.protocol&&"data"===e.protocol?void g("Ajax/DataUrl/Excluded"):void(e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):i(this,t),n.cbTime=this.cbTime,s("xhr",[e,n,this.startTime,this.endTime,"xhr"],this)))}}function o(t,e){var n=c(e),r=t.params;r.hostname=n.hostname,r.port=n.port,r.protocol=n.protocol,r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=n,t.sameOrigin=n.sameOrigin}function i(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable&&!a.disabled){var s=t("handle"),c=t(18),f=t(16).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],p=d.length,l=t("id"),h=t(24),m=t(22),v=t(19),w=t(23),g=t(25).recordSupportability,y=NREUM.o.REQ,x=window.XMLHttpRequest;a.features.xhr=!0,t(15),t(8),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,e.params=this.params||{},e.metrics=this.metrics||{},t.addEventListener("load",function(n){i(e,t)},w(!1)),h&&(h>34||h<10)||t.addEventListener("progress",function(t){e.lastSize=t.loaded},w(!1))}),u.on("open-xhr-start",function(t){this.params={method:t[0]},o(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],o=this;if(n&&r){var i=m(r);i&&(n.txSize=i)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==t.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof e.onload))&&o.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var s=0;s<p;s++)e.addEventListener(d[s],this.listener,w(!1))}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("xhr-resolved",function(){this.endTime=a.now()}),u.on("addEventListener-end",function(t,e){e instanceof x&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof x&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof x&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url?n=t[0].url:window.URL&&t[0]&&t[0]instanceof URL&&(n=t[0].href),n&&(this.parsedOrigin=c(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var o=f(this.parsedOrigin);if(o&&(o.newrelicHeader||o.traceContextParentHeader))if("string"==typeof t[0]||window.URL&&t[0]&&t[0]instanceof URL){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),e(i.headers,o)&&(this.dt=o),t.length>1?t[1]=i:t.push(i)}else t[0]&&t[0].headers&&e(t[0].headers,o)&&(this.dt=o)}),u.on("fetch-start",function(t,e){this.params={},this.metrics={},this.startTime=a.now(),this.dt=e,t.length>=1&&(this.target=t[0]),t.length>=2&&(this.opts=t[1]);var n,r=this.opts||{},i=this.target;if("string"==typeof i?n=i:"object"==typeof i&&i instanceof y?n=i.url:window.URL&&"object"==typeof i&&i instanceof URL&&(n=i.href),o(this,n),"data"!==this.params.protocol){var s=(""+(i&&i instanceof y&&i.method||r.method||"GET")).toUpperCase();this.params.method=s,this.txSize=m(r.body)||0}}),u.on("fetch-done",function(t,e){if(this.endTime=a.now(),this.params||(this.params={}),"data"===this.params.protocol)return void g("Ajax/DataUrl/Excluded");this.params.status=e?e.status:0;var n;"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var r={txSize:this.txSize,rxSize:n,duration:a.now()-this.startTime};s("xhr",[this.params,r,this.startTime,this.endTime,"fetch"],this)})}},{}],18:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];if(0===(t||"").indexOf("data:"))return{protocol:"data"};var e=document.createElement("a"),n=window.location,o={};e.href=t,o.port=e.port;var i=e.href.split("://");!o.port&&i[1]&&(o.port=i[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===i[0]?"443":"80"),o.hostname=e.hostname||n.hostname,o.pathname=e.pathname,o.protocol=i[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,s=e.hostname===document.domain&&e.port===n.port;return o.sameOrigin=a&&(!e.hostname||s),"/"===o.pathname&&(r[t]=o),o}},{}],19:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?o(t.response):"text"===n||""===n||void 0===n?o(t.responseText):void 0}var o=t(22);e.exports=r},{}],20:[function(t,e,n){function r(){}function o(t,e,n,r){return function(){return u.recordSupportability("API/"+e+"/called"),i(t+e,[f.now()].concat(s(arguments)),n?null:this,r),n?void 0:this}}var i=t("handle"),a=t(31),s=t(32),c=t("ee").get("tracer"),f=t("loader"),u=t(25),d=NREUM;"undefined"==typeof window.newrelic&&(newrelic=d);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],l="api-",h=l+"ixn-";a(p,function(t,e){d[e]=o(l,e,!0,"api")}),d.addPageAction=o(l,"addPageAction",!0),d.setCurrentRouteName=o(l,"routeName",!0),e.exports=newrelic,d.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(t,e){var n={},r=this,o="function"==typeof e;return i(h+"tracer",[f.now(),t,n],r),function(){if(c.emit((o?"":"no-")+"fn-start",[f.now(),r,o],n),o)try{return e.apply(this,arguments)}catch(t){throw c.emit("fn-err",[arguments,this,t],n),t}finally{c.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){m[e]=o(h,e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),u.recordSupportability("API/noticeError/called"),i("err",[t,f.now(),!1,e])}},{}],21:[function(t,e,n){function r(t){if(NREUM.init){for(var e=NREUM.init,n=t.split("."),r=0;r<n.length-1;r++)if(e=e[n[r]],"object"!=typeof e)return;return e=e[n[n.length-1]]}}e.exports={getConfiguration:r}},{}],22:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],23:[function(t,e,n){var r=!1;try{var o=Object.defineProperty({},"passive",{get:function(){r=!0}});window.addEventListener("testPassive",null,o),window.removeEventListener("testPassive",null,o)}catch(i){}e.exports=function(t){return r?{passive:!0,capture:!!t}:!!t}},{}],24:[function(t,e,n){var r=0,o=navigator.userAgent.match(/Firefox[\/\s](\d+\.\d+)/);o&&(r=+o[1]),e.exports=r},{}],25:[function(t,e,n){function r(t,e){var n=[a,t,{name:t},e];return i("storeMetric",n,null,"api"),n}function o(t,e){var n=[s,t,{name:t},e];return i("storeEventMetrics",n,null,"api"),n}var i=t("handle"),a="sm",s="cm";e.exports={constants:{SUPPORTABILITY_METRIC:a,CUSTOM_METRIC:s},recordSupportability:r,recordCustom:o}},{}],26:[function(t,e,n){function r(){return s.exists&&performance.now?Math.round(performance.now()):(i=Math.max((new Date).getTime(),i))-a}function o(){return i}var i=(new Date).getTime(),a=i,s=t(33);e.exports=r,e.exports.offset=a,e.exports.getLastTimestamp=o},{}],27:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?l("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&l("timing",["fcp",Math.floor(t.startTime)])})}function o(t,e){var n=t.getEntries();if(n.length>0){var r=n[n.length-1];if(f&&f<r.startTime)return;var o=[r],i=a({});i&&o.push(i),l("lcp",o)}}function i(t){t.getEntries().forEach(function(t){t.hadRecentInput||l("cls",[t])})}function a(t){var e=navigator.connection||navigator.mozConnection||navigator.webkitConnection;if(e)return e.type&&(t["net-type"]=e.type),e.effectiveType&&(t["net-etype"]=e.effectiveType),e.rtt&&(t["net-rtt"]=e.rtt),e.downlink&&(t["net-dlink"]=e.downlink),t}function s(t){if(t instanceof w&&!y){var e=Math.round(t.timeStamp),n={type:t.type};a(n),e<=h.now()?n.fid=h.now()-e:e>h.offset&&e<=Date.now()?(e-=h.offset,n.fid=h.now()-e):e=h.now(),y=!0,l("timing",["fi",e,n])}}function c(t){"hidden"===t&&(f=h.now(),l("pageHide",[f]))}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var f,u,d,p,l=t("handle"),h=t("loader"),m=t(30),v=t(23),w=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){u=new PerformanceObserver(r);try{u.observe({entryTypes:["paint"]})}catch(g){}d=new PerformanceObserver(o);try{d.observe({entryTypes:["largest-contentful-paint"]})}catch(g){}p=new PerformanceObserver(i);try{p.observe({type:"layout-shift",buffered:!0})}catch(g){}}if("addEventListener"in document){var y=!1,x=["click","keydown","mousedown","pointerdown","touchstart"];x.forEach(function(t){document.addEventListener(t,s,v(!1))})}m(c)}},{}],28:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var o,i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",s=0;s<i.length;s++)o=i[s],"x"===o?a+=t().toString(16):"y"===o?(o=3&t()|8,a+=o.toString(16)):a+=o;return a}function o(){return a(16)}function i(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,o=window.crypto||window.msCrypto;o&&o.getRandomValues&&Uint8Array&&(n=o.getRandomValues(new Uint8Array(t)));for(var i=[],a=0;a<t;a++)i.push(e().toString(16));return i.join("")}e.exports={generateUuid:r,generateSpanId:o,generateTraceId:i}},{}],29:[function(t,e,n){function r(t,e){if(!o)return!1;if(t!==o)return!1;if(!e)return!0;if(!i)return!1;for(var n=i.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var o=null,i=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var s=navigator.userAgent,c=s.match(a);c&&s.indexOf("Chrome")===-1&&s.indexOf("Chromium")===-1&&(o="Safari",i=c[1])}e.exports={agent:o,version:i,match:r}},{}],30:[function(t,e,n){function r(t){function e(){t(s&&document[s]?document[s]:document[i]?"hidden":"visible")}"addEventListener"in document&&a&&document.addEventListener(a,e,o(!1))}var o=t(23);e.exports=r;var i,a,s;"undefined"!=typeof document.hidden?(i="hidden",a="visibilitychange",s="visibilityState"):"undefined"!=typeof document.msHidden?(i="msHidden",a="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(i="webkitHidden",a="webkitvisibilitychange",s="webkitVisibilityState")},{}],31:[function(t,e,n){function r(t,e){var n=[],r="",i=0;for(r in t)o.call(t,r)&&(n[i]=e(r,t[r]),i+=1);return n}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],32:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(o<0?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=r},{}],33:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function o(t){function e(t){return t&&t instanceof r?t:t?f(t,c,a):a()}function n(n,r,o,i,a){if(a!==!1&&(a=!0),!l.aborted||i){t&&a&&t(n,r,o);for(var s=e(o),c=m(n),f=c.length,u=0;u<f;u++)c[u].apply(s,r);var p=d[y[n]];return p&&p.push([x,n,r,s]),s}}function i(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return p[t]=p[t]||o(n)}function w(t,e){l.aborted||u(t,function(t,n){e=e||"feature",y[n]=e,e in d||(d[e]=[])})}var g={},y={},x={on:i,addEventListener:i,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:s,aborted:!1};return x}function i(t){return f(t,c,a)}function a(){return new r}function s(){(d.api||d.feature)&&(l.aborted=!0,d=l.backlog={})}var c="nr@context",f=t("gos"),u=t(31),d={},p={},l=e.exports=o();e.exports.getOrSetContext=i,l.backlog=d},{}],gos:[function(t,e,n){function r(t,e,n){if(o.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return t[e]=r,r}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){o.buffer([t],r),o.emit(t,e,n)}var o=t("ee").get("handle");e.exports=r,r.ee=o},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,i,function(){return o++})}var o=1,i="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!T++){var t=O.info=NREUM.info,e=m.getElementsByTagName("script")[0];if(setTimeout(f.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return f.abort();c(E,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+O.offset],null,"api"),s("timing",["load",n]);var r=m.createElement("script");0===t.agent.indexOf("http://")||0===t.agent.indexOf("https://")?r.src=t.agent:r.src=l+"://"+t.agent,e.parentNode.insertBefore(r,e)}}function o(){"complete"===m.readyState&&i()}function i(){s("mark",["domContent",a()+O.offset],null,"api")}var a=t(26),s=t("handle"),c=t(31),f=t("ee"),u=t(29),d=t(21),p=t(23),l=d.getConfiguration("ssl")===!1?"http":"https",h=window,m=h.document,v="addEventListener",w="attachEvent",g=h.XMLHttpRequest,y=g&&g.prototype,x=!1;NREUM.o={ST:setTimeout,SI:h.setImmediate,CT:clearTimeout,XHR:g,REQ:h.Request,EV:h.Event,PR:h.Promise,MO:h.MutationObserver};var b=""+location,E={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-spa-1216.min.js"},R=g&&y&&y[v]&&!/CriOS/.test(navigator.userAgent),O=e.exports={offset:a.getLastTimestamp(),now:a,origin:b,features:{},xhrWrappable:R,userAgent:u,disabled:x};if(!x){t(20),t(27),m[v]?(m[v]("DOMContentLoaded",i,p(!1)),h[v]("load",r,p(!1))):(m[w]("onreadystatechange",o),h[w]("onload",r)),s("mark",["firstbyte",a.getLastTimestamp()],null,"api");var T=0}},{}],"wrap-function":[function(t,e,n){function r(t,e){function n(e,n,r,c,f){function nrWrapper(){var i,a,u,p;try{a=this,i=d(arguments),u="function"==typeof r?r(i,a):r||{}}catch(l){o([l,"",[i,a,c],u],t)}s(n+"start",[i,a,c],u,f);try{return p=e.apply(a,i)}catch(h){throw s(n+"err",[i,a,h],u,f),h}finally{s(n+"end",[i,a,p],u,f)}}return a(e)?e:(n||(n=""),nrWrapper[p]=e,i(e,nrWrapper,t),nrWrapper)}function r(t,e,r,o,i){r||(r="");var s,c,f,u="-"===r.charAt(0);for(f=0;f<e.length;f++)c=e[f],s=t[c],a(s)||(t[c]=n(s,u?c+r:r,o,c,i))}function s(n,r,i,a){if(!h||e){var s=h;h=!0;try{t.emit(n,r,i,e,a)}catch(c){o([c,n,r,i],t)}h=s}}return t||(t=u),n.inPlace=r,n.flag=p,n}function o(t,e){e||(e=u);try{e.emit("internal-error",t)}catch(n){}}function i(t,e,n){if(Object.defineProperty&&Object.keys)try{var r=Object.keys(t);return r.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(i){o([i],n)}for(var a in t)l.call(t,a)&&(e[a]=t[a]);return e}function a(t){return!(t&&t instanceof Function&&t.apply&&!t[p])}function s(t,e){var n=e(t);return n[p]=t,i(t,n,u),n}function c(t,e,n){var r=t[e];t[e]=s(r,n)}function f(){for(var t=arguments.length,e=new Array(t),n=0;n<t;++n)e[n]=arguments[n];return e}var u=t("ee"),d=t(32),p="nr@original",l=Object.prototype.hasOwnProperty,h=!1;e.exports=r,e.exports.wrapFunction=s,e.exports.wrapInPlace=c,e.exports.argsToArray=f},{}]},{},["loader",2,17,5,3,4]);</script><meta charset="UTF-8"/><meta name="robots" content="index, follow"/><meta name="DC.Creator" content="Manivannan Ethirajan"/><meta name="DC.Creator" content="Yihui Chen"/><meta name="DC.Creator" content="Penny Joshi"/><meta name="DC.Creator" content="Ravindra K. Pandey"/><meta name="DC.title" content="The role of porphyrin chemistry in tumor imaging and photodynamic therapy "/><meta name="DC.publisher" content="Royal Society of Chemistry"/><meta name="DC.Date" content="2010/12/15"/><meta name="DC.Identifier" scheme="doi" content="10.1039/B915149B"/><meta name="DC.Language" content="en"/><meta name="citation_title" content="The role of porphyrin chemistry in tumor imaging and photodynamic therapy "/><meta name="citation_author" content="Manivannan Ethirajan"/><meta name="citation_author" content="Yihui Chen"/><meta name="citation_author" content="Penny Joshi"/><meta name="citation_author" content="Ravindra K. Pandey"/><meta name="citation_online_date" content="2010/08/09"/><meta name="citation_date" content="2011"/><meta name="citation_journal_title" content="Chemical Society Reviews"/><meta name="citation_volume" content="40"/><meta name="citation_issue" content="1"/><meta name="citation_firstpage" content="340"/><meta name="citation_lastpage" content="362"/><meta name="citation_doi" content="10.1039/B915149B"/><meta name="citation_pdf_url" content="https://pubs.rsc.org/en/content/articlepdf/2011/cs/b915149b"/><meta name="citation_abstract_html_url" content="https://pubs.rsc.org/en/content/articlelanding/2011/cs/b915149b"/><meta name="citation_fulltext_html_url" content="https://pubs.rsc.org/en/content/articlehtml/2011/cs/b915149b"/><link rel="shortcut icon" href=""/><link type="text/css" rel="stylesheet" href="/content/stylesheets/rschtml2.css?ver=6_2_1"/><link href="https://www.rsc-cdn.org/oxygen/assets/webfonts/fonts.min.css" rel="stylesheet" type="text/css"/><link type="text/css" rel="stylesheet" href="/content/stylesheets/pubs-ui.min.css"/><meta name="viewport" content="width=device-width, initial-scale=1"/><script type="text/javascript" src="/content/scripts/prospect.js?ver=6_2_1"> </script><script type="text/javascript" src="/content/scripts/JQueryPlugins.min.js"> </script><script type="text/javascript" src="/content/scripts/GetAnchorText.js"> </script><script type="text/javascript">
    
      $(function() {
      $("table.tgroup tfoot th").attr("colspan", "100");
      $("table.tgroup.rtable").each( function (idx, el) {
      var tw = $(this).width();
      $(this).parent().css("min-width", tw+"px");
      });

      });
      
    </script><!--6_2_1--></head><body class="oxy-ui pubs-ui ahtml-page"><!--Google Tag Manager (noscript)--><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-56FZ7G" height="0" width="0" style="display:none;visibility:hidden"> </iframe></noscript><!--End Google Tag Manager (noscript)--><div class="viewport autopad"><div class="pnl pnl--drop autopad"><span id="top"/><div id="wrapper"><div class="left_head"><a class="simple" href="/"><img class="rsc-logo" border="0" src="/content/NewImages/royal-society-of-chemistry-logo.png" alt="Royal Society of Chemistry"/></a><br/><span class="btnContainer"><a class="btn btn--tiny btn--primary" target="_blank" title="Link to PDF version" href="/en/content/articlepdf/2011/cs/b915149b">View PDF Version</a></span><span class="btnContainer"><a class="btn btn--tiny btn--nobg" title="Link to previous article (id:b914943k)" href="/en/content/articlehtml/2011/cs/b914943k" target="_BLANK">Previous Article</a></span><span class="btnContainer"><a class="btn btn--tiny btn--nobg" title="Link to next article (id:c0cs00030b)" href="/en/content/articlehtml/2011/cs/c0cs00030b" target="_BLANK">Next Article</a></span></div><div class="right_head"> </div><div class="article_info"> DOI: <a target="_blank" title="Link to landing page via DOI" href="https://doi.org/10.1039/B915149B">10.1039/B915149B</a>
(Critical Review)
<span class="italic"><a title="Link to journal home page" href="https://doi.org/10.1039/1460-4744/1972">Chem. Soc. Rev.</a></span>, 2011, <strong>40</strong>, 340-362<div id="chemnav"><a class="tab" onmouseover="this.style.cursor='pointer';" title="Select to toggle highlighting of compound names" onclick="toggleColour('TC');"><span alt="Show Compounds button" id="btnTC">Show Compounds</span></a><input id="inpTC" type="hidden" value="off"/><a class="tab" onmouseover="this.style.cursor='pointer';" title="Select to toggle highlighting of chem-ontology terms" onclick="toggleColour('CH');"><span alt="Show Chemical Terms button" id="btnCH">Show Chemical Terms</span></a><input id="inpCH" type="hidden" value="off"/></div></div><h1 id="sect196"><span class="title_heading">The role of <span class="TC"><a class="simple" title="Chemspider Compound link for:porphyrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10447586.html">porphyrin</a></span> chemistry in tumor imaging and photodynamic therapy</span></h1><p class="header_text">
      <span class="bold">
        
          
            Manivannan 
            Ethirajan
          
          
        
      </span>, 
      <span class="bold">
        
          
            Yihui 
            Chen
          
          
        
      </span>, 
      <span class="bold">
        
          
            Penny 
            Joshi
          
          
        
      </span><span class="bold"> and </span>
      <span class="bold">
        
          
            Ravindra K. 
            Pandey
          
          
        
      </span>*
      <br/><span class="italic">PDT Center, Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. E-mail: <a href="mailto:ravindra.pandey@roswellpark.org">ravindra.pandey@roswellpark.org</a>;  Fax: 716-845-8920;   Tel: 716-845-3203</span>
    </p><div id="art-admin"><span class="italic bold">Received 
      5th January 2010
    </span></div><p class="bold italic">First published on 9th August 2010</p><hr/><div class="abstract"><h2>Abstract</h2><p>In recent years several review articles and books have been published on the use of <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrin</a></span>-based compounds in photodynamic therapy (PDT). This <span class="italic">critical review</span> is focused on (i) the basic concept of PDT, (ii) advantages of long-wavelength absorbing photosensitizers (<span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span>), (iii) a brief discussion on recent advances in developing PDT agents, and (iv) the various synthetic strategies designed at the Roswell Park Cancer Institute, Buffalo, for developing highly effective long-wavelength PDT agents and their utility in constructing the conjugates with tumor-imaging and therapeutic potential (Theranostics). The clinical status of certain selected PDT agents is also summarized (205 references).</p></div><hr/><table><tr><td class="biogPlate"><img alt="&#xA;                  Manivannan Ethirajan&#xA;                " src="/image/article/2011/CS/b915149b/b915149b-p1.gif"/><p><span class="graphic_title">
                  <span class="bold">Manivannan Ethirajan</span>
                </span></p></td><td><i><p>Manivannan Ethirajan, PhD was born in Chennai, India. He obtained his PhD from IIT-Bombay. In 2001, he joined Prof. Gregory R. Cook's research group at NDSU, where he worked on small molecule inhibitors for MMP enzymes and then he moved to Prof. Jin K. Cha's research group at Wayne State University, where he focused on synthesizing carbocycles using palladium as a catalyst. Currently, he is working with Prof. Ravindra. K. Pandey at Roswell Park Cancer Institute and his research interest focuses on the synthesis of certain chemotherapeutic agents and porphyrin-based compounds, Silica and PAA-based nanoparticles for tumor-imaging and phototherapy (theronostics).</p></i></td></tr></table><table><tr><td class="biogPlate"><img alt="&#xA;                  Yihui Chen&#xA;                " src="/image/article/2011/CS/b915149b/b915149b-p2.gif"/><p><span class="graphic_title">
                  <span class="bold">Yihui Chen</span>
                </span></p></td><td><i><p>Yihui Chen, PhD is a research scientist in Roswell Park Cancer Institute and research assistant professor in Nuclear Medicine Department of State University of New York at Buffalo. He obtained his BS degree from Jiangxi Normal University, China and MS degree from Chinese Academy of Sciences. In 2002, he finished his PhD from State University of New York under the tutelage of Professor Ravindra K. Pandey. His publications are widely cited and his research expertise is the interdisciplinary field of organic chemistry, nuclear chemistry, medicinal chemistry and molecular biology.</p></i></td></tr></table><table><tr><td class="biogPlate"><img alt="&#xA;                  Penny Joshi&#xA;                " src="/image/article/2011/CS/b915149b/b915149b-p3.gif"/><p><span class="graphic_title">
                  <span class="bold">Penny Joshi</span>
                </span></p></td><td><i><p>Penny Joshi, PhD was born in Haldwani, India. She obtained her BS degree (2001) from Kumaun University, Nainital (India). After completing her Masters in Chemistry (2003) from University of Delhi, she joined Professor Diwan. S. Rawat, University of Delhi to earn her PhD in Chemistry (2008). Presently, she is working as a Post doctoral fellow with Prof. Ravindra. K. Pandey at Roswell Park Cancer Institute and her research work involves the synthesis of Porphyrin based “Multifunctional Agents” for tumor imaging with or without PDT.</p></i></td></tr></table><table><tr><td class="biogPlate"><img alt="&#xA;                  Ravindra K. Pandey&#xA;                " src="/image/article/2011/CS/b915149b/b915149b-p4.gif"/><p><span class="graphic_title">
                  <span class="bold">Ravindra K. Pandey</span>
                </span></p></td><td><i><p>Ravindra K. Pandey, PhD is currently a Distinguished Professor of the PDT Center and Director, Pharmaceutical Chemistry at Roswell Park Cancer Institute, Buffalo, NY, USA. His research work is mainly focused on developing (i) porphyrin-based compounds for tumor-imaging and therapy (PDT, chemotherapy) and (ii) nanoparticles as delivery vehicles. One of the photosensitizers synthesized by his research group is currently in Phase II clinical trials and a few PDT/imaging compounds are at advanced preclinical stages. Several therapeutic and imaging compounds developed in his laboratory are licensed to pharmaceutical companies for clinical trials and commercialization.</p></i></td></tr></table><hr/>
    
      
      <h2 id="sect265"><span class="a_heading">A. Introduction</span></h2>
      <span>Cancer is one of the deadliest diseases of our time and throughout the world, billions of dollars are spent annually on research in order to cure or improve the life-standards of the cancer treatment. The traditional cancer treatments, including surgery, radiation therapy and chemotherapy, (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1</a>) result in serious side effects caused by the loss of normal organ function.</span>
      <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig1"><img alt="Major cancer treatment therapies." src="/image/article/2011/CS/b915149b/b915149b-f1.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 1 </b> <span id="fig1"><span class="graphic_title">Major cancer treatment therapies.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      <p class="otherpara">In contrast, photodynamic therapy (PDT) is more controllable and has the potential to selectively destroy malignant cells while sparing the normal tissues. PDT, a relatively new therapy has several advantages over other traditional therapies: (i) it can be applied to places where surgery cannot be performed, (ii) the older patients and others who are vulnerable to surgery, chemotherapy or radiation therapy can be treated with this modality, (iii) the current treatment modalities, <span class="italic">e.g.</span>, chemotherapy, often lead to nausea and vomiting and in some cases leading to depress the immune system which leads to various immune disorders. Similarly, cancer treatment by radiation also has side effects such as severe damage to epithelial surfaces, infertility, swelling of soft tissues, and other ill effects. On the other hand, the photosensitizers alone do not exhibit any organ toxicity. Their presence in liver and kidney for days or months do not produce any damage to these organs, (iv) it is relatively a non-invasive treatment and (v) it can be used either as a primary or adjunctive treatment for solid cancers of the bladder, esophagus, head and neck, brain, lung, prostate, intraperitoneal cavity, breast, prostate and skin.<a title="Select to navigate to reference" href="#cit1"><sup><span class="sup_ref">1–6</span></sup></a></p>
      <p class="otherpara">The application of PDT is not only limited to oncology, but is also being explored for the treatment of cardiovascular, dermatological, ophthalmic and infectious diseases.<a title="Select to navigate to references" href="#cit7"><sup><span class="sup_ref">7</span></sup></a></p>
      <p class="otherpara">The PDT procedure consists of administering the photosensitizer to cancer patients by either intravenous or intraperitoneal injection. Depending on the pharmacokinetic characteristics of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span>(s), the tumor is irradiated with light at the time of its maximum <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> uptake. This procedure ultimately produces singlet oxygen, a cytotoxic agent, which is believed to be responsible for tumor destruction (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1</a> and section C.1).<a title="Select to navigate to reference" href="#cit7"><sup><span class="sup_ref">7,8</span></sup></a></p>
      <p class="otherpara">When the photosensitizer returns to its ground state through inter system crossing, the energy is transferred to triplet molecular oxygen to produce singlet oxygen, which is extremely cytotoxic and is believed to play a major role in cell killing, promoting vascular shutdown leading to tumor destruction (<a title="Select to navigate to figure" href="#imgfig2">Fig. 2</a>).</p>
      <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig2"><img alt="In PDT, singlet oxygen is a key cytotoxic agent that is responsible for the destruction of tumor." src="/image/article/2011/CS/b915149b/b915149b-f2.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 2 </b> <span id="fig2"><span class="graphic_title">In PDT, singlet oxygen is a key cytotoxic agent that is responsible for the destruction of tumor.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      <p class="otherpara">In recent years, a large number of review articles on photodynamic therapy (PDT) have been published. Some of them deal with general discussions on PDT<a title="Select to navigate to reference" href="#cit9"><sup><span class="sup_ref">9–11</span></sup></a> while others summarize the progress on specific aspects<a title="Select to navigate to reference" href="#cit12"><sup><span class="sup_ref">12–18</span></sup></a> or its application in special fields such as dermatology<a title="Select to navigate to reference" href="#cit19"><sup><span class="sup_ref">19,20</span></sup></a> Barrett's esophagus and other diseases.<a title="Select to navigate to reference" href="#cit21"><sup><span class="sup_ref">21–24</span></sup></a> A few articles are focused on particular classes of photosensitizers including <span class="TC"><a class="simple" title="Chemspider Compound link for:5-aminolevulinic acid" target="_blank" href="http://www.chemspider.com/Chemical-Structure.134.html">5-aminolevulinic acid</a></span><a title="Select to navigate to reference" href="#cit25"><sup><span class="sup_ref">25,26</span></sup></a> (ALA), <span class="CH"><a class="simple" title="ChEBI Ontology link for: phthalocyanines" href="javascript:popupOBO('CHEBI:51580','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51580')">phthalocyanines</a></span>, naphthalocyanines<a title="Select to navigate to reference" href="#cit27"><sup><span class="sup_ref">27–30</span></sup></a> and their metallated analogues such as aluminium, cobalt, gallium, silicon and zinc complexes<a title="Select to navigate to references" href="#cit27"><sup><span class="sup_ref">27</span></sup></a> or <span class="CH"><a class="simple" title="ChEBI Ontology link for: expanded porphyrins" href="javascript:popupOBO('CHEBI:47884','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=47884')">expanded porphyrins</a></span> related to <span class="CH"><a class="simple" title="ChEBI Ontology link for: texaphyrin" href="javascript:popupOBO('CHEBI:50181','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=50181')">texaphyrin</a></span>.<a title="Select to navigate to reference" href="#cit31"><sup><span class="sup_ref">31–36</span></sup></a></p>
      <p class="otherpara">The present article is mainly focused on (i) a brief history on PDT and its active component, (ii) a summary on approved photosensitizers or those which are at advanced stages of clinical trials and finally (iii) the strategies developed at the Roswell Park Cancer Institute, Buffalo for the development of effective PDT and multifunctional agents for the use in tumor-imaging (MRI, PET, fluorescence) and phototherapy.</p>
    
    
      
      <h2 id="sect300"><span class="a_heading">B. A brief history of PDT-drug development</span></h2>
      <span>The first observation of chemical sensitization of tissue by light was reported in 1900 by Rabb.<a title="Select to navigate to references" href="#cit37"><sup><span class="sup_ref">37</span></sup></a> The idea of using light to treat cancer dates from 1903 when Tappeiner and Jesionek used topically applied <span class="TC"><a class="simple" title="Chemspider Compound link for:eosin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10580.html">eosin</a></span> and sunlight to treat skin cancer patients. However, it was not until early 1980 when an active component of hematoporphyrin derivative (HpD) was isolated and partially identified.<a title="Select to navigate to reference" href="#cit11"><sup><span class="sup_ref">11,38</span></sup></a> Additional studies by Roswell Park and other groups<a title="Select to navigate to reference" href="#cit38"><sup><span class="sup_ref">38–52,11,25</span></sup></a> demonstrated that this “active” fraction of HpD (Photofrin®) consists of a mixture of <span class="TC"><a class="simple" title="Chemspider Compound link for:porphyrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10447586.html">porphyrin</a></span> dimers and higher oligomers in which the porphyrin units are joined by <span class="CH"><a class="simple" title="ChEBI Ontology link for: ether" href="javascript:popupOBO('CHEBI:25698','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=25698')">ether</a></span>, <span class="CH"><a class="simple" title="ChEBI Ontology link for: ester" href="javascript:popupOBO('CHEBI:35701','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35701')">ester</a></span> and carbon–carbon bonds. Since then, a rekindled interest in photodynamic action arose all over the world. Currently Photofrin® has been approved by health organization in the United States, Canada, Europe, and Japan, for the treatment of various types of cancers.<a title="Select to navigate to references" href="#cit11"><sup><span class="sup_ref">11</span></sup></a> Though Photofrin® is an effective photosensitizer, it suffers from several limitations, especially, skin photosensitivity and relatively weak long wavelength absorption which affords less than optimal light penetration depth. To overcome these problems, a set of second generation photosensitizers such as Levulan®, Radachlorin®, Visudyne® and Foscan® were developed in various laboratories. Radachlorin® is a product of Radapharma, Russia, which absorbs at 662 nm. Visudyne®, also known as <span class="TC"><a class="simple" title="Chemspider Compound link for:verteporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482080.html">verteporfin</a></span>™ is a product of Novartis <span class="CH"><a class="simple" title="ChEBI Ontology link for: pharmaceuticals" href="javascript:popupOBO('CHEBI:52217','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52217')">pharmaceuticals</a></span>; the clinical studies revealed that it is quite effective for age-related macular degeneration (AMD). Foscan® is a <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorin" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorin</a></span> based photosensitizer (652 nm) and is approved in Europe for the treatment of head and neck cancer patients. Certain chlorophyll-a and bacteriochlorophyll-a<span class="italic">e.g.</span> HPPH, purpurinimide, bacteriopurpurinimde and Tookad® are also at various stages of advanced clinical and preclinical studies (See the section Clinical Status of Selected Photosensitizers).</span>
    
    
      
      <h2 id="sect316"><span class="a_heading">C. Active components of PDT</span></h2>
      <span>As discussed before, PDT requires three elements for an effective treatment: photosensitizer, light, and oxygen. Singlet oxygen is believed to be the main <span class="CH"><a class="simple" title="ChEBI Ontology link for: reactive oxygen species" href="javascript:popupOBO('CHEBI:26523','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26523')">reactive oxygen species</a></span> (ROS) which destroys tumor cells by necrotic and apoptotic cell-death mechanisms.</span>
      
        
        <h3 id="sect321"><span class="b_heading">C.1 Singlet oxygen</span></h3>
        <span>Following the absorption of light, the photosensitizer is transformed from its ground singlet state (S<small><sub>0</sub></small>) into an electronically excited triplet state (T<small><sub>1</sub></small>, ∼10<small><sup>−2</sup></small> s) <span class="italic">via</span> a short-lived excited singlet state (S<small><sub>1,</sub></small> ∼10<small><sup>−6</sup></small> s). The excited triplet can undergo two kinds of reactions as shown in the Jablonski diagram (<a title="Select to navigate to figure" href="#imgfig3">Fig. 3</a>). First, it can participate in an electron-transfer process with a biological substrate to form radicals and radical ions, which, after interaction with oxygen, can produce oxygenated products such as superoxide ion, O<small><sub>2</sub></small><small><sup>−</sup></small> (type I reaction). Alternatively, it can undergo a photochemical process known as a type II reaction, which results in the conversion of stable triplet oxygen (<small><sup>3</sup></small>O<small><sub>2</sub></small>) to the short-lived but highly reactive singlet oxygen (<small><sup>1</sup></small>O<small><sub>2</sub></small>), the putative cytotoxic agent. Singlet oxygen is produced by inverting the spin of one of the outer most electrons. For ground-state oxygen,<a title="Select to navigate to references" href="#cit25"><sup><span class="sup_ref">25</span></sup></a> the two electrons of highest energy reside separately in the outermost antibonding orbitals with same spin: (σ<small><sub>2p</sub></small>)<small><sup>2</sup></small>(π<small><sub>2px</sub></small>)<small><sup>2</sup></small>(π<small><sub>2py</sub></small>)<small><sup>2</sup></small>(π<small><sub>2px*</sub></small>)<small><sup>1</sup></small>(π<small><sub>2py*</sub></small>)<small><sup>1</sup></small>, while in the singlet oxygen, the two highest energy electrons reside together in the same antibonding orbital in opposite spin: (σ<small><sub>2p</sub></small>)<small><sup>2</sup></small>(π<small><sub>2px</sub></small>)<small><sup>2</sup></small>(π<small><sub>2py</sub></small>)<small><sup>2</sup></small>(π<small><sub>2px*</sub></small>)<small><sup>2</sup></small>.</span>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig3"><img alt="Modified Jablonski diagram showing the formation of singlet oxygen." src="/image/article/2011/CS/b915149b/b915149b-f3.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 3 </b> <span id="fig3"><span class="graphic_title">Modified Jablonski diagram showing the formation of singlet oxygen.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        <p class="otherpara">That is why singlet oxygen is much more reactive than ground state oxygen. In most organic <span class="CH"><a class="simple" title="ChEBI Ontology link for: solvents" href="javascript:popupOBO('CHEBI:46787','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=46787')">solvents</a></span>, the lifetime is 10–100 μs <a title="Select to navigate to references" href="#cit26"><sup><span class="sup_ref">26</span></sup></a> (<a title="Select to navigate to figure" href="#imgfig3">Fig. 3</a>). This restricts its activity to a spherical volume 10 nm in diameter, centered at its point of production. In <span class="TC"><a class="simple" title="Chemspider Compound link for:water" target="_blank" href="http://www.chemspider.com/Chemical-Structure.937.html">water</a></span>, the lifetime of <small><sup>1</sup></small>O<small><sub>2</sub></small> is reduced to approximately 1–3 μs because the excited-state energy of singlet oxygen is almost equal to the energy of oxygen–hydrogen (O–H) stretching in <span class="TC"><a class="simple" title="Chemspider Compound link for:water" target="_blank" href="http://www.chemspider.com/Chemical-Structure.937.html">water</a></span> molecule and is easy to dissipate as heat by the stretching and vibrational motions of <span class="TC"><a class="simple" title="Chemspider Compound link for:water" target="_blank" href="http://www.chemspider.com/Chemical-Structure.937.html">water</a></span> molecules.<a title="Select to navigate to references" href="#cit25"><sup><span class="sup_ref">25</span></sup></a> However, the lifetime of <small><sup>1</sup></small>O<small><sub>2</sub></small> is considerably shorter in cellular systems, ranging from 100 ns in the <span class="CH"><a class="simple" title="ChEBI Ontology link for: lipid" href="javascript:popupOBO('CHEBI:18059','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=18059')">lipid</a></span> regions of membranes to 250 ns in the cytoplasm. Therefore, the diffusion range of <small><sup>1</sup></small>O<small><sub>2</sub></small> is predicted to be limited to approximately 45 nm in cellular media.<a title="Select to navigate to references" href="#cit53"><sup><span class="sup_ref">53</span></sup></a> Because the diameter of human cells ranges from approximately 10 to 100 μm, they cannot diffuse more than a single cell length. Thus, the site of the primary generation of <small><sup>1</sup></small>O<small><sub>2</sub></small> determines which sub cellular structures may be accessed and attacked. Singlet oxygen is a powerful, fairly indiscriminate oxidant that reacts with a variety of biological molecules. It is generally agreed that singlet oxygen is the key agent for cellular damage produced by irradiating the <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrin</a></span>-based photosensitizers (<a title="Select to navigate to figure" href="#imgfig4">Fig. 4</a>).<a title="Select to navigate to references" href="#cit53"><sup><span class="sup_ref">53</span></sup></a></p>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig4"><img alt="Basic structure of porphyrins, reduced porphyrins (chlorins, bacteriochlorins) and phthalocyanines." src="/image/article/2011/CS/b915149b/b915149b-f4.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 4 </b> <span id="fig4"><span class="graphic_title">Basic structure of <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrins</a></span>, reduced <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrins</a></span> (<span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span>, <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span>) and <span class="CH"><a class="simple" title="ChEBI Ontology link for: phthalocyanines" href="javascript:popupOBO('CHEBI:51580','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51580')">phthalocyanines</a></span>.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      
      
        
        <h3 id="sect387"><span class="b_heading">C.2 Importance of tumor tissue oxygenation</span></h3>
        <span>As discussed above, for the Type II photochemical reactions ground state molecular oxygen (<small><sup>3</sup></small>O<small><sub>2</sub></small>) is necessary. When tumors are not well oxygenated, conditions such as anoxia and hypoxia have the potential to arise. During an anoxic condition the excited PS transfers its energy to organic substrates by oxidizing the substrate and reducing the PS. During a hypoxic condition the already reduced <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span> interacts with <small><sup>3</sup></small>O<small><sub>2</sub></small> to produce superoxide anions (O<small><sub>2</sub></small><small><sup>−</sup></small>) and then eventually produces highly reactive <span class="TC"><a class="simple" title="Chemspider Compound link for:hydroxyl" target="_blank" href="http://www.chemspider.com/Chemical-Structure.138477.html">hydroxyl</a></span> radicals (OH˙).</span>
        <p class="otherpara">Several research groups have suggested that the Type II reaction dominates, while Type I occurs only when the PS is highly concentrated in the tumor or if the tumor is hypoxic in nature. Therefore, the success of PDT has been weighted heavily upon the dependence or presence of oxygen within the tumor treatment site.<a title="Select to navigate to reference" href="#cit54"><sup><span class="sup_ref">54,55</span></sup></a> Researchers have been observing oxygen diffusion models in which lower fluence rates generate singlet oxygen more efficiently so that more <small><sup>1</sup></small>O<small><sub>2</sub></small> is exposed to the tumor over longer periods of time. Busch <span class="italic">et al.</span>, have demonstrated that oxygen is depleted as a function of fluence rate.<a title="Select to navigate to references" href="#cit56"><sup><span class="sup_ref">56</span></sup></a> Other conditions such as necrosis and vascular damage can also aid in the destruction of the tumor and microvasculature by starving the diseased tissue of additional <span class="CH"><a class="simple" title="ChEBI Ontology link for: nutrients" href="javascript:popupOBO('CHEBI:33284','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33284')">nutrients</a></span> and oxygen, which can result in enhancement of tumor tissue hypoxia.<a title="Select to navigate to references" href="#cit57"><sup><span class="sup_ref">57</span></sup></a></p>
      
      
        
        <h3 id="sect407"><span class="b_heading">C.3 Importance of light dosimetry</span></h3>
        <span>The most frequently used PDT light sources are lasers. They produce highly coherent monochromatic light that can be focused, passed down through an optical fiber and directly delivered to the target site through specially designed fiber optics. Early on, most laser systems used (such as the Argon-pumped <span class="CH"><a class="simple" title="ChEBI Ontology link for: dye" href="javascript:popupOBO('CHEBI:37958','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37958')">dye</a></span> laser) were bulky and expensive. These lasers were only fit for laboratory research purposes, not for clinical environment. Recently, diode lasers are now well developed; they are portable, lightweight, less expensive, thus making PDT more economical and practical.</span>
        <p class="otherpara">A critical parameter for consideration in discussing the efficacy of PDT is the depth of light penetration through tissue. The light penetration is dependant on the optical properties of the tissue including reflection, scattering, transmission and absorption. Therefore, pigment-rich tissues, such as those of melanoma, are resistant to PDT. Tissue penetration is also affected by the wavelength of the light. It was demonstrated that light with a wavelength near 800 nm passes most deeper in tissues.<a title="Select to navigate to references" href="#cit38"><sup><span class="sup_ref">38</span></sup></a> Both absorption and scattering of light by tissue increase as the wavelength decrease. Light with wavelength shorter than 580 nm is not suitable because of strong absorption by <span class="CH"><a class="simple" title="ChEBI Ontology link for: hemoglobin" href="javascript:popupOBO('CHEBI:35143','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35143')">hemoglobin</a></span>. Typically, the depth of penetration is from 3 to 8 mm for light in the range from 630 to 800 nm.</p>
        <p class="otherpara">Light dosimetry is another important vector to determine the efficiency of PDT treatment. It includes two parameters: fluence and fluence rate. Fluence is the total energy of exposed light across a sectional area of irradiated spot (energy per unit area of exposed light, J/m<small><sup>2</sup></small>). Fluence rate is the radiant energy incident per second across a sectional area of irradiated spot (power per unit area of light, W/m<small><sup>2</sup></small>, 1 W = 1 J/s). As the fluence rate lowers, the exposure time gets longer to provide the same fluence (dose) of light. Clinically, high fluence rates are usually chosen to reduce treatment time. However it was reported that high fluence rate may not be appropriate for eliciting an optimal effect. It has been reported by Wilson <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit58"><sup><span class="sup_ref">58</span></sup></a> that when fluence rates are high, the depletion of oxygen can occur to such an extent that it results in a reduced photodynamic effect since there is not an effective production of the cytotoxic species. Studies are underway in several laboratories to develop oxygen diffusion models in which lower fluence rates generate singlet oxygen more efficiently so that more singlet oxygen is exposed to the tumor over longer periods of time. The degree of damage to healthy tissue is also reduced, possibly, because the healthy tissue can repair minor damage more efficiently, avoiding a greater inflammatory response.</p>
      
      
        
        <h3 id="sect420"><span class="b_heading">C.4 Photosensitizers</span></h3>
        <span>Photosensitizers (<span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span>) are the key element in PDT. After the approval of <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span>® for the PDT treatment, researchers from all over the world got actively involved in developing efficient <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span>. An ideal <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span> should fulfill the following requirements.</span>
        <p class="otherpara">(1) It should be able to produce singlet oxygen efficiently because singlet oxygen is believed to be the key cytotoxic agent responsible for the destruction of tumors by PDT.</p>
        <p class="otherpara">(2) It should have a high absorption coefficient in the long wavelength region (700 nm to 800 nm). <span class="CH"><a class="simple" title="ChEBI Ontology link for: Porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">Porphyrin</a></span>-based photosensitizers have a strong absorption band around 400 nm called the “Soret” band, and a satellite absorption band (Q-band) between 600 and 800 nm. Only the Q-band is useful for PDT treatment. <span class="CH"><a class="simple" title="ChEBI Ontology link for: Porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">Porphyrins</a></span>, <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span> and <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span> are aromatic molecules having 22-, 20-, and 18-π electrons, respectively. Besides exhibiting a strong Soret band, the long-wavelength absorption of <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrins</a></span> is usually in the region of 600–650 nm. Chlorins' Q-bands are around 630 nm to 700 nm The <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span>' long-wavelength absorption falls between 700 nm and 800 nm depending on the nature of substituents present at the peripheral positions, photosensitizers at this wavelength region are capable of treating large and deeply seated tumors.</p>
        <p class="otherpara">(3) It should have no dark toxicity, minimal skin photosensitivity and should selectively accumulate in tumor tissue (preferential tumor retention, fast tumor accumulation and rapid clearance from other organs).</p>
        <p class="otherpara">(4) The distribution of a PS is important in PDT processes and is influenced by its chemical structure. It is particularly useful if a PS is amphiphilic water-soluble but also containing a hydrophobic matrix.</p>
        <p class="otherpara">(5) It should be stable and easy to dissolve in injectable <span class="CH"><a class="simple" title="ChEBI Ontology link for: solvents" href="javascript:popupOBO('CHEBI:46787','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=46787')">solvents</a></span> (formulation).</p>
        <p class="otherpara">(6) It should be chemically pure and can be prepared <span class="italic">via</span> a short synthetic route involving simple technique(s) with high yield.</p>
      
      
        
        <h3 id="sect442"><span class="b_heading">C.5 Basic Structures of <span class="CH"><a class="simple" title="ChEBI Ontology link for: tetrapyrrole" href="javascript:popupOBO('CHEBI:26932','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26932')">tetrapyrrole</a></span>-based photosensitizers and the IUPAC approved numbering for nomenclature</span></h3>
        <span>
          <span class="CH"><a class="simple" title="ChEBI Ontology link for: Porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">Porphyrins</a></span> are 18π-electron aromatic <span class="CH"><a class="simple" title="ChEBI Ontology link for: macrocycles" href="javascript:popupOBO('CHEBI:51026','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51026')">macrocycles</a></span> that exhibit characteristic optical <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: spectra" href="javascript:popupOBO('CMO:0000800','b915149b')">spectra</a></span> with a strong π–π* transition aroud 400 nm (Soret band) and usually four Q bands in the visible region. Two of the peripheral double bonds in opposite pyrrolic rings are cross-conjugated and are not required to maintain aromaticity. Thus <span class="CH"><a class="simple" title="Molecular Process Ontology link for: reduction" href="javascript:popupOBO('MOP:0000569','b915149b')">reduction</a></span> of one or both these cross-conjugated bonds maintains much of the aromaticity (<span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorin" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorin</a></span> and <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorin" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorin</a></span>, respectively). A change in symmetry results in red shifted Q-bands (640 to 800 nm) with high extinction coefficient. <span class="CH"><a class="simple" title="ChEBI Ontology link for: Phthalocyanines" href="javascript:popupOBO('CHEBI:51580','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51580')">Phthalocyanines</a></span> are a class of <span class="CH"><a class="simple" title="ChEBI Ontology link for: tetrapyrroles" href="javascript:popupOBO('CHEBI:26932','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26932')">tetrapyrroles</a></span> in which the C- at <span class="italic">meso</span>-positions (5-, 10- 15 and 20) is replaced by N. The longest wavelength absorption in this class of compounds falls near 700 nm.</span>
      
    
    
      
      <h2 id="sect456"><span class="a_heading">D. Light penetration depth of photosensitizers</span></h2>
      <span>As discussed above, the diffusion range of <small><sup>1</sup></small>O<small><sub>2</sub></small> is predicted to be limited to approximately 45 nm in cellular media.<a title="Select to navigate to reference" href="#cit58"><sup><span class="sup_ref">58–60</span></sup></a> So the tissue-penetration distance of light is an important consideration for PDT. It is well established that both absorption and scattering of light by tissue increase as the wavelength decreases.<a title="Select to navigate to references" href="#cit38"><sup><span class="sup_ref">38</span></sup></a> The tissue absorption components include nucleic acids, <span class="CH"><a class="simple" title="ChEBI Ontology link for: amino acids" href="javascript:popupOBO('CHEBI:33709','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33709')">amino acids</a></span>, <span class="CH"><a class="simple" title="ChEBI Ontology link for: hemoglobin" href="javascript:popupOBO('CHEBI:35143','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35143')">hemoglobin</a></span>, melanin<span class="italic">etc</span>. For nucleic acids and <span class="CH"><a class="simple" title="ChEBI Ontology link for: amino acids" href="javascript:popupOBO('CHEBI:33709','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33709')">amino acids</a></span>, their absorption wavelengths are usually from 250 to 300 nm, so that they have little effect on the absorption of longer wavelength of light over 600 nm. The intrinsic absorption of most tissue is dominated by <span class="CH"><a class="simple" title="ChEBI Ontology link for: hemoglobin" href="javascript:popupOBO('CHEBI:35143','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35143')">hemoglobin</a></span>. <span class="CH"><a class="simple" title="ChEBI Ontology link for: Hemoglobin" href="javascript:popupOBO('CHEBI:35143','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35143')">Hemoglobin</a></span> in the oxygenated state is referred to as <span class="CH"><a class="simple" title="ChEBI Ontology link for: oxyhemoglobin" href="javascript:popupOBO('CHEBI:7861','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=7861')">oxyhemoglobin</a></span> (HbO<small><sub>2</sub></small>); in the reduced state, it is called <span class="CH"><a class="simple" title="ChEBI Ontology link for: deoxyhemoglobin" href="javascript:popupOBO('CHEBI:5656','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=5656')">deoxyhemoglobin</a></span> (Hb). The strong absorption peaks of <span class="CH"><a class="simple" title="ChEBI Ontology link for: hemoglobins" href="javascript:popupOBO('CHEBI:35143','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35143')">hemoglobins</a></span> are found at wavelengths shorter than 620 nm. The tails of these bands grow weaker with increasing wavelength from 620 to 800 nm. Another endogenous <span class="CH"><a class="simple" title="ChEBI Ontology link for: chromophore" href="javascript:popupOBO('CHEBI:23240','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23240')">chromophore</a></span> is <span class="CH"><a class="simple" title="ChEBI Ontology link for: melanin" href="javascript:popupOBO('CHEBI:25179','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=25179')">melanin</a></span>, which is a <span class="CH"><a class="simple" title="ChEBI Ontology link for: polymer" href="javascript:popupOBO('CHEBI:60027','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=60027')">polymer</a></span><a title="Select to navigate to references" href="#cit60"><sup><span class="sup_ref">60</span></sup></a> built by condensation of <span class="TC"><a class="simple" title="Chemspider Compound link for:tyrosine" target="_blank" href="http://www.chemspider.com/Chemical-Structure.5833.html">tyrosine</a></span> molecules and has a broad absorption spectrum exhibiting stronger absorption at shorter wavelengths. All these factors account for the fact that light penetration is very low at the wavelengths &lt;550 nm. However, as shown in <a title="Select to navigate to figure" href="#imgfig5">Fig. 5</a>, it almost doubles from 550 nm to 630 nm<a title="Select to navigate to references" href="#cit38"><sup><span class="sup_ref">38</span></sup></a> (where Photofrin® is activated) and doubles again in going to 700 nm. This is followed by a 10% increase in tissue penetration as the wavelength moves towards 800 nm. The optical window for PDT studies is in the range of 600 nm to 900 nm.Wavelength beyond 900 nm is not desirable.</span>
      <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig5"><img alt="Relative diffusion depth of penetration with light at various wavelengths (assuming the depth of tissue penetration at 800 nm is 100%) [The Porphyrin Hand]." src="/image/article/2011/CS/b915149b/b915149b-f5.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 5 </b> <span id="fig5"><span class="graphic_title">Relative diffusion depth of penetration with light at various wavelengths (assuming the depth of tissue penetration at 800 nm is 100%) [<span class="italic">The </span><span class="italic">Porphyrin</span><span class="italic"> Hand</span>].</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
    
    
      
      <h2 id="sect486"><span class="a_heading">E. Clinical status of selected photosensitizers</span></h2>
      <span>Two different approaches- (i) active and (ii) passive <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> development approaches have been followed for designing photosensitizers in various laboratories. Among the two approaches, the passive approach, mainly based on a structure–activity relationship (SAR), has been more successful. The active approach, which basically deals with targeting the PS to certain receptors known for a high experssion in tumor cells showed promising efficacy <span class="italic">in vitro</span>, but have produced limited <span class="italic">in vivo</span> activity and tumor-selectivity.</span>
      <p class="otherpara">In general, amphiphilicity (the presence of hydrophilic and hydrophobic groups at various positions of the molecule that intereact with the <span class="CH"><a class="simple" title="ChEBI Ontology link for: solvent" href="javascript:popupOBO('CHEBI:46787','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=46787')">solvent</a></span> independently), which can be correlated to partition coefficient values, seems to play an important role in tumor uptake of the photosensitizes. It can also affect the aggregation characteristics of the highly conjugated tetrapyrrolic systems, which in turn could alter the photophysical properties and intracellular site(s) of localization of the molecules. Aggregation shortens the triplet-state lifetime and decreases the singlet-oxygen quantum yield by dissipating the energy through internal conversion. Therefore, highly aggregated photosensitizers <span class="italic">in vivo</span> are considered to be less effective. However, the aggregation characteristics of the photosensitizer <span class="italic">in vitro</span> could be different than the <span class="italic">in vivo</span> environment, and, not much is known about the behavior of these agents <span class="italic">in vivo.</span><a title="Select to navigate to references" href="#cit61"><sup><span class="sup_ref">61</span></sup></a></p>
      <p class="otherpara">A brief description on selected photosensitizers approved by various health organizations or are at various stages of human clinical trials are as follows:</p>
      
        
        <h3 id="sect502"><span class="b_heading">E.1 Photofrin</span></h3>
        <span>An effort led by Dougherty to prepare purified version HpD in large quantities following the US FDA regulations produced the first approved photosensitizing <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span>, <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span>® <strong>1</strong>, for clinical use. Photofrin4<a title="Select to navigate to reference" href="#cit42"><sup><span class="sup_ref">42,62,63</span></sup></a> is a mixture enriched in the more active dimeric and oligomeric components. <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span> has been approved for clinical use in the treatment of early- and late-stage lung cancers, esophageal cancer, bladder cancer, malignant and nonmalignant skin diseases and early-stage cervical cancer. It is also being considered as a potential therapy against Kaposi's sarcoma, Barrett's esophagus with high-grade dysplasia, psoriasis and cancers of the head, brain, neck and breast. For early-stage lung cancer, Photofrin-mediated PDT is a relatively recent addition to the already well-established treatment methods of surgical resection, radiotherapy and chemotherapy.<a title="Select to navigate to references" href="#cit64"><sup><span class="sup_ref">64</span></sup></a> Successful application of Photofrin-based PDT has been achieved in patients with nonsmall cell lung cancer (NSCLC), each of which were considered suitable surgical candidates prior to PDT treatment. Of one group of 13 patients, 10 patients demonstrated complete response following the initial PDT treatment. The remaining patients required a second treatment for a complete response to be obtained. In a pilot study using Photofrin-mediated PDT in patients with inoperable NSCLC, 10 of 11 stage 1 NSCLC patients achieved complete remission. The remaining patient and 11 out of 15 stage III NSCLC patients showed only a partial response to treatment. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr1"><img alt="ugraphic, filename = b915149b-u1.gif" src="/image/article/2011/CS/b915149b/b915149b-u1.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr1"/><span id="ugr1"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect513"><span class="b_heading">E.2 
          <span class="TC"><a class="simple" title="Chemspider Compound link for:Temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">Temoporfin</a></span>
        </span></h3>
        <span>
          <span class="TC"><a class="simple" title="Chemspider Compound link for:Temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">Temoporfin</a></span>
          <a title="Select to navigate to references" href="#cit65"><sup><span class="sup_ref">65</span></sup></a><strong>2</strong> (<span class="italic">meso</span>-tetra-hydroxyphenyl-chlorin, <span class="TC"><a class="simple" title="Chemspider Compound link for:mTHPC" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html"><span class="italic">m</span>THPC</a></span>, Foscan®; biolitex AG, Jena, Germany) is a tissue-based photosensitizer that is activated 2–5 days after intravenous administration. It accumulates in the skin, and requires protection of the eyes and skin from sunlight for up to 6 weeks. <span class="TC"><a class="simple" title="Chemspider Compound link for:Temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">Temoporfin</a></span> was the first sensitizer to be used in a formal clinical study of PDT for prostate cancer, which was conducted in 2002. The study was performed by Nathan and colleagues<a title="Select to navigate to reference" href="#cit65"><sup><span class="sup_ref">65,66</span></sup></a> at University College London, London, UK. The authors assessed the effects of PDT using <span class="TC"><a class="simple" title="Chemspider Compound link for:Temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">Temoporfin</a></span> in the postradiotherapy setting. The first five patients in the study received low light doses (20 J/cm<small><sup>2</sup></small>), and small areas of devascularization were seen on postprocedure CT. Four of these patients chose to undergo re-treatment at a higher light dose, and an additional nine patients were then given <span class="TC"><a class="simple" title="Chemspider Compound link for:Temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">Temoporfin</a></span> and a light dose of 50 J/cm<small><sup>2</sup></small>. The study design allowed the treatment of selected areas of the prostate on the basis of results from biopsy and pretreatment imaging. The selected treatment area could have been the whole of the peripheral zone from base to apex; whole-gland treatment was not performed, in order to avoid adverse effects. Post-treatment imaging showed areas of necrosis, which were often patchy. Volumes of necrosis varied from 0.9 cm<small><sup>3</sup></small> to 13.4 cm<small><sup>3</sup></small>, with up to 91% necrosis of the prostate for a bilateral treatment (nine treatments were bilateral). In 2006, this same group carried out a pilot study of PDT in the primary setting.<a title="Select to navigate to references" href="#cit67"><sup><span class="sup_ref">67</span></sup></a> Six patients were included, and a total of 10 PDT treatments were administered; patients received a second treatment if residual cancer was detected on post-treatment biopsy. The two patients who received only one treatment also showed residual cancer. However, one patient chose to continue on an active surveillance program, and the other chose to undergo radiotherapy. Treatment was aimed at areas of cancer (identified on biopsy or imaging) and the adjacent peripheral lobe. Only one lobe of the prostate was treated during each session. A combination of bare-tip and cylindrical light diffusers were used, with total light doses of up to 1800 J per lobe. The volumes of necrosis, as measured by post-treatment MRI, varied from 1.2 cm<small><sup>3</sup></small> to 51.1 cm<small><sup>3</sup></small>. Adverse effects were minimal in this group. One patient required intravenous <span class="CH"><a class="simple" title="ChEBI Ontology link for: antibiotics" href="javascript:popupOBO('CHEBI:22582','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=22582')">antibiotics</a></span> for Gram-negative sepsis 24 h after light delivery. Only one of the patients reported deterioration in erectile function, which he attributed to worsening angina and performance anxiety. His erectile dysfunction resolved spontaneously after 5 months. These two studies demonstrated the potential efficacy of <span class="TC"><a class="simple" title="Chemspider Compound link for:temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">temoporfin</a></span> in the treatment of prostate cancer; however, owing to the financial collapse of the company that produced <span class="TC"><a class="simple" title="Chemspider Compound link for:temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">temoporfin</a></span>, and the subsequent takeover of the drug's manufacture by a company who did not wish to continue prostate PDT research, further work with <span class="TC"><a class="simple" title="Chemspider Compound link for:temoporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html">temoporfin</a></span> in prostate cancer was not carried out. <span class="TC"><a class="simple" title="Chemspider Compound link for:m-THPC" target="_blank" href="http://www.chemspider.com/Chemical-Structure.54754.html"><span class="italic">m</span>-THPC</a></span> was also reported for the treatment of breast cancer,<a title="Select to navigate to references" href="#cit68"><sup><span class="sup_ref">68</span></sup></a> head and neck cancer,<a title="Select to navigate to references" href="#cit69"><sup><span class="sup_ref">69</span></sup></a> and pancreatic cancer.<a title="Select to navigate to references" href="#cit70"><sup><span class="sup_ref">70</span></sup></a><br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr2"><img alt="ugraphic, filename = b915149b-u2.gif" src="/image/article/2011/CS/b915149b/b915149b-u2.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr2"/><span id="ugr2"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect545"><span class="b_heading">E.3 
          <span class="TC"><a class="simple" title="Chemspider Compound link for:Aminolevulinic acid" target="_blank" href="http://www.chemspider.com/Chemical-Structure.410.html">Aminolevulinic acid</a></span>-induced <span class="TC"><a class="simple" title="Chemspider Compound link for:protoporphyrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10469486.html">protoporphyrin</a></span> IX</span></h3>
        <span>Several types of skin conditions are among the first to be studied due to their accessibility to photosensitizer and external light. The RPCI group pioneered skin cancer PDT in the 1970s using HpD and red light from a xenon arc lamp in patients who suffered primary or secondary skin cancers. This early study demonstrated that the primary skin cancers which showed a complete response (CR) included squamous cell carcinomas (SCCs, 20%), basal cell carcinomas (BCCs, 70–80%) and malignant melanomas (50%), and the secondary cancers originated from primary breast cancer, colon cancer, and endometrium cancer (80%).<a title="Select to navigate to reference" href="#cit71"><sup><span class="sup_ref">71,72</span></sup></a> Interstitial PDT might be an option for subcutaneous and cutaneous tumors of a larger volume.<a title="Select to navigate to references" href="#cit73"><sup><span class="sup_ref">73</span></sup></a> Since the discovery of endogenous <span class="TC"><a class="simple" title="Chemspider Compound link for:protoporphyrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10469486.html">protoporphyrin</a></span> IX (PpIX) <strong>3</strong> photosensitization induced by exogenous administration of ALA<a title="Select to navigate to references" href="#cit74"><sup><span class="sup_ref">74</span></sup></a> skin premalignant and malignant lesions also become a favorite target of ALA-PDT with the exception of the pigmented malignant melanomas due to limited light penetration. Studies demonstrated ALA-PDT to be effective, safe, and well tolerated by patients, and led to the US FDA approval in 2000 which marked another historic event for PDT. ALA-PDT was also approved for moderate inflammatory acne vulgaris in US in 2003. A number of other nonmalignant conditions (<span class="italic">e.g.</span>, psoriasis, viral warts, and hair removal) are currently under clinical investigation worldwide.<a title="Select to navigate to reference" href="#cit75"><sup><span class="sup_ref">75–78</span></sup></a> Clinical investigational studies of ALA-PDT have also extended to BCCs, basaloid follicular hamartomas, SCC<span class="italic">in situ</span> (Bowen's disease), cutaneous T-cell lymphoma, and sebaceous gland hyperplasia in recent years.<a title="Select to navigate to reference" href="#cit79"><sup><span class="sup_ref">79–88</span></sup></a> Zaak and colleagues<a title="Select to navigate to references" href="#cit89"><sup><span class="sup_ref">89</span></sup></a> have assessed the use of ALA in patients with prostate cancer. The authors initially investigated whether ALA would be taken up by the cancer cells: ALA was given orally, at a dose of 20 mg/kg, 4 h before patients underwent radical retropubic prostatectomy; prostatectomy specimens were then analyzed by <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: fluorescence microscopy" href="javascript:popupOBO('CMO:0000087','b915149b')">fluorescence microscopy</a></span>. ALA was detected in cancer cells, but not the surrounding epithelial cells or stroma. This study is interesting because of the selectivity of the photosensitizer for prostate cancer cells<span class="italic">versus</span> benign epithelial cells. The investigators then administered interstitial PDT to six patients using 633 nm light (250 J/cm <span class="italic">via</span> a 1 cm diffusing fiber) to activate the ALA. The results were quite encouraging. Besides ALA corresponding <span class="CH"><a class="simple" title="ChEBI Ontology link for: ester" href="javascript:popupOBO('CHEBI:35701','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35701')">ester</a></span> analogs are also being used for the treatment of treating a variety of superficial tumors. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr3"><img alt="ugraphic, filename = b915149b-u3.gif" src="/image/article/2011/CS/b915149b/b915149b-u3.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr3"/><span id="ugr3"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect566"><span class="b_heading">E.4 
          Motexafin lutetium
        </span></h3>
        <span>
          Motexafin lutetium
          <strong>4</strong> (MLu, LuTex; Lutrin, a member of the family of <span class="CH"><a class="simple" title="ChEBI Ontology link for: texaphyrin" href="javascript:popupOBO('CHEBI:50181','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=50181')">texaphyrin</a></span> molecules), which is predominantly a vascular-acting photosensitizer, has undergone testing in a canine model<a title="Select to navigate to references" href="#cit90"><sup><span class="sup_ref">90</span></sup></a> and has also been used in the postradiotherapy setting in human patients of prostate cancer. In a phase I trial, PDT using this photosensitizer was performed in 17 patients, 8 of whom had previously undergone external beam radiotherapy and 9 of whom had undergone brachytherapy.<a title="Select to navigate to reference" href="#cit91"><sup><span class="sup_ref">91–95</span></sup></a> This study used a dose-escalation design; therefore, a wide variation in <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> dose, light dose and <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span>–light interval was used. High-dose PDT was defined as that using the highest <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> dose (2 mg/kg), the highest light dose (150 J/cm<small><sup>2</sup></small>), and the shortest <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span>-light interval (3 h); this group included 8 patients. Those patients undergoing high-dose PDT experienced the greatest initial rise in PSA level, followed by a <span class="CH"><a class="simple" title="Molecular Process Ontology link for: reduction" href="javascript:popupOBO('MOP:0000569','b915149b')">reduction</a></span> in PSA levels to below baseline values. By contrast, patients who received low-dose PDT (<span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> dose 0.5 mg/kg, light dose 25 J/cm<small><sup>2</sup></small>, and <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span>-light interval 24 h) had a treatment-related rise in PSA level that did not subsequently fall below baseline. So that it seems that high-dose PDT by LuTex is more promising than low-dose PDT. However, the authors did not report any post-treatment imaging. Changes in PSA levels are difficult to interpret in such a small number of patients. Motexafin lutetium was also reported for successful treatment of breast cancer<a title="Select to navigate to references" href="#cit96"><sup><span class="sup_ref">96</span></sup></a> and ophthalmic disease.<a title="Select to navigate to references" href="#cit97"><sup><span class="sup_ref">97</span></sup></a><br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr4"><img alt="ugraphic, filename = b915149b-u4.gif" src="/image/article/2011/CS/b915149b/b915149b-u4.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr4"/><span id="ugr4"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect586"><span class="b_heading">E.5 Padoporfin and padeliporfin</span></h3>
        <span>Padoporfin <strong>5</strong><a title="Select to navigate to reference" href="#cit98"><sup><span class="sup_ref">98–100</span></sup></a>(WST-09, Tookad®) and padeliporfin <strong>6</strong> (WST-11, Stakel®) are palladium bacteriopheophorbide photosensitizers. Padoporfin is a lipophillic photosensitizer, and so needs a carrier (<span class="italic">e.g.</span> cremaphor) in order to be given as an intravenous infusion; padeliporfin is water-based, and does not need a carrier to be given intravenously. Padoporfin was the first of this family of photosensitizers to be used in prostate clinical studies, and padeliporfin, which was developed later, is now being investigated for the same indication. Both are vascular-acting photosensitizers. Padoporfin is administered by a 20 min continuous venous infusion. Delivery of the activating light begins within a few minutes of starting the infusion. Extensive skin testing has shown that no skin phototoxicity occurs 3 h after the procedure, and that patients could be treated in the ambulatory care setting.<a title="Select to navigate to references" href="#cit101"><sup><span class="sup_ref">101</span></sup></a> The first padoporfin trial included 28 Canadian patients who had recurrent prostate cancer following radiation therapy. A <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> dose of 2 mg/kg was shown to be most effective. Response was assessed one week after treatment by dynamic gadolinium-enhanced MRI, and by biopsy and further MRI at 6 months post-treatment. In patients who received at least the threshold light dose, 60% were complete responders—that is, the one-week MRI showed extensive avascular areas, and the 6-month biopsy did not show any evidence of residual cancer. Two patients developed rectourethral fistulae, one of which healed spontaneously, and the other one was still causing intermittent problems at 6 months post-PDT. Other irregular and extraprostatic treatment effect was also reported. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr5"><img alt="ugraphic, filename = b915149b-u5.gif" src="/image/article/2011/CS/b915149b/b915149b-u5.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr5"/><span id="ugr5"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
        <p class="otherpara">Initial work with padoporfin has been carried out in Europe in men who have not received any other treatment for prostate cancer, and who are suitable candidates for active surveillance. Preliminary results from this study have shown that it is possible to create ablative lesions within the prostate that show good conformation to the prostate boundaries, and that vary dependent on light dose.<a title="Select to navigate to references" href="#cit102"><sup><span class="sup_ref">102</span></sup></a> This group has gone on to use padeliporfin in their next study with men with previously untreated prostate cancer. Studies have been also published of its use in choroidal vessel occlusion in rabbits and rats, and in a melanoma tumor model.<a title="Select to navigate to references" href="#cit103"><sup><span class="sup_ref">103</span></sup></a></p>
      
      
        
        <h3 id="sect600"><span class="b_heading">E.6 
          Npe<small><sub>6</sub></small></span></h3>
        <span>Npe<small><sub>6</sub></small><strong>7b</strong> (LS11, mono-<span class="small_caps">L</span>-aspartyl chlorine, <span class="TC"><a class="simple" title="Chemspider Compound link for:talaporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.16737134.html">talaporfin</a></span> sodium and laserphyrin) is a chemically pure second generation photosensitizer which has been approved in Japan for treatment of early centrally located lung cancer. It is a hydrophilic <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorin" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorin</a></span>, mainly due to the presence of an aspartyl residue, which is derived from Chl-a.<a title="Select to navigate to reference" href="#cit104"><sup><span class="sup_ref">104,105</span></sup></a> Phase I clinical trials assessing the safety and tolerability of NPe6 in recurrent subcutaneous tumors have also been completed. In all cases, tumor necrosis was observed followed by regression of tumor 24–48 h post-treatment, eventually leading to formation of an eschar over the site of the tumor. A Phase II trial investigating the effect of NPe6-PDT in patients with early superficial SCC of the lung has also been performed. A complete response rate of 84.6% was attained with the 39 lesions treated and, on a per patient basis; a complete response rate of 82.9% was achieved. Minimal skin photosensitivity and pulmonary toxicity were also observed. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr6"><img alt="ugraphic, filename = b915149b-u6.gif" src="/image/article/2011/CS/b915149b/b915149b-u6.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr6"/><span id="ugr6"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
        <p class="otherpara">There was quite-a-bit of controversey over the structure of the title compounds, which was finally assigned as <strong>7b</strong> instead of <strong>7a</strong> reported previously.<a title="Select to navigate to references" href="#cit106"><sup><span class="sup_ref">106</span></sup></a></p>
      
      
        
        <h3 id="sect617"><span class="b_heading">E.6 
          Radachlorin
        </span></h3>
        <span>
          Radachlorin® (RADA-PHARMA Ltd., Russia) is the registered trade mark of a chlorophyll-a derivative. This <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> substance represents an aqueous solution of three <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span>, including sodium chlorin e<small><sub>6</sub></small> (90–95%), sodium chlorin p<small><sub>6</sub></small> (5–7%), and a third <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorin" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorin</a></span> with unknown structure (1–5%). The <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> as a mixture has been reported to be stable in aqueous solution by the authors.<a title="Select to navigate to references" href="#cit107"><sup><span class="sup_ref">107</span></sup></a>Radachlorin is in clinical trials for several cancer indications in Russia. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr7"><img alt="ugraphic, filename = b915149b-u7.gif" src="/image/article/2011/CS/b915149b/b915149b-u7.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr7"/><span id="ugr7"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect629"><span class="b_heading">E.7 Purlytin</span></h3>
        <span>Purlytin <strong>10</strong> (Tin ethyl etiopurpurin, also called)<a title="Select to navigate to references" href="#cit108"><sup><span class="sup_ref">108</span></sup></a> is a second generation photosensitizer which has shown significant potential in Phase I/II studies in the treatment of metastatic breast adenocarcinoma, basal cell carcinoma (BCC) and Kaposi's sarcoma in patients with acquired immunodeficiency syndrome.<a title="Select to navigate to references" href="#cit109"><sup><span class="sup_ref">109</span></sup></a> The application of SnET2 in the treatment of prostate cancer in a canine model has been assessed. Significant amounts of SnET2 were found to be retained within the prostate up to 168 h postadministration. The greatest volume <span class="CH"><a class="simple" title="Molecular Process Ontology link for: reduction" href="javascript:popupOBO('MOP:0000569','b915149b')">reduction</a></span> of prostate tumor (60%) was observed using multiple diffusers for transperineal interstitial light delivery compared with transurethral and transperineal illumination (52%). Studies have assessed the efficacy of tin ethyl etiopurpurin in a single patient suffering from BCC with 13 lesions in total. A complete response was observed in the patient treated with Purlytin-PDT, with the effect maintained up to 6 months post-treatment.<br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr8"><img alt="ugraphic, filename = b915149b-u8.gif" src="/image/article/2011/CS/b915149b/b915149b-u8.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr8"/><span id="ugr8"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect638"><span class="b_heading">E.8 
          <span class="CH"><a class="simple" title="ChEBI Ontology link for: Phthalocyanines" href="javascript:popupOBO('CHEBI:51580','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51580')">Phthalocyanines</a></span>
        </span></h3>
        <span>
          <span class="CH"><a class="simple" title="ChEBI Ontology link for: Phthalocyanines" href="javascript:popupOBO('CHEBI:51580','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51580')">Phthalocyanines</a></span> (Pc) are a group of second generation photosensitizers which are structurally related to <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrins</a></span>. The first known appearance of the blue colored pigment was observed by Braun and Tcherniac in 1907; however, it was not until 1933 that the structure of Pc was elucidated. There are numerous commercial uses associated with Pc in the textile, photography and electrical industries, which have been broadly published over the years; however, Pc have attracted attention over the last number of decades in the area of PDT due to their optimal photophysical and photochemical properties. Pc exhibit strong absorption bands at 670–770 nm in the red region of the spectrum and the presence of an appropriate central atom, such as zinc, aluminium or silicon, yields high singlet oxygen production with long-lived triplet states. Thus far, studies using the silicon phthalocyanine photosensitizer Pc4 both in vitro and <span class="italic">in vivo</span> are promising and certainly warrant further assessment. Clinical evaluation of Pc4 has been assessed in cutaneous and subcutaneous lesions from diverse solid tumor origins.<a title="Select to navigate to reference" href="#cit110"><sup><span class="sup_ref">110,111</span></sup></a><br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr9"><img alt="ugraphic, filename = b915149b-u9.gif" src="/image/article/2011/CS/b915149b/b915149b-u9.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr9"/><span id="ugr9"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
        <p class="otherpara">A Phase I clinical trial of topically applied Pc4 <strong>11</strong> for treatment of mycosis fungoides, the most common form of cutaneous T-cell lymphoma is currently ongoing.</p>
      
      
        
        <h3 id="sect650"><span class="b_heading">E.9 Verteporfin</span></h3>
        <span><span class="TC"><a class="simple" title="Chemspider Compound link for:Verteporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482080.html">Verteporfin</a></span> <strong>12</strong> (BPD-MA, benzoporphyrin derivative monoacid ring A) was synthesized in the mid-1980s with an intention of cancer treatment. However, it has been used primarily for ocular PDT and approved for age-related macular degeneration (AMD) worldwide since 2000. <span class="TC"><a class="simple" title="Chemspider Compound link for:Verteporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482080.html">Verteporfin</a></span> in photodynamic therapy involves intravenous administration of Visudyne® (<span class="TC"><a class="simple" title="Chemspider Compound link for:verteporfin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482080.html">verteporfin</a></span>) followed by <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: activation" href="javascript:popupOBO('CMO:0002196','b915149b')">activation</a></span> through an ophthalmoscope equipped with a 690 nm diode laser while the photosensitizer is still in the general circulation. Several well designed clinical studies in North America and Europe showed that AMD patients treated with verteporfin-PDT were more likely to experience stabilized vision than those given a placebo.<a title="Select to navigate to references" href="#cit112"><sup><span class="sup_ref">112</span></sup></a> <span class="CH"><a class="simple" title="ChEBI Ontology link for: Verteporfin" href="javascript:popupOBO('CHEBI:32293','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=32293')">Verteporfin</a></span> therapy should be considered as a first-line therapy in these difficult-to-manage conditions such as subfoveal choroidal neovascularisation secondary to AMD, pathological myopia or presumed ocular histoplasmosis syndrome.<br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr10"><img alt="ugraphic, filename = b915149b-u10.gif" src="/image/article/2011/CS/b915149b/b915149b-u10.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr10"/><span id="ugr10"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect662"><span class="b_heading">E.10 Photosensitizer derived from pyropheo- phorbide-a (alkyl ether analogs)</span></h3>
        <span>The RPCI group was the first to use the concept of structure–activity relationship (SAR) and quantitative structure–activity relationship (QSAR) in developing effective PDT agents. An initial study was performed in the pyropheophorbide-a series. In brief, <span class="italic">Pandey et al.</span><a title="Select to navigate to references" href="#cit113"><sup><span class="sup_ref">113</span></sup></a> synthesized and evaluated a series of the alkyl ether derivatives of pyropheophorbide <strong>13</strong> (derived from chlorophyll-a) with variable lipophilicity. The study indicated that overall lipophilicity of the molecule played an important role in biological efficacy. The results from the <span class="italic">in vivo</span> quantitative structure–activity relationship (QSAR) study<a title="Select to navigate to references" href="#cit114"><sup><span class="sup_ref">114</span></sup></a> displayed a parabolic relationship in that there was a minimal PDT response with analogs of Log <span class="italic">P</span> ≤ 5, with activity peaking between Log <span class="italic">P</span> of 5.5–6.0 and then eventually decreasing at Log <span class="italic">P</span> ≥ 6. In summary, the <span class="italic">in vivo</span> photosensitizing efficacy was optimal for the hexyl ether analog (C6). Currently, the hexyl ether analog <strong>14</strong>, HPPH (λ<small><sub>max</sub></small> = 665 nm), is progressing through Phase I/II human clinical trials for BCC, obstructive esophageal, head and neck cancers and Barrett's esophagus with high grade dysplasia.<a title="Select to navigate to references" href="#cit115"><sup><span class="sup_ref">115</span></sup></a> The early clinical results are promising (see the section Clinical PDT). F.11a. HPPH or Photochlor. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr11"><img alt="ugraphic, filename = b915149b-u11.gif" src="/image/article/2011/CS/b915149b/b915149b-u11.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr11"/><span id="ugr11"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
        <p class="otherpara">HPPH <strong>14</strong> derived from chlorophyll-a is an excellent PDT agent with limited skin phototoxicity.<a title="Select to navigate to reference" href="#cit116"><sup><span class="sup_ref">116,117</span></sup></a> It is currently in advanced clinical trials for various indications: lung, esophagus, including Barrett's and head and neck cancer. The clinical results are excellent. In contrast to to <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span> or Foscan, none of the patients treated with HPPH showed any significant long-term skin phototoxicity. The animal and human clinical data of HPPH-PDT,<a title="Select to navigate to reference" href="#cit118"><sup><span class="sup_ref">118–129</span></sup></a> shows its enormous potential in treating certain types of cancers and are briefly summarized:</p>
        <div>
          
          <span id="sect684"/><span class="c_heading_indent">E.10a Treatment of squamous cell carcinoma. </span>
          <span>In general, PDT has been shown to be effective treatment modality for surface-oriented neoplasms of the skin, esophageal, gastro- intestinal, and urogenital systems. Magne <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit126"><sup><span class="sup_ref">126</span></sup></a> at U.C. Davis investigated the use of HPPH <strong>14</strong> in the treatment of squamous cell carcinomas of the feline facial skin. Tumors were exposed to the laser light (665 nm) at 24 h post injection of HPPH. Following treatment, tumors were evaluated for complete response rates and local control duration. Complete response rates as well as local control durations were significantly (<span class="italic">p</span>, 0.05) related to stage (<a title="Select to navigate to figure" href="#imgfig6">Fig. 6</a>).</span>
          <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig6"><img alt="Squamous carcinoma treated with HPPH-PDT (Cat)." src="/image/article/2011/CS/b915149b/b915149b-f6.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 6 </b> <span id="fig6"><span class="graphic_title">Squamous carcinoma treated with HPPH-PDT (Cat).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
          <p class="otherpara">For example complete response was achieved in 100% of the T1 tumors, 56% of T1b tumors and 18% of T2b tumors. One year control rate was 100% for T1a tumor, 53% for T1b tumors. Clinical, hematological and biochemical evidence of toxicity was not seen in any cat following <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> administration. HPPH was also investigated in horses bearing squamous carcinoma in eyelids. In this case, HPPH <strong>14</strong> was formulated in <span class="TC"><a class="simple" title="Chemspider Compound link for:DMSO" target="_blank" href="http://www.chemspider.com/Chemical-Structure.659.html">DMSO</a></span> and used topically. Light treatment (665 nm) produced a complete response (<a title="Select to navigate to figure" href="#imgfig7">Fig. 7</a>). Please note that both type of animals were previously treated with radiation and surgery, but showed significant tumor-recurrence.</p>
          <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig7"><img alt="Squamous carcinoma treated with HPPH-PDT (Horse) (Lasers in surgery and Medicine 2006, 5, 445)." src="/image/article/2011/CS/b915149b/b915149b-f7.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 7 </b> <span id="fig7"><span class="graphic_title">Squamous carcinoma treated with HPPH-PDT (Horse) (<span class="italic">Lasers in surgery and Medicine</span> 2006, <span class="bold">5</span>, 445).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        </div>
        <div>
          
          <span id="sect704"/><span class="c_heading_indent">E.10b Treatment of canine tumor. </span>
          <span>Another significant outcome of HPPH-PDT was also observed in a canine tumor. HPPH <strong>14</strong> at a dose of 0.3 mg/kg and 24 h postinjection (light dose: 135J/cm<small><sup>2</sup></small>, 75 mW/cm<small><sup>2</sup></small>) produced 100% tumor cure. (<a title="Select to navigate to figure" href="#imgfig8">Fig. 8</a>).</span>
          <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig8"><img alt="Treatment of canine tumor by HPPH-PDT. The tumors were treated with light at 24 h postinjection." src="/image/article/2011/CS/b915149b/b915149b-f8.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 8 </b> <span id="fig8"><span class="graphic_title">Treatment of canine tumor by HPPH-PDT. The tumors were treated with light at 24 h postinjection.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        </div>
        <div>
          
          <span id="sect714"/><span class="c_heading_indent">E.10c 
            HPPH for treating human cancers (skin, lung, high grade dysplasis in Barrett's esophagus, obstructing esophagus and oral cancers (head and neck). </span>
          <span>Central airway obstruction is a common complication of lung cancer, and local failure with endobronchial recurrence is frequently seen in patients who have been previously treated with radiotherapy or chemotherapy. While PDT with FDA approved <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span> is a highly effective treatment modality, the persistence of <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span> in skin necessitates complete protection from sunlight and other sources of bright light for periods typically 30 to 60 days. However, certain 2nd and 3rd generation photosensitizers including HPPH show minimal skin phototoxicity.<a title="Select to navigate to references" href="#cit120"><sup><span class="sup_ref">120</span></sup></a></span>
          <p class="otherpara">
            HPPH
            <strong>14</strong> has been entered into PhaseI/II trials at Roswell Park Cancer Institute for early and late stage lung cancer. INDs were also obtained for treatment of partially obstructing esophageal carcinoma, high grade dysplasia in Barrett's esophagus, and basal cell carcinoma of the skin. Pharmacokinetics studies of 25 patients revealed estimated half-lives of 7.77 h (3.46–17.6 h) and 596 h (120–2951 h), respectively. No <span class="CH"><a class="simple" title="ChEBI Ontology link for: metabolites" href="javascript:popupOBO('CHEBI:25212','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=25212')">metabolites</a></span> were detected in serum. An extensive study of skin phototoxicity in 48 patients with HPPH receiving variable <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> doses and solar simulator light doses has demonstrated that even one day after <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> administration the highest <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> and light doses elicited a response of only erythema without edema. Even these mild responses declined over a few days.</p>
          <p class="otherpara">A total of 16 lung cancer patients have been treated with HPPH-PDT. All patients except one have had complete or partial response and skin phototoxicity has been negligible (<a title="Select to navigate to figure" href="#imgfig9">Fig. 9</a>).</p>
          <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig9"><img alt="Lung tumors (human) treated with HPPH-PDT." src="/image/article/2011/CS/b915149b/b915149b-f9.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 9 </b> <span id="fig9"><span class="graphic_title">Lung tumors (human) treated with HPPH-PDT.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
          <p class="otherpara">Among esophageal cancer patients including Barretts' esophagus or obstructing esophageal carcinoma, the HPPH-PDT response was excellent (<a title="Select to navigate to figure" href="#imgfig10">Fig. 10</a>).</p>
          <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig10"><img alt="Esophageal tumor (human) treated with HPPH-PDT (Lasers in Surgery and Medicine, 2006, 4, 445)." src="/image/article/2011/CS/b915149b/b915149b-f10.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 10 </b> <span id="fig10"><span class="graphic_title">Esophageal tumor (human) treated with HPPH-PDT (<span class="italic">Lasers in Surgery and Medicine</span>, 2006, <span class="bold">4</span>, 445).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
          <p class="otherpara">Another indication where Photofrin-PDT has shown excellent outcome is in head &amp; neck cancer patients, especially in oral cancer. A number of patients with oral cancers are not suitable for most of the current treatment modalities (surgery, chemotherapy or radiation), but Photofrin-PDT has elicited excellent results (<a title="Select to navigate to figure" href="#imgfig11">Fig. 11</a>).</p>
          <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig11"><img alt="Oral cancer treated by photodynamic therapy." src="/image/article/2011/CS/b915149b/b915149b-f11.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 11 </b> <span id="fig11"><span class="graphic_title">Oral cancer treated by photodynamic therapy.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
          <p class="otherpara">At Roswell Park Cancer Institute the treatment of oral-cancer with HPPH-PDT (Phase I/II) is underway and the results are as good as reported by using <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span> as a photosensitizer, but without any significant skin phototoxicity.</p>
        </div>
      
    
    
      
      <h2 id="sect744"><span class="a_heading">F. Photosensitizers (700–800 nm) under advanced preclinical studies</span></h2>
      <span>This part mainly focuses on the description of certain effective long-wavelength photosensitizers<a title="Select to navigate to reference" href="#cit38"><sup><span class="sup_ref">38,130</span></sup></a> derived from methyl pyropheophorbide-a <strong>15</strong>purpurin-18 methyl ester <strong>16</strong>, methyl bacteriopheophorbide-a <strong>17</strong>, methyl bacteriopurpurin <strong>18</strong> and developed at the PDT Center, Roswell Park Cancer Institute, Buffalo. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr12"><img alt="ugraphic, filename = b915149b-u12.gif" src="/image/article/2011/CS/b915149b/b915149b-u12.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr12"/><span id="ugr12"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
        
        <h3 id="sect754"><span class="b_heading">F.1 Photosensitizers derived from <span class="italic">N</span>-substituted purpurinimide (alkyl ether analogs)</span></h3>
        <span>As discussed above, the SAR approach followed in developing effective photosensitizer from a series of alkyl ether analogs of pyropheophorbide-a was extremely useful in selecting the highly effective photosensitizer HPPH. We therefore extended this approach to the <span class="italic">purpurinimide</span> system and synthesized a series of the corresponding alkyl ether analogs with variable carbon units (Log P 5.32–16.44) at two different positions (3-(1<small><sup>1</sup></small>-<span class="italic">O</span>-alkyl) and 13<small><sup>2</sup></small>-<span class="italic">N</span>-alkyl) with long-wavelength absorption near 700 nm (<span class="italic">ε</span><small><sub>max</sub></small> = 45<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>000 in CH<small><sub>2</sub></small>Cl<small><sub>2</sub></small>) and efficient <small><sup>1</sup></small>O<small><sub>2</sub></small> generation (57–60%).<a title="Select to navigate to references" href="#cit131"><sup><span class="sup_ref">131</span></sup></a> Interestingly in this series, in contrast to the alkyl ether of pyropheophorbide-a, which showed a parabolic relationship between the log <span class="italic">P</span> value and PDT efficacy, the purpurinimide analogs demonstrated a linear relationship. These data suggest that overall lipophilicity (log <span class="italic">P</span>) could be an important property in selecting the best candidate in a particular series, but the use of these values in designing photosensitizers with another system may not be beneficial. We extended this approach in synthesizing certain fluorinated analogs in which the alkyl ether side chain was replaced with trifluoromethyl benzyl ether groups. Among these photosensitizers, compared to non fluorinated analogs, the corresponding fluorinated derivatives showed improved PDT efficacy.<a title="Select to navigate to references" href="#cit132"><sup><span class="sup_ref">132</span></sup></a> However, in the purpurinimide series, a photosensitizer <strong>19</strong> containing the <span class="italic">N</span>-butyl and <span class="italic">O</span>-butyl side chains is currently being evaluated for toxicological studies and was selected on the basis of its <span class="italic">in vivo</span> PDT efficacy and ease of synthesis.<br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr13"><img alt="ugraphic, filename = b915149b-u13.gif" src="/image/article/2011/CS/b915149b/b915149b-u13.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr13"/><span id="ugr13"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect779"><span class="b_heading">F.2 Photosensitizers derived from <span class="italic">N</span>-Substituted bacteriourpurinimide (alkyl ether analogs)</span></h3>
        <span>
          <span class="CH"><a class="simple" title="ChEBI Ontology link for: Bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">Bacteriochlorins</a></span> are a class of <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrins</a></span> in which two <span class="TC"><a class="simple" title="Chemspider Compound link for:pyrrole" target="_blank" href="http://www.chemspider.com/Chemical-Structure.7736.html">pyrrole</a></span> rings diagonal to each other are reduced. Such systems exhibit long-wavelength absorption in the range of 720–800 nm depending upon the nature of substituents and the fused aromatic ring present at the peripheral positions. Pandey and coworkers<a title="Select to navigate to reference" href="#cit133"><sup><span class="sup_ref">133,134</span></sup></a> converted the bacteriochlorophyll-a (isolated from <span class="italic">Rb</span><span class="italic">. sphaeroides</span>) to a series of <span class="italic">N</span>-substituted bacteriopurpurin imides <strong>20</strong> in a sequence of reactions. The <span class="CH"><a class="simple" title="ChEBI Ontology link for: acetyl" href="javascript:popupOBO('CHEBI:40574','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=40574')">acetyl</a></span>-group present at position-3 was then replaced with a variety of substituents. Among the compounds investigated so far the methyl 3-(1′-butyloxyethyl)-3-deacetyl-bacteriopurpurin-18-<span class="italic">N</span>-butylimide was found to be most effective in various tumor models at 24 h post treatment. The toxicological studies of this compound are currently in progress. Interestingly, in this series similar to the purpurinimide system, a direct relationship between PDT efficacy and overall lipophilicity was observed. This could be due to similar structural features between the two systems.<br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr14"><img alt="ugraphic, filename = b915149b-u14.gif" src="/image/article/2011/CS/b915149b/b915149b-u14.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr14"/><span id="ugr14"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
      
      
        
        <h3 id="sect795"><span class="b_heading">F.3 Photophysical characteristics of highly effective photosensitizers selected from pyropheo phorbide-a, purpurinimides and bacteriopur purinimides</span></h3>
        <span>Photosensitizers derived from chlorophyll-a and bacteriochlorophyll-a produce their long-wavelength absorptions <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span> developed at RPCI, Buffalo in the range of 660 to 800 nm. For example, the hexyl ether derivative of pyropheophorbide-a (HPPH <strong>14</strong>) shows the long-wavelength absorption at 660 nm (<span class="italic">in vitro</span>). Replacing the five member iso-cyclic ring with a fused a six member imide ring system gives a significant red-shift (40 nm) and shows a strong peak at 700 nm. Interestingly, a similar system in which instead of only ring-D, both ring-B and ring-D are reduced (diagonal to each other) a further red-shift in the electronic absorption spectrum was observed, exhibiting the long-wavelength absorption near 800 nm. This example illustrates a very simple and well designed SAR approach for the development of highly effective long wavelength photosensitizers.<a title="Select to navigate to references" href="#cit135"><sup><span class="sup_ref">135</span></sup></a> See <a title="Select to navigate to figure" href="#imgfig12">Fig. 12</a>.</span>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig12"><img alt="&#xA;            Electronic absorption spectra of long-wavelength photosensitizers (in CH2Cl2) related to chlorins and bacteriochlorins developed at RPCI, Buffalo." src="/image/article/2011/CS/b915149b/b915149b-f12.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 12 </b> <span id="fig12"><span class="graphic_title">
            <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: Electronic absorption spectra" href="javascript:popupOBO('CMO:0000799','b915149b')">Electronic absorption spectra</a></span> of long-wavelength photosensitizers (in CH<small><sub>2</sub></small>Cl<small><sub>2</sub></small>) related to <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span> and <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span> developed at RPCI, Buffalo.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        <p class="otherpara">Unlike naturally occurring <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorophylls" href="javascript:popupOBO('CHEBI:38201','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=38201')">bacteriochlorophylls</a></span>, the modified analogs are quite stable and show high singlet oxygen producing efficiency in the range of 45–50%.</p>
      
      
        
        <h3 id="sect813"><span class="b_heading">F.4 Structural modifications of pyropheo phorbide chlorin <span class="italic">e</span><small><sub>6</sub></small>, chlorin<span class="italic">p</span><small><sub><span class="italic">6</span></sub></small> and purpurinimide systems</span></h3>
        <span>During the last 15 years several new classes of <span class="TC"><a class="simple" title="Chemspider Compound link for:porphyrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10447586.html">porphyrin</a></span> based photosensitizers related to benzochlorin, benzoporphyrin derivatives and <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span> have been evaluated for PDT efficacy. Some of these compounds were found to be quite effective in both <span class="italic">in vitro</span> and <span class="italic">in vivo</span> models. Here a brief summary on the synthesis of such analogs mainly derived from methyl pyropheophorbide-a (a chlorophyll-a analog) is presented.</span>
        <div>
          
          <span id="sect826"/><span class="c_heading_indent">F.4a Benzochlorins. </span>
          <span>The reduced ring-D in <span class="CH"><a class="simple" title="ChEBI Ontology link for: methyl" href="javascript:popupOBO('CHEBI:32875','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=32875')">methyl</a></span> pyrophrophorbide-a was converted into the corresponding Ni(<span class="small_caps">II</span>) derivative, which on <span class="CH"><a class="simple" title="Molecular Process Ontology link for: hydrogenation" href="javascript:popupOBO('MOP:0000589','b915149b')">hydrogenation</a></span> produced Ni(<span class="small_caps">II</span>) mesopyropheophorbide-a <strong>21</strong>. This product on subsequent Vilsmeier <span class="CH"><a class="simple" title="Molecular Process Ontology link for: formylation" href="javascript:popupOBO('MOP:0000003','b915149b')">formylation</a></span> with dimethyl aminoacrolein and <span class="TC"><a class="simple" title="Chemspider Compound link for:phosphorous oxychloride" target="_blank" href="http://www.chemspider.com/Chemical-Structure.23198.html">phosphorous oxychloride</a></span> gave the 20-(2-formylvinyl) derivative <strong>21a</strong>. Reaction of this intermediate under acidic conditions and subsequent treatment with DDQ yielded the desired benzochlorin derivative <strong>22</strong>.<a title="Select to navigate to references" href="#cit136"><sup><span class="sup_ref">136</span></sup></a> In both <span class="italic">in vitro</span> and animal models this compound showed photosensitizing activity, but compared to HPPH <strong>14</strong> it was less active.<br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr15"><img alt="ugraphic, filename = b915149b-u15.gif" src="/image/article/2011/CS/b915149b/b915149b-u15.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr15"/><span id="ugr15"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
        </div>
        <div>
          
          <span id="sect844"/><span class="c_heading_indent">F.4b 
            Benzoporphyrin and benzobacteriochlorin derivatives. </span>
          <span>
            Benzoporphyrin was initially prepared by Johnson <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit137"><sup><span class="sup_ref">137</span></sup></a> on reacting propotoporphyrin IX dimethyl ester with <span class="TC"><a class="simple" title="Chemspider Compound link for:dimethylacetylenedicarboxylate" target="_blank" href="http://www.chemspider.com/Chemical-Structure.12440.html">dimethylacetylenedicarboxylate</a></span> under Diels Alder reaction conditions. By following a similar methodology, a series of pyropheophorbide-a analogs related to <strong>24</strong> were synthesized by Pandey and Smith <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit138"><sup><span class="sup_ref">138</span></sup></a><br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr16"><img alt="ugraphic, filename = b915149b-u16.gif" src="/image/article/2011/CS/b915149b/b915149b-u16.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr16"/><span id="ugr16"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
          <p class="otherpara">Pandey <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit139"><sup><span class="sup_ref">139</span></sup></a> also extended this approach for the construction of <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorin" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorin</a></span> <strong>26</strong> from 8-vinyl mesopyro pheophorbide-a <strong>25</strong>, which was obtained in a sequence of reactions from methyl pheophorbide-a <strong>23</strong>.</p>
        </div>
        <div>
          
          <span id="sect864"/><span class="c_heading_indent">F.4c Ketobacteriochlorins. </span>
          <span>Porphyins on reacting with <span class="TC"><a class="simple" title="Chemspider Compound link for:osmium tetroxide" target="_blank" href="http://www.chemspider.com/Chemical-Structure.28158.html">osmium tetroxide</a></span> produce <span class="CH"><a class="simple" title="ChEBI Ontology link for: diols" href="javascript:popupOBO('CHEBI:23824','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23824')">diols</a></span> or <span class="CH"><a class="simple" title="ChEBI Ontology link for: triols" href="javascript:popupOBO('CHEBI:27136','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=27136')">triols</a></span>, which on following Pinacol–Pinacolone reaction conditions generate the corresponding ketochlorins or <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span>. Pandey <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit140"><sup><span class="sup_ref">140</span></sup></a> used this approach in pyropheophorbide-a <strong>15</strong> and other chlorin systems resulting into the corresponding ketobacteriochlorins <strong>27</strong> and <strong>28</strong>. The nature and position of the substituents present at the peripheral position(s) exhibited a remarkable difference in long wavelength absorption of the resulting <span class="CH"><a class="simple" title="ChEBI Ontology link for: chromophores" href="javascript:popupOBO('CHEBI:23240','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23240')">chromophores</a></span>.<br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr17"><img alt="ugraphic, filename = b915149b-u17.gif" src="/image/article/2011/CS/b915149b/b915149b-u17.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr17"/><span id="ugr17"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
        </div>
        <div>
          
          <span id="sect879"/><span class="c_heading_indent">F.4d Regioselective synthesis of ring-B<span class="italic">vs.</span> ring-D <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span>. </span>
          <span>
            <span class="CH"><a class="simple" title="Molecular Process Ontology link for: Oxidation" href="javascript:popupOBO('MOP:0000568','b915149b')">Oxidation</a></span> of <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span>, <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorins" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorins</a></span> and their stability under <span class="italic">in vitro</span> and <span class="italic">in vivo</span> conditions has been a subject of discussion for a long time. Several oxidizing agents have been used to oxidize the <span class="CH"><a class="simple" title="ChEBI Ontology link for: pyrrole" href="javascript:popupOBO('CHEBI:26455','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26455')">pyrrole</a></span>-ring reduced system. To understand the biological efficacy of ring-B<span class="italic">vs.</span>ring-D reduced chlorophyll-a analogs in PDT efficacy, Pandey and coworkers<a title="Select to navigate to references" href="#cit141"><sup><span class="sup_ref">141</span></sup></a> have reported a highly effective FeCl<small><sub>3</sub></small> mediated oxidation of a certain <span class="CH"><a class="simple" title="ChEBI Ontology link for: bacteriochlorin" href="javascript:popupOBO('CHEBI:52581','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52581')">bacteriochlorin</a></span> analog to produce ring-B reduced <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span>. Interestingly, both ring-B and ring-D reduced <span class="CH"><a class="simple" title="ChEBI Ontology link for: chlorins" href="javascript:popupOBO('CHEBI:33910','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33910')">chlorins</a></span> (<strong>29</strong> and <strong>30</strong>, respectively) derived by FeCl<small><sub>3</sub></small> and DDQ mediated oxidation showed mitochondrial localization and similar <span class="italic">in vivo</span> PDT efficacy (BALB/c mice bearing Colon26 tumors).<br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr18"><img alt="ugraphic, filename = b915149b-u18.gif" src="/image/article/2011/CS/b915149b/b915149b-u18.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr18"/><span id="ugr18"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
        </div>
        <div>
          
          <span id="sect902"/><span class="c_heading_indent">F.4e Target-specific photosensitizers. </span>
          <span>Since the approval of <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span>®, efforts are underway in various laboratories to develop target-specific photosensitizers, but with limited success. Attempts have been made to target photosensitizers to known cellular targets by creating photosensitizer conjugates, where the non-porphyrin molecule is a <span class="CH"><a class="simple" title="ChEBI Ontology link for: ligand" href="javascript:popupOBO('CHEBI:52214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52214')">ligand</a></span> that is specific for targeting the tumor (<span class="italic">e.g.</span>cholesterol, certain chemotherapeutic <span class="CH"><a class="simple" title="ChEBI Ontology link for: drugs" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drugs</a></span>, DNA intercalators<span class="italic">etc.</span>).<a title="Select to navigate to references" href="#cit38"><sup><span class="sup_ref">38</span></sup></a>Conjugation of certain <span class="CH"><a class="simple" title="ChEBI Ontology link for: peptides" href="javascript:popupOBO('CHEBI:16670','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=16670')">peptides</a></span> and monoclonal antibody conjugates showed promising activity <span class="italic">in vitro</span> with limited <span class="italic">in vivo</span> target-specificity.<a title="Select to navigate to references" href="#cit142"><sup><span class="sup_ref">142</span></sup></a> However, cRGD <span class="CH"><a class="simple" title="ChEBI Ontology link for: peptide" href="javascript:popupOBO('CHEBI:16670','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=16670')">peptide</a></span>, a most common integrin binding motif having the sequence of <span class="TC"><a class="simple" title="Chemspider Compound link for:Arg-Gly-Asp" target="_blank" href="http://www.chemspider.com/Chemical-Structure.2575945.html">Arg-Gly-Asp</a></span> (RGD) and <span class="CH"><a class="simple" title="ChEBI Ontology link for: carbohydrate" href="javascript:popupOBO('CHEBI:16646','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=16646')">carbohydrate</a></span> conjugates (<strong>31</strong> and <strong>32</strong>) have shown promising photosensitizing activity both <span class="italic">in vitro</span> and <span class="italic">in vivo</span> models. Starting from pyropheophorbide-a and <span class="italic">N</span>-substituted purpurinimides, Pandey <span class="italic">et al.</span> have prepared a series of photosensitizers in which the targeting groups (carbohydrate,<a title="Select to navigate to references" href="#cit143"><sup><span class="sup_ref">143</span></sup></a>cRGD<a title="Select to navigate to references" href="#cit144"><sup><span class="sup_ref">144</span></sup></a> or <span class="TC"><a class="simple" title="Chemspider Compound link for:folic acid" target="_blank" href="http://www.chemspider.com/Chemical-Structure.5815.html">folic acid</a></span><a title="Select to navigate to references" href="#cit144"><sup><span class="sup_ref">144</span></sup></a> moieties) were introduced at variable peripheral position(s) of the parent molecules. Interestingly, the position of the substitent(s) made a significant difference in target-specificity. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr19"><img alt="ugraphic, filename = b915149b-u19.gif" src="/image/article/2011/CS/b915149b/b915149b-u19.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr19"/><span id="ugr19"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
          <p class="otherpara">During the last 15 years, the RPCI group synthesized and evaluated a series of PDT and imaging agents following the both active and passive approaches of <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> development and <span class="italic">the observed findings can be summarized as follows</span>:</p>
          <p class="otherpara">(a) Compared to the active, the passive approach based on SAR/QSAR studies was found to be more useful in identifying the improved PDT and PDT/imaging agents.</p>
          <p class="otherpara">(b) The overall lipophilicity established in one series of compounds for identifying the most effective candidate could not be translated to other series of compounds. For example, the alkyl ether analogs of pyropheophorbide-a showed a parabolic relationship between the PDT efficacy and partition coefficient values and the compounds with log <span class="italic">P</span> values in the range of 5.5–6.00 produced the best efficacy. In contrast, the alkyl ether analogs of purpurinimide and bacteriopurpurprinimide showed a linear relationship between the lipophilicity and PDT efficacy. The log <span class="italic">P</span> value of the most effective candidates were in the range of 10.5–12.5 (determined by the PALLAS program). The extremely hydrophobic compounds were difficult to purify. Therefore, in these series of compounds, the most effective candidate was selected not only on the basis of best efficacy, but also the ease of synthesis.</p>
          <p class="otherpara">(c) Presence of central metal (<span class="italic">e.g.</span> In, Ga, Pd and Zn) showed a remarkable enhancement in singlet oxygen yields and PDT efficacy is certain photosensitizers.</p>
          <p class="otherpara">(d) Aggregation is another factor which seems to play an important role in altering the photophysical properties of the photosensitizers and should be considered an important factor in designing effective PDT agents.</p>
          <p class="otherpara">(e) Most of the effective photosensitizers in pyropheophorbide series (<span class="italic">e.g.</span> HPPH) showed mitochondrial localization. However, the effective photosensitizers related to purpurinimide and bacteriopurpurinimides showed both mitochondrial and lysosomal localization. Interestingly, some of the highly effective carbohydrate analogs were mainly localized lysosomes.</p>
          <p class="otherpara">(f) Depending on the nature of photosensitizer(s), the mechanism of tumor-uptake (cell-uptake) of the photosensitizer was determined to be either <span class="italic">via</span> simple diffusion or endocytosis.</p>
          <p class="otherpara">(g) Varying the lipophilicity makes a remarkable difference in pharmacokinetic and pharmacodynamic properties of the molecule and it could also play an important role in tumor uptake and biodistribution of the photosensitizer.</p>
          <p class="otherpara">(h) Vascular shutdown seems to be an important factor for the destruction of tumor by PDT.</p>
          <p class="otherpara">(i) In PDT, both apoptotic and necrotic mechanisms play important role in cell death.</p>
          <p class="otherpara">(j) In pyrppheophorbide-a series, the HPPH was found to be a substrate for ABCG-2 (ATP–binding Cassette, Sub-Family G, Member 2) In contrast, the corresponding <span class="CH"><a class="simple" title="ChEBI Ontology link for: carbohydrate" href="javascript:popupOBO('CHEBI:16646','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=16646')">carbohydrate</a></span> analogs (<span class="TC"><a class="simple" title="Chemspider Compound link for:glucose" target="_blank" href="http://www.chemspider.com/Chemical-Structure.9484839.html">glucose</a></span> and <span class="CH"><a class="simple" title="ChEBI Ontology link for: galactose" href="javascript:popupOBO('CHEBI:28260','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28260')">galactose</a></span> derivatives) as well as the In(<span class="small_caps">III</span>)-HPPH were not the substrate for ABCG-2, and thus do not pump out quickly from tumor cells. This ould be one of the reasons for their higher efficacy than HPPH, which pumps out quickly.</p>
          <p class="otherpara">(k) Recent results suggest that STAT-3 (Signal Transducer and Activator of Transcription-3) dimerization could be a useful <span class="CH"><a class="simple" title="ChEBI Ontology link for: biomarker" href="javascript:popupOBO('CHEBI:59163','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=59163')">biomarker</a></span> to monitor the PDT response <span class="italic">in vivo</span>.</p>
          <p class="otherpara">(l) Naturally occurring Chlorophyll-a and bacterio chlorophyll-a moities provide unique opportunities for developing effective agents with long wavelength absorption in the range of 660–800 nm.</p>
          <p class="otherpara">(m) In general, photosensitizers containing the hydrophobic group(s) on one side of the molecule and hydrophilic substituent(s) on the opposite side of molecule were found to be more effective than those in which these substituents were introduced all over the molecule.</p>
          <p class="otherpara">(n) Tumor-avid <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrin</a></span>-based compounds can be used as vehicles for delivering the desired imaging moiety to tumors. These “multifunctional” agents could be extremely useful for a “See and theTreat” approach.</p>
        </div>
      
    
    
      
      <h2 id="sect959"><span class="a_heading">G. Activatable photosensitizers</span></h2>
      <span>Another approach for designing improved photosensitizers with increased tumor-specificity is to take advantage of lesion-specific expression of enzymes such as proteases. Weissleder and Ntziachristos<a title="Select to navigate to references" href="#cit145"><sup><span class="sup_ref">145</span></sup></a> were the first to use this approach in developing multifunctional agents, which is currently being used in various laboratories not limited to PDT. Zheng <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit146"><sup><span class="sup_ref">146</span></sup></a> reported the utility of this approach in developing a photodynamic molecular beacon as an activator photosensitizer <strong>33</strong> (derived from methyl pyropheoporphide-a <strong>15</strong>) based on protease-controlled singlet oxygen quenching and <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: activation" href="javascript:popupOBO('CMO:0002196','b915149b')">activation</a></span>. In this report the authors describe the synthesis and characterization of an MMP7-triggered photodynamic molecular beacon using pyropheophorbide-a as the photosensitizer, another molecule as a dual fluorescence and singlet oxygen quencher, and a short <span class="CH"><a class="simple" title="ChEBI Ontology link for: peptide" href="javascript:popupOBO('CHEBI:16670','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=16670')">peptide</a></span> sequence as the MM7 cleavable linker, with the cleavage site between G and L aminoacids. However, no <span class="italic">in vivo</span> photosensitizing data of the conjugate are reported. <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgugr20"><img alt="ugraphic, filename = b915149b-u20.gif" src="/image/article/2011/CS/b915149b/b915149b-u20.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td><a id="ugr20"/><span id="ugr20"/></td><td class="pushTitleLeft"> </td></tr></table></div></span>
    
    
      
      <h2 id="sect972"><span class="a_heading">H. Utility of tumor-avid photosensitizer (HPPH) in developing “Multifunctional Agents” for tumor imaging and therapy (Theronostics)</span></h2>
      <span>The diagnosis of various diseases including cancer at its initial stages is of continued interest and quite challenging. In general, pathology provides the most widely used clinical method for elucidating chemical information from diseased tissues. Traditional techniques of histology can be used to probe the microscopic structural alternations of diseased tissue. Utilizing histological stains, many of the corresponding chemical alternations accompanying disease can be mapped on a microscopic scale.<a title="Select to navigate to reference" href="#cit147"><sup><span class="sup_ref">147,148</span></sup></a> The main disadvantage of these techniques is that they can only be applied <span class="italic">in vitro</span>, necessitating the removal of tissue. It implies that, using histological techniques, only small areas of tissue, accessible either to biopsy forceps or needles, can be sampled. A more useful diagnostic technique would combine the advantages of pathological, radiological and nuclear (PET/SPECT) methods, allowing for real time imaging of tissue <span class="italic">in vivo</span> to extract diagnostically relevant structural and histological information.<a title="Select to navigate to references" href="#cit149"><sup><span class="sup_ref">149</span></sup></a> Currently several noninvasive standard clinical diagnostic modalities, <span class="italic">e.g.</span>, magnetic resonance imaging (MRI),<a title="Select to navigate to references" href="#cit150"><sup><span class="sup_ref">150</span></sup></a> computed tomography (CT),<a title="Select to navigate to references" href="#cit151"><sup><span class="sup_ref">151</span></sup></a><span class="CH"><a class="simple" title="ChEBI Ontology link for: positron" href="javascript:popupOBO('CHEBI:30225','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30225')">positron</a></span> emission tomography (PET),<a title="Select to navigate to references" href="#cit152"><sup><span class="sup_ref">152</span></sup></a> X-ray, single <span class="CH"><a class="simple" title="ChEBI Ontology link for: photon" href="javascript:popupOBO('CHEBI:30212','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30212')">photon</a></span> emission computed tomography (SPECT)<a title="Select to navigate to references" href="#cit153"><sup><span class="sup_ref">153</span></sup></a> and ultrasound (US)<a title="Select to navigate to references" href="#cit154"><sup><span class="sup_ref">154</span></sup></a> that are used suffer with several major drawbacks resulting in data yielding high resolution anatomic (structural) images of soft tissue but little physiologic (functional) information. The ability to readily provide researchers and clinicians with both structural and functional information during a single examination would significantly advance the field of diagnostics. Considerable progress has been made in the <span class="italic">in vitro</span> and preclinical development of molecular imaging agents. Small molecule imaging agents that can detect specific <span class="CH"><a class="simple" title="ChEBI Ontology link for: proteins" href="javascript:popupOBO('CHEBI:36080','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=36080')">proteins</a></span> or nucleic acids within living human cells, including mutant oncoproteins, have been studied, and some progress has been made in preclinical models. Antibody therapeutics represents a class for where imaging is particularly promising. Cell surface receptors offer opportunities for antibody-mediated target imaging. At the clinical level, the value of molecular imaging has also become important. Target imaging can be extremely helpful in determining the outcome of a particular treatment. Currently, the development of compounds for tumor-imaging and therapy, so-called “multifunctional agents,” is of enormous interest because this provides an opportunity to use a single agent for tumor-imaging and therapy.</span>
      
        
        <h3 id="sect990"><span class="b_heading">H.1 
          PS-Cyanine <span class="CH"><a class="simple" title="ChEBI Ontology link for: dye" href="javascript:popupOBO('CHEBI:37958','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37958')">dye</a></span> conjugates for <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: fluorescence imaging" href="javascript:popupOBO('CMO:0000087','b915149b')">fluorescence imaging</a></span> and PDT</span></h3>
        <span>
          <span class="TC"><a class="simple" title="Chemspider Compound link for:Porphyrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10447586.html">Porphyrin</a></span>-based <span class="CH"><a class="simple" title="ChEBI Ontology link for: photosensitizing agents" href="javascript:popupOBO('CHEBI:47868','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=47868')">photosensitizing agents</a></span> for PDT possess unique advantages due to their ability to be retained in tumors and to produce cytotoxic singlet oxygen upon exposure to an appropriate wavelength of light. In addition to therapy, the fluorescence characteristics of these porphyrins<span class="italic">in vivo</span> have been exploited in very early studies by Policard and others that can be dated back to 1924 for the detection of various early-stage cancers of the lung and bladder, and cancers of other sites.<a title="Select to navigate to references" href="#cit155"><sup><span class="sup_ref">155</span></sup></a> <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span>®, a hematoporphyrin-based photosensitizer, is selectively retained by tumor tissues compared to most normal tissues except for liver, spleen, and kidney. Consequently, the difference in concentration of <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span>® in malignant tissue is the basis of <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: fluorescence imaging" href="javascript:popupOBO('CMO:0000087','b915149b')">fluorescence imaging</a></span>. In an early diagnosis of microscopic lesions in pre-clinical and clinical studies, Mang <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit156"><sup><span class="sup_ref">156</span></sup></a> showed the utility of nontherapeutic <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span>® doses that are 80–90% lower than those used therapeutically, for tumor <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: fluorescence detection" href="javascript:popupOBO('CMO:0001721','b915149b')">fluorescence detection</a></span> of metastatic diseases.</span>
        <p class="otherpara">Unfortunately, Photofrin® and most of the tumor-avid long-wavelength photosensitizers (<span class="italic">e.g.</span>bacteriochlorins) have very small wavelength differences between their NIR absorption and emission bands (Stokes shifts). Such an inherent property limits application of these molecules for NIR tumor-imaging. The <span class="italic">in vivo</span> imaging is preferably performed in the NIR (700-900 nm) because of efficient optical tissue penetration and minimal auto-fluorescence in this spectral region. At NIR wavelengths, light penetrates several centimeters in tissue (however, light penetration also depends on tissue-type) so that the fluorophore can be imaged deep within the body.<a title="Select to navigate to references" href="#cit157"><sup><span class="sup_ref">157</span></sup></a> In recent years, a number of different NIR fluorophores (e.g. <span class="CH"><a class="simple" title="ChEBI Ontology link for: cyanine dyes" href="javascript:popupOBO('CHEBI:37960','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37960')">cyanine dyes</a></span>) have been described.<a title="Select to navigate to references" href="#cit158"><sup><span class="sup_ref">158</span></sup></a> In spite of excellent photophysical properties, most of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: cyanine dyes" href="javascript:popupOBO('CHEBI:37960','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37960')">cyanine dyes</a></span> are not tumor-specific and are eliminated from tissue rapidly. Therefore, efforts are underway in various laboratories to develop tumor-specific optical imaging agents by conjugating these moieties with various target-specific agents.<a title="Select to navigate to reference" href="#cit159"><sup><span class="sup_ref">159–165</span></sup></a> Targeted delivery of long-wavelength emitting fluorophores to tumors is a new and exciting method for cancer diagnosis, intra-operative tumor detection, and for investigations of <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> delivery and tumor physiology. Targeting can be assessed in real time, with high sensitivity and resolution. <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: Fluorescence imaging" href="javascript:popupOBO('CMO:0000087','b915149b')">Fluorescence imaging</a></span> has been extended from <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: microscopy" href="javascript:popupOBO('CMO:0000067','b915149b')">microscopy</a></span> to <span class="italic">in vivo</span> imaging of biological targets and disease.<a title="Select to navigate to references" href="#cit166"><sup><span class="sup_ref">166</span></sup></a><span class="CH"><a class="simple" title="Chemical Methods Ontology link for: Fluorescence imaging" href="javascript:popupOBO('CMO:0000087','b915149b')">Fluorescence imaging</a></span> relies on the properties of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: fluorochromes" href="javascript:popupOBO('CHEBI:51217','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51217')">fluorochromes</a></span> or fluorophores. These particular molecules absorb the energy carried by <span class="CH"><a class="simple" title="ChEBI Ontology link for: photons" href="javascript:popupOBO('CHEBI:30212','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30212')">photons</a></span> in a given band of wavelengths and give back a fraction of this energy by emitting new <span class="CH"><a class="simple" title="ChEBI Ontology link for: photons" href="javascript:popupOBO('CHEBI:30212','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30212')">photons</a></span> in a band of longer wavelengths. Optical contrast agents can provide planar and tomographic images at millimeter to centimeter depth, with millimeter to sub-millimeter resolution and very high sensitivity. For small animals, planar images are adequate, but optical tomographic reconstruction of fluorescence images is becoming feasible.<a title="Select to navigate to references" href="#cit165"><sup><span class="sup_ref">165</span></sup></a> Briefly, NIR optical tomography takes advantage of a “therapeutic window” between 700–900 nm in which tissues exhibit low absorbance, but high scattering capacity. As a result, light in this wavelength regime can scatter through several centimeters of tissues before being extinguished by absorption. The ability to detect diseased tissues with NIR light depends critically on the “optical contrast”, or the consistent differences between the absorption and scattering properties of normal and diseased tissue volumes. The potential clinical advantages of the fluorescence technique include high signal sensitivity, especially if point measurements are used, the suitability in examination of tissue surfaces (compared to the “volume” imaging of most radiological techniques), flexibility in the anatomical sites that can be interpreted with small diameter optical fiber probes, <span class="CH"><a class="simple" title="Molecular Process Ontology link for: reduction" href="javascript:popupOBO('MOP:0000569','b915149b')">reduction</a></span> in the use of random tissue biopsies, and ease of use by clinicians. <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: Fluorescence imaging" href="javascript:popupOBO('CMO:0000087','b915149b')">Fluorescence imaging</a></span> also offers the possibility of associating a given fluorophore with a particular molecule. Thus it is possible to label specifically and simultaneously different targets with different fluorophores that can be easily discriminated on the basis of their emission wavelengths.</p>
        <p class="otherpara">By realizing the importance of <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrin</a></span>-based compounds in tumor-avidity and photosensitizing efficacy and the advantages of the photophysical properties of <span class="CH"><a class="simple" title="ChEBI Ontology link for: cyanine dyes" href="javascript:popupOBO('CHEBI:37960','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37960')">cyanine dyes</a></span>, Pandey and co-workers conjugated a tumor-avid photosensitizer, <span class="italic">e.g.</span>HPPH, which is currently in Phase II multicenter clinical trials, to a <span class="CH"><a class="simple" title="ChEBI Ontology link for: cyanine dye" href="javascript:popupOBO('CHEBI:37960','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37960')">cyanine dye</a></span>.<a title="Select to navigate to reference" href="#cit167"><sup><span class="sup_ref">167,168</span></sup></a> The resulting “bifunctional agent” <strong>34</strong> (<a title="Select to navigate to figure" href="#imgfig13">Fig. 13 and 14</a>) showed both PDT efficacy and tumor-imaging capabilities.</p>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig13"><img alt="&#xA;            HPPH-Cyanine dye conjugate for tumor-imaging (fluorescence) and Therapy (PDT)." src="/image/article/2011/CS/b915149b/b915149b-f13.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 13 </b> <span id="fig13"><span class="graphic_title">
            HPPH-Cyanine <span class="CH"><a class="simple" title="ChEBI Ontology link for: dye" href="javascript:popupOBO('CHEBI:37958','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37958')">dye</a></span> conjugate for tumor-imaging (fluorescence) and Therapy (PDT).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig14"><img alt="Whole body imaging of (A) BALB/c mouse bearing Colon 26 tumors (before PDT) at 24 h post injection of HPPH-CD conjugate 34 (dose: 0.03 μmol/kg). (B) Tumor image at 30 day post-treatment with the same conjugate shows complete tumor response. (Photochem. Photobiol. Sci. 2007, 6, 1257–1267)." src="/image/article/2011/CS/b915149b/b915149b-f14.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 14 </b> <span id="fig14"><span class="graphic_title">Whole body imaging of (A) BALB/c mouse bearing Colon 26 tumors (before PDT) at 24 h post injection of HPPH-CD conjugate <strong>34</strong> (dose: 0.03 μmol/kg). (B) Tumor image at 30 day post-treatment with the same conjugate shows complete tumor response. (<span class="italic">Photochem. Photobiol. Sci.</span> 2007, <span class="bold">6</span>, 1257–1267).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        <p class="otherpara">At a therapeutic/imaging dose the conjugate did not show any significant skin phototoxicity. It was also found to be a promising imaging agent even at low doses. Results of whole body <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: fluorescence imaging" href="javascript:popupOBO('CMO:0000087','b915149b')">fluorescence imaging</a></span> in RIF tumor-bearing C3H mice, with excitation of the fluorescent <span class="CH"><a class="simple" title="ChEBI Ontology link for: cyanine dye" href="javascript:popupOBO('CHEBI:37960','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37960')">cyanine dye</a></span> (780<small><sub>Ex</sub></small> and 865<small><sub>Em</sub></small><span class="italic">in vivo</span>) 24 h post injection are shown in <a title="Select to navigate to figure" href="#imgfig13">Fig. 13</a>. As can been seen even at a dose of 0.03 μmol/kg, which was later found to be 8–10 fold less than the therapeutic dose, the conjugate produced significant tumor imaging capability. Under similar conditions, the unconjugated <span class="CH"><a class="simple" title="ChEBI Ontology link for: cyanine dye" href="javascript:popupOBO('CHEBI:37960','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37960')">cyanine dye</a></span> showed limited tumor-localizing ability. The bifunctional conjugate provides an opportunity to independently select and associate appropriate photosensitizers and fluorophores. For treating large and deeply seated tumors, photosensitizers exhibiting long-wavelengths absorption in the range of 780–800 nm and higher tumor-avidity than HPPH could generate more effective agents.</p>
        <p class="otherpara">Planar imaging (<span class="italic">epi</span>- and <span class="italic">trans</span>-illumination) has gained wide popularity with significant advancements in the field of fluorescence molecular imaging. On the other hand, it suffers from significant drawbacks because fluorescence intensity has a strong non-linear dependence on lesion depth and on the optical properties of the lesion and the surrounding tissues.<a title="Select to navigate to reference" href="#cit169"><sup><span class="sup_ref">169,170</span></sup></a> Therefore, having the same concentration of <span class="CH"><a class="simple" title="ChEBI Ontology link for: fluorochrome" href="javascript:popupOBO('CHEBI:51217','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51217')">fluorochrome</a></span> in tumors with differences in their vascularities and depth will yield different fluorescence intensities. Fluorescence tomography aims at three-dimensional reconstruction of the internal distribution of <span class="CH"><a class="simple" title="ChEBI Ontology link for: fluorochromes" href="javascript:popupOBO('CHEBI:51217','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=51217')">fluorochromes</a></span> in tissues based on light measurements collected at the tissue boundary. Fluorescence tomography not only yields three-dimensional and “deep-tissue” imaging but also offers true quantification of optical contrast. A high resolution (512 × 512 <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: CCD" href="javascript:popupOBO('CMO:0000948','b915149b')">CCD</a></span> pixels) photographic image was obtained to get a structural map of each mouse imaged. This result clearly proved that tumor-avid HPPH-CD accumulated in tumor 24 h post injection. Liver uptake was also significant at this specific time point.<a title="Select to navigate to references" href="#cit171"><sup><span class="sup_ref">171</span></sup></a> Studies are underway to design improved agents with high tumor-avidity and reduced liver-specificity.</p>
      
      
        
        <h3 id="sect1059"><span class="b_heading">H.2 PS-MR contrast agents conjugates for MR imaging and PDT</span></h3>
        <span>Magnetic resonance (MR) imaging has become the method-of-choice for many procedures. Unlike nuclear imaging, conventional radiography, or computed tomography, MR often relies on “contrast-enhancing agents” to improve inherent contrast between normal and diseased tissue. MR signal intensity or signal intensity differences (contrast) are dependent upon longitudinal (1/T<small><sub>1</sub></small>) and transverse relaxation rates (1/T<small><sub>2</sub></small>) of tissue <span class="CH"><a class="simple" title="ChEBI Ontology link for: protons" href="javascript:popupOBO('CHEBI:24636','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=24636')">protons</a></span>. Agents containing paramagnetic ions have been shown to effectively alter 1/T<small><sub>1</sub></small> and/or 1/T<small><sub>2</sub></small> by changing the local magnetic field when they come in close proximity to water <span class="CH"><a class="simple" title="ChEBI Ontology link for: protons" href="javascript:popupOBO('CHEBI:24636','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=24636')">protons</a></span>. The paramagnetic ion most widely used in this regard is gadolinium [Gd(<span class="small_caps">III</span>)] because of its seven unpaired electrons and large paramagnetic moment.<a title="Select to navigate to references" href="#cit172"><sup><span class="sup_ref">172</span></sup></a> The Gd(<span class="small_caps">III</span>)-based contrast agents approved by the United States <span class="CH"><a class="simple" title="ChEBI Ontology link for: Food" href="javascript:popupOBO('CHEBI:33290','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33290')">Food</a></span> and <span class="CH"><a class="simple" title="ChEBI Ontology link for: Drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">Drug</a></span> Administration (FDA) are Magnavist®, Omniscan®, and Prohance®, and all these are carboxylate-containing water-soluble complexes. Typical plasma clearance rates for FDA approved agents are on the order of 15 min or less, thereby limiting the usable time frame for MR data acquisition, which can take between 5–15 min/acquisition. The tumor selectivity of the current contrast enhancing agents is singularly dependent upon perturbations in normal vascular permeability; small foci of metastatic tumor cells, particularly those in minimally enlarged or normal sized lymph nodes, may not be detectable by current methods. However, by selective or nonselective binding of a MR contrast-enhancing agent to a tumor target or by simply slowing <span class="italic">in vivo</span> tumor clearance rates, several improvements can be made.</span>
        <p class="otherpara">The use of tumor-avid <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrins</a></span> in delivering the desired MR imaging agent to tumor has been investigated by a independent studies of Hoffman <span class="italic">et al.</span><a title="Select to navigate to references" href="#cit173"><sup><span class="sup_ref">173</span></sup></a> and Pandey and co-workers.<a title="Select to navigate to references" href="#cit174"><sup><span class="sup_ref">174</span></sup></a> Among these conjugates, gadolinium-based <span class="TC"><a class="simple" title="Chemspider Compound link for:porphyrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10447586.html">porphyrin</a></span> contrast media, particularly gadoporphyrin-2 has been extensively studies and found to be necrosis-avid.<a title="Select to navigate to references" href="#cit175"><sup><span class="sup_ref">175</span></sup></a> Although such compounds may be useful for tumor imaging (5–30% mass is commonly necrotic), a MR agent that targets living tumor cells, particularly those that are actively undergoing metabolic processes, would be superior. As discussed previously, for quite some time Pandey and co-workers have been developing effective photosensitizers by following the SAR and QSAR approaches, which afforded a series of tumor-avid photosensitizers with long wavelength absorption in the range of 660 to 800 nm. Among these compounds HPPH <strong>14</strong> is currently undergoing Phase II clinical trials and shows limited skin phototoxicity. In order to develop a “bifunctional agent” for MR imaging and PDT, Pandey and co-workers initially conjugated HPPH to aminobenzyl-DTPAs with variable lipophilicity, which produced long-term PDT efficacy in mice with enhanced tumor contrast.<a title="Select to navigate to references" href="#cit175"><sup><span class="sup_ref">175</span></sup></a> For investigating the number of gadolinium units for MR imaging, HPPH <strong>14</strong> was conjugated with multiple magnetic resonance imaging (MRI) functional groups by following the methodology depicted in our laboratory.<a title="Select to navigate to references" href="#cit176"><sup><span class="sup_ref">176</span></sup></a> Among these analogs HPPH containing three gadolinium(<span class="small_caps">III</span>)aminobenzyldiethylene triamine pentaacetic acid [Gd(<span class="small_caps">III</span>)ADTPA] <strong>35</strong> (<a title="Select to navigate to figure" href="#imgfig15">Fig. 15</a>) produced the best tumor contrast and PDT efficacy. The <span class="italic">in vivo</span> studies performed in both mice and rat tumor models resulted in a significant MR signal enhancement of tumors relative to surrounding tissues at 24 h post-injection.</p>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig15"><img alt="MR imaging of HPPH-3 Gd(iii)ADTPA conjugate at 24 h postinjection (dose: 10.0 μmol/kg) [Bioconjugate. Chem. 2005, 16, 32–42]." src="/image/article/2011/CS/b915149b/b915149b-f15.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 15 </b> <span id="fig15"><span class="graphic_title">MR imaging of HPPH-3 Gd(<span class="small_caps">III</span>)ADTPA conjugate at 24 h postinjection (dose: 10.0 μmol/kg) [<span class="italic">Bioconjugate. Chem</span>. 2005, <span class="bold">16</span>, 32–42].</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        <p class="otherpara">The <span class="TC"><a class="simple" title="Chemspider Compound link for:water" target="_blank" href="http://www.chemspider.com/Chemical-Structure.937.html">water</a></span> soluble (pH 7.4) HPPH-3Gd(<span class="small_caps">III</span>)amino benzylDTPA conjugate <strong>35</strong> also demonstrated great potential for <span class="italic">in vivo</span>fluorescence imaging.<a title="Select to navigate to references" href="#cit176"><sup><span class="sup_ref">176</span></sup></a> An <span class="italic">in vivo</span> biodistribution study with the corresponding <small><sup>14</sup></small>C-analog also showed a significant tumor-uptake at 24 h post-injection. Toxicological evaluations of the lead conjugate at therapeutic and higher imaging/therapeutic doses did not show any evidence of organ toxicity.<a title="Select to navigate to references" href="#cit177"><sup><span class="sup_ref">177</span></sup></a> The structures of the bifunctional conjugates with variable number of Gd(<span class="small_caps">III</span>)aminobenzyl DTPA are shown in <a title="Select to navigate to figure" href="#imgfig15">Fig. 15</a>. The dual agent showed the capability of tumor-imaging by MR at 10-fold lower dose than Magnavist, a clinical standard, and also produced significant photosensitizing activity.<a title="Select to navigate to references" href="#cit178"><sup><span class="sup_ref">178</span></sup></a> Currently, efforts by these authors are directed in developing tumor-targeted agents by introducing a variety of tumor-targeting moieties.</p>
      
      
        
        <h3 id="sect1108"><span class="b_heading">H.3 Radiolabeled <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span> for nuclear imaging (SPECT/PET) and PDT</span></h3>
        <span>With the advancement in “non-invasive” imaging technologies and imaging probes, the field of imaging science is growing exponentially and therefore, fusion of <span class="italic">in vivo</span> imaging techniques (CT, SPECT, PET, bioluminescence, fluorescence, MRI) to observe events at the molecular and cellular levels are expected to accelerate the <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> discovery and development process.<a title="Select to navigate to references" href="#cit179"><sup><span class="sup_ref">179</span></sup></a> The imaging of specific molecular targets that are associated with cancer should allow for earlier diagnosis and better assessment of oncology patients. Whole-body <span class="CH"><a class="simple" title="ChEBI Ontology link for: positron" href="javascript:popupOBO('CHEBI:30225','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30225')">positron</a></span> emission tomography (PET) is a diagnostic modality that can noninvasively survey the entire body and sensitively detect various cancers. <span class="CH"><a class="simple" title="ChEBI Ontology link for: Positron" href="javascript:popupOBO('CHEBI:30225','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30225')">Positron</a></span> emission tomography (PET) with <small><sup>18</sup></small>F-fluorodeoxyglucose (FDG) has been developed to quantitatively assess local <span class="TC"><a class="simple" title="Chemspider Compound link for:glucose" target="_blank" href="http://www.chemspider.com/Chemical-Structure.9484839.html">glucose</a></span> metabolism.<a title="Select to navigate to references" href="#cit180"><sup><span class="sup_ref">180</span></sup></a> Because malignant tumors exhibit increased <span class="TC"><a class="simple" title="Chemspider Compound link for:glucose" target="_blank" href="http://www.chemspider.com/Chemical-Structure.9484839.html">glucose</a></span> metabolism, quantification of FDG uptake using PET helps to differentiate between benign and malignant tumours, to determine the degree of malignancy,<a title="Select to navigate to references" href="#cit181"><sup><span class="sup_ref">181</span></sup></a> to evaluate the effectiveness of chemotherapy or radiotherapy<a title="Select to navigate to references" href="#cit182"><sup><span class="sup_ref">182</span></sup></a> and to predict prognosis.<a title="Select to navigate to reference" href="#cit183"><sup><span class="sup_ref">183–185</span></sup></a> Since the invention of the whole-body imaging technique,<a title="Select to navigate to references" href="#cit186"><sup><span class="sup_ref">186</span></sup></a> PET has also been used to depict hypermetabolic cancers. PET imaging has been shown to be sensitive enough to detect various cancers including lung, breast, colorectal, pancreatic, head and neck cancer, and malignant lymphoma and melanoma.<a title="Select to navigate to reference" href="#cit180"><sup><span class="sup_ref">180,187,188</span></sup></a> It can also be used successfully in patients with an unknown primary tumor. Thus PET imaging has the potential to detect cancers of many types at early stages with a single study.</span>
        <p class="otherpara">With recent advent of small animal micro-PET systems whose resolution could reach near 1.2 millimeters, PET has widened appeal for research at the <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> development stage as it allows studying the <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> distribution <span class="italic">in vivo</span> by using radiolabeled <span class="CH"><a class="simple" title="ChEBI Ontology link for: tracers" href="javascript:popupOBO('CHEBI:35204','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35204')">tracers</a></span>, which are injected in non-therapeutic doses, 3-D images can be reconstructed using a computer to show the location(s) and concentration of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: tracer" href="javascript:popupOBO('CHEBI:35204','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=35204')">tracer</a></span>, which then can be coupled with a therapeutic agent to treat the target. The approaches now focus on the development of a common molecule which is first used in low mass (as a radioactive material) to image and measure the target function, and then the mass of the molecule is increased by using the same unlabeled compound at therapeutic levels to treat the target function.<a title="Select to navigate to references" href="#cit189"><sup><span class="sup_ref">189</span></sup></a><span class="CH"><a class="simple" title="ChEBI Ontology link for: Drugs" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">Drugs</a></span> labeled with <small><sup>11</sup></small>C (<span class="italic">t</span><small><sub>1/2</sub></small> = 20.4 min) and <small><sup>18</sup></small>F (<span class="italic">t</span><small><sub>1/2</sub></small> = 110 min) are the most commonly used PET isotopes. The short half-life of <small><sup>11</sup></small>C and <small><sup>18</sup></small>F limits their use in studies involving monoclonal antibodies, and other molecules like photosensitizers (<span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span>), which take a long time (hours instead of minutes) for accumulation in tumors. <small><sup>124</sup></small>I is a more suitable candidate as it has a half-life of 4.2 days and is compatible with sequential imaging using microPET due to its longer biological half-life. <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: Labeling" href="javascript:popupOBO('CMO:0001675','b915149b')">Labeling</a></span> techniques with radioiodine (<small><sup>123</sup></small>I, <small><sup>124</sup></small>I, <span class="italic">etc.</span>) are well-defined and one can obtain the labeled products in good yield with radiochemical purity.<a title="Select to navigate to references" href="#cit190"><sup><span class="sup_ref">190</span></sup></a> Despite the complex decay scheme of <small><sup>124</sup></small>I which results in only 25% abundance of <span class="CH"><a class="simple" title="ChEBI Ontology link for: positrons" href="javascript:popupOBO('CHEBI:30225','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30225')">positrons</a></span>, (compared with 100% <span class="CH"><a class="simple" title="ChEBI Ontology link for: positron" href="javascript:popupOBO('CHEBI:30225','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30225')">positron</a></span> emission of <small><sup>18</sup></small>F), <span class="italic">in vivo</span> quantitative imaging with <small><sup>124</sup></small>I labeled antibodies has been successfully carried out under realistic conditions using a PET/CT scanner<a title="Select to navigate to references" href="#cit191"><sup><span class="sup_ref">191</span></sup></a> and 3D-dosimetry. As for now, <small><sup>124</sup></small>I has been complexed to a variety of biomolecules such as, for example, monoclonal antibodies and dibodies,<a title="Select to navigate to references" href="#cit192"><sup><span class="sup_ref">192</span></sup></a> annexinV,<a title="Select to navigate to references" href="#cit193"><sup><span class="sup_ref">193</span></sup></a>iodoazomycingalactoside (IAZG)<a title="Select to navigate to references" href="#cit194"><sup><span class="sup_ref">194</span></sup></a>and 5-iodo-2'-fluoro-1-β-<span class="small_caps">D</span>-arabinofuranosyl <span class="TC"><a class="simple" title="Chemspider Compound link for:uracil" target="_blank" href="http://www.chemspider.com/Chemical-Structure.1141.html">uracil</a></span> (FIAU).<a title="Select to navigate to references" href="#cit195"><sup><span class="sup_ref">195</span></sup></a> There are a few reports in the PDT field in which various <small><sup>18</sup></small>F based radiotracers FDG,<a title="Select to navigate to references" href="#cit196"><sup><span class="sup_ref">196</span></sup></a><small><sup>18</sup></small>F-FHBG{9-(4-<small><sup>18</sup></small>F-fluoro-3-hydroxymethyl-butyl) guanine}<a title="Select to navigate to references" href="#cit197"><sup><span class="sup_ref">197</span></sup></a> and FLT (3′-deoxy-3′-<small><sup>18</sup></small>F-fluorothymidine) or <small><sup>125</sup></small>I labeled photosensitizers<a title="Select to navigate to reference" href="#cit198"><sup><span class="sup_ref">198–200</span></sup></a> have been used to monitor cellular events post PDT in mice at variable time intervals.</p>
        <p class="otherpara">In their approach for developing “bifunctional agents” for PET and PDT, Pandey and co-workers have initially conjugated 3-(1′-hexyloxyethyl)-3-devinylpyropheophorbide-<span class="italic">a</span> (HPPH), an effective PS, to the mono- and di-bis-aminoethanethiols (N<small><sub>2</sub></small>S<small><sub>2</sub></small> <span class="CH"><a class="simple" title="ChEBI Ontology link for: ligand" href="javascript:popupOBO('CHEBI:52214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=52214')">ligand</a></span>).<a title="Select to navigate to references" href="#cit201"><sup><span class="sup_ref">201</span></sup></a> The <span class="italic">in vivo</span> biodistribution data of the related <small><sup>99m</sup></small>Tc complexes were collected in rats bearing Ward colon tumors at 4 h and 24 h post injection. However, the short 6 h half-life time of <small><sup>99m</sup></small>Tc was found to be incompatible with the 24 h imaging time (HPPH takes around 24 h to reach maximum accumulation in tumors), suggesting that the introduction of a longer lived isotope (<span class="italic">e.g.</span>, <small><sup>111</sup></small>In) in a tumor-avid PS could provide a more useful scanning agent with phototherapeutic properties.</p>
        <p class="otherpara">To investigate the utility of <small><sup>111</sup></small>In (half-life, 72 h) complexes of tumor-avid photosensitizer in tumor-imaging by SPECT, Chen <span class="italic">et al.</span> established the reaction conditions by reacting cold InCl<small><sub>3</sub></small>with HPPH <strong>14</strong> under various reaction conditions. The resulting In(<span class="small_caps">III</span>)-HPPH maintained its tumor avidity. In preliminary screening, compared to HPPH, the corresponding In(<span class="small_caps">III</span>) analog [In(<span class="small_caps">III</span>) HPPH] was found to be 40-fold more effective <span class="italic">in vitro</span> and 8-fold more effective <span class="italic">in vivo</span> with limited skin phototoxicity (no skin phototoxicity was observed at day 3 post injection of the photosensitizer).<a title="Select to navigate to references" href="#cit202"><sup><span class="sup_ref">202</span></sup></a> The SPECT (single <span class="CH"><a class="simple" title="ChEBI Ontology link for: photon" href="javascript:popupOBO('CHEBI:30212','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30212')">photon</a></span> emission computed tomography) imaging studies with the corresponding In-HPPH are currently in progress<a title="Select to navigate to references" href="#cit203"><sup><span class="sup_ref">203</span></sup></a></p>
        <p class="otherpara">For synthesizing photosensitizers with PET imaging potential, the methyl 3-(1′-<span class="italic">m</span>-iodobenzyloxyethyl)-3-devinylpyropheo- phorbide-<span class="italic">a</span><strong>36</strong> (and the corresponding <small><sup>124</sup></small>I-analog) were obtained in a sequence of reactions from pyropheophorbide-<span class="italic">a</span> and showed promising potential as a tumor-imaging phototherapeutic agent. The electrophilic aromatic <span class="CH"><a class="simple" title="Molecular Process Ontology link for: iodination" href="javascript:popupOBO('MOP:0000554','b915149b')">iodination</a></span> of the corresponding trimethylstannyl intermediate with Na<small><sup>124</sup></small>I in the presence of an Iodogen bead afforded <small><sup>124</sup></small>I-labeled photosensitizer with &gt;95% radioactive specificity.<a title="Select to navigate to references" href="#cit204"><sup><span class="sup_ref">204</span></sup></a> The non-labeled iodo-photosensitizer produced an excellent long-term tumor cure in mice. The photosensitizer also showed promising tumor fluorescence and PET imaging ability and this was the first report demonstrating the utility of an <small><sup>124</sup></small>I-labeled photosensitizer as a “multimodality agent” for tumor imaging (PET/fluorescence) with and without PDT (<a title="Select to navigate to figure" href="#imgfig16">Fig. 16</a>, only comparative PET imaging with F-FDG is shown).<a title="Select to navigate to references" href="#cit204"><sup><span class="sup_ref">204</span></sup></a></p>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig16"><img alt="Comparative tumor-imaging potential of 124I-photosensitizer 36 and 18F-FDG in BALB/c mice bearing Colon26 tumors (J. Med. Chem. 2005, 48, 6286–6296)." src="/image/article/2011/CS/b915149b/b915149b-f16.gif"/></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 16 </b> <span id="fig16"><span class="graphic_title">Comparative tumor-imaging potential of <small><sup>124</sup></small>I-photosensitizer <strong>36</strong> and <small><sup>18</sup></small>F-FDG in BALB/c mice bearing Colon26 tumors (<span class="italic">J. Med. Chem.</span> 2005, <span class="bold">48</span>, 6286–6296).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        <p class="otherpara">This approach clearly demonstrates that relatively selective accumulation of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrin</a></span>-based PS provides an opportunity to be utilized as a single agent for imaging (PET and optical) and therapy. The techniques employed in this study are non-invasive and the use of a single agent rules out any chances for variability in the pharmacokinetic and pharmacodynamic pattern of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> at any stage. This is in contrast to other studies where either more than one agent or a <span class="CH"><a class="simple" title="ChEBI Ontology link for: bioconjugate" href="javascript:popupOBO('CHEBI:64985','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=64985')">bioconjugate</a></span> molecule in which tethered imaging probes are used, which could make significant changes in pharmacokinetic and pharmacodynamic characteristics of the individual moieties.</p>
        <p class="otherpara">This methodology was further extended to purpurinimides, highly effective photosensitizers with long-wavelength absorption near 700 nm. A series of <span class="CH"><a class="simple" title="ChEBI Ontology link for: carbohydrate" href="javascript:popupOBO('CHEBI:16646','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=16646')">carbohydrate</a></span> conjugated pyropheophorbides were also prepared to target certain carbohydrate recognized <span class="CH"><a class="simple" title="ChEBI Ontology link for: proteins" href="javascript:popupOBO('CHEBI:36080','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=36080')">proteins</a></span>, known for over-expression in certain tumors. Compared to non-carbohydrate analog, the corresponding <span class="CH"><a class="simple" title="ChEBI Ontology link for: galactose" href="javascript:popupOBO('CHEBI:28260','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28260')">galactose</a></span> and <span class="CH"><a class="simple" title="ChEBI Ontology link for: glucose" href="javascript:popupOBO('CHEBI:17234','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=17234')">glucose</a></span> derivatives showed higher uptake in mice bearing either Colon26 or RIF tumors. However, the <span class="italic">in vivo</span> biodistribution results obtained from C3H mice bearing RIF tumors revealed that of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: galactose" href="javascript:popupOBO('CHEBI:28260','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28260')">galactose</a></span> and <span class="CH"><a class="simple" title="ChEBI Ontology link for: glucose" href="javascript:popupOBO('CHEBI:17234','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=17234')">glucose</a></span> conjugates, the <span class="CH"><a class="simple" title="ChEBI Ontology link for: galactose" href="javascript:popupOBO('CHEBI:28260','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28260')">galactose</a></span> analog had higher tumor uptake.<a title="Select to navigate to references" href="#cit205"><sup><span class="sup_ref">205</span></sup></a> As expected, due to high uptake of the <span class="CH"><a class="simple" title="ChEBI Ontology link for: carbohydrate derivatives" href="javascript:popupOBO('CHEBI:63299','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=63299')">carbohydrate derivatives</a></span> in liver and spleen, the parent molecule produced the best tumor contrast. However, using certain <span class="CH"><a class="simple" title="ChEBI Ontology link for: nanoparticles" href="javascript:popupOBO('CHEBI:50803','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=50803')">nanoparticles</a></span> for blocking the liver and spleen uptake resulted in a remarkably reduced rate of uptake in these organs and produced substantial increase in tumor-uptake.</p>
      
    
    
      
      <h2 id="sect1232"><span class="a_heading">I. Future prospects</span></h2>
      <span>Though PDT has been mainly a cancer therapy, it has also shown enormous applications in many noncancerous conditions. <span class="CH"><a class="simple" title="ChEBI Ontology link for: Porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">Porphyrin</a></span>-based photosensitizer (PpIX derived from ALA) fluorescence as a marker has proven capable of detecting lesions in the bladder not detectable by ordinary cystoscopy. FDA-approved fluorescence-endoscopic method called LIFE (Light Induced Fluorescence Excitation) has been shown at least 3-fold as likely to detect an early lesion when used with whitelight bronchoscopy. Unfortunately, <span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrin" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrin</a></span>-based compounds have limited applications for detecting deeply seated tumors due to a small Stokes Shift between long-wavelength absorption and fluorescence bands, which limits their application in <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: fluorescence imaging" href="javascript:popupOBO('CMO:0000087','b915149b')">fluorescence imaging</a></span>. Therefore, the recent approaches for developing photosensitizer-cynanine <span class="CH"><a class="simple" title="ChEBI Ontology link for: dye" href="javascript:popupOBO('CHEBI:37958','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37958')">dye</a></span> conjugates as bifunctional agents provides a unique approach for tumor-detection and therapy. The Roswell Park group has extended this approach in developing “Multifunctional Agents” for MR imaging-PDT and PET-imaging–PDT. Advances constantly being made in the design of targeting vehicles used for delivery therapies (<span class="italic">e.g.</span> multifunctional <span class="CH"><a class="simple" title="ChEBI Ontology link for: nanoparticles" href="javascript:popupOBO('CHEBI:50803','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=50803')">nanoparticles</a></span>) could lead to the development of “Multifunctional Theranostics”.</span>
      <p class="otherpara">Another application of PDT is for treating infectious disease. There has been an increasing international concern about multidrug-resistant bacteria and the spread of infectious disease, which has become untreatable by <span class="CH"><a class="simple" title="ChEBI Ontology link for: antibiotics" href="javascript:popupOBO('CHEBI:22582','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=22582')">antibiotics</a></span> and become a great concern in medical community. The potential of PDT with certain cationic photosensitizers (<span class="CH"><a class="simple" title="ChEBI Ontology link for: porphyrins" href="javascript:popupOBO('CHEBI:26214','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26214')">porphyrins</a></span> and nonporphyrins) as <span class="CH"><a class="simple" title="ChEBI Ontology link for: antimicrobial agents" href="javascript:popupOBO('CHEBI:33281','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=33281')">antimicrobial agents</a></span> is currently being explored as a simple and highly effective therapy for infectious disease.</p>
      <p class="otherpara">Since the approval of <span class="TC"><a class="simple" title="Chemspider Compound link for:Photofrin" target="_blank" href="http://www.chemspider.com/Chemical-Structure.10482043.html">Photofrin</a></span>® by various health organizations, PDT has made many significant advances. The skin phototoxicity associated with most of the photosensitizers has significantly been reduced with new agents. For treating large and deeply seated tumors various 700–800 nm photosensitizers are currently in various stages of clinical trials. For developing PDT agents with imaging capability (multifunctional agents) improved tumor-specificity is still a challenge and several laboratories are investigating the use of activatable and <span class="CH"><a class="simple" title="ChEBI Ontology link for: nanoparticles" href="javascript:popupOBO('CHEBI:50803','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=50803')">nanoparticles</a></span> approaches to achieve the desired goal of developing improved target-specific multimodality agents.</p>
      <p class="otherpara">For future <span class="CH"><a class="simple" title="ChEBI Ontology link for: drug" href="javascript:popupOBO('CHEBI:23888','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=23888')">drug</a></span> development, it is extremely important to have a strong collaboration between chemists, biologists, physicists and clinicians. The understanding of the effect of overall lipophilicity, aggregation characteristics and its impact on photophysical properties, the pharmacokinetic and pharmacodynamic characteristics of new compounds could be extremely useful in developing improved tumor-imaging and therapeutic agents.</p>
    
    
      <h2 id="sect1251"><span class="a_heading">Abbreviations</span></h2>
      <table cellspacing="5">
        <tr><td>
            PDT
          </td><td>Photodynamic Therapy</td></tr>
        <tr><td>NIR</td><td>Near Infra Red</td></tr>
        <tr><td>ROS</td><td>
            <span class="CH"><a class="simple" title="ChEBI Ontology link for: Reactive Oxygen Species" href="javascript:popupOBO('CHEBI:26523','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=26523')">Reactive Oxygen Species</a></span>
          </td></tr>
        <tr><td>
            <span class="CH"><a class="simple" title="Chemical Methods Ontology link for: PS" href="javascript:popupOBO('CMO:0002186','b915149b')">PS</a></span>
          </td><td>Photosensitizer</td></tr>
        <tr><td>SAR</td><td>Structure–Activity Relationship</td></tr>
        <tr><td>
            QSAR
          </td><td>Quantitative Structure Activity Relationship</td></tr>
        <tr><td>MRI</td><td>Magnetic Resonance Imaging</td></tr>
        <tr><td>PET</td><td>
            <span class="CH"><a class="simple" title="ChEBI Ontology link for: Positron" href="javascript:popupOBO('CHEBI:30225','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30225')">Positron</a></span> Emission Tomography</td></tr>
        <tr><td>CT</td><td>Computed Tomography</td></tr>
        <tr><td>
            SPECT
          </td><td>Single <span class="CH"><a class="simple" title="ChEBI Ontology link for: Photon" href="javascript:popupOBO('CHEBI:30212','b915149b','http://www.ebi.ac.uk/chebi/searchId.do?chebiId=30212')">Photon</a></span> Emission Computed Tomography</td></tr>
        <tr><td>
            cRGD
          </td><td>(cyclic-Arg-Gly-Asp)</td></tr>
        <tr><td>
            STAT
          </td><td>
            Signal Transducer and Activator of Transcription-3</td></tr>
        <tr><td>
            ABCG-2
          </td><td>ATPBinding Cassette, Sub-Family G, Member)</td></tr>
      </table>
    
  
    <h2 id="sect1298"><span class="a_heading">Acknowledgements</span></h2>
      <span>RKP is highly thankful to all the members (past and present) of his research group and the collaborators, whose names are cited in the references. We are thankful to Dr Nestor Rigual and Michele Cooper, Clinical PDT for the clinical results (<a title="Select to navigate to figure" href="#imgfig9">Fig. 9–11</a>). The financial support from the NIH (CA 55791, CA 114053, CA-109914, CA 127369, CA 127369-02S1),CA-119358, Oishei Foundation, Oncologic Foundation of Buffalo and Roswell Park Alliance Foundation, The Mallinckrodt Medical Inc. St. Louis (USA) is highly appreciated. The authors are thankful to Mr Joseph Missert for his help in preparing this manuscript.</span>
    
    <span id="sect1301"><h2 id="sect1297"><span class="a_heading">Notes and references</span></h2></span><ol type="1">
      <li><span id="cit1">R. K. Pandey, L. N. Goswami, Y. Chen, A. Gryshuk, J. R. Missert, A. Oseroff and T. J. Dougherty, <span class="italic">Lasers Surg. Med.</span>, 2006, <span class="bold">38</span>, 445–467 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/lsm.20352" title="DOI Link to resource 10.1002/lsm.20352">CrossRef</a>.</span></li>
      <li><span id="cit2">M. R. Detty, S. L. Gibson and S. J. Wagner, <span class="italic">J. Med. Chem.</span>, 2004, <span class="bold">47</span>, 3897–3915 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm040074b" title="DOI Link to resource 10.1021/jm040074b">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2cXkvFyht7c%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit3">S. B. Brown, E. A. Brown and I. Walker, <span class="italic">Lancet Oncol.</span>, 2004, <span class="bold">5</span>, 497–508 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S1470-2045(04)01529-3" title="DOI Link to resource 10.1016/S1470-2045(04)01529-3">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Kjsrw%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit4">Z. Huang, <span class="italic">Technology in Cancer Research &amp; Treatment</span>, 2005, <span class="bold">4</span>, 283–293 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Technology%20in%20Cancer%20Research%20&amp;%20Treatment%5BJour%5D%20AND%204%5Bvolume%5D%20AND%20283%5Bpage%5D%20and%202005%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit5">R. Bonnett and G. Martinez, <span class="italic">Tetrahedron</span>, 2001, <span class="bold">57</span>, 9513–9547 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0040-4020(01)00952-8" title="DOI Link to resource 10.1016/S0040-4020(01)00952-8">CrossRef</a>.</span></li>
      <li><span id="cit6">T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan and Q. Peng, <span class="italic">J. Natl. Cancer Inst.</span>, 1998, <span class="bold">90</span>, 889–905 <a target="_blank" class="DOILink" href="https://doi.org/10.1093/jnci/90.12.889" title="DOI Link to resource 10.1093/jnci/90.12.889">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK1cXktFOqsLY%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit7">
          M. R. Hamblin and P. Mroz, in <span class="italic">Photodynamic Therapy in Advances in Photodynamic Therapy</span>, Artech House, Boston,  2008 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Photodynamic%20Therapy%20in%20Advances%20in%20Photodynamic%20Therapy%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202008%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit8">I. J. MacDonald and T. J. Dougherty, <span class="italic">J. Porphyrins Phthalocyanines</span>, 2001, <span class="bold">5</span>, 105–129 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/jpp.328" title="DOI Link to resource 10.1002/jpp.328">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXht1SgtLY%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit9">L. D. Via and S. M. Magno, <span class="italic">Curr. Med. Chem.</span>, 2001, <span class="bold">8</span>, 1405–1418 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXntFags78%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit10">J. S. McCaughan, <span class="italic">Drugs Aging</span>, 1999, <span class="bold">15</span>, 49–68 <a target="_blank" class="DOILink" href="https://doi.org/10.2165/00002512-199915010-00005" title="DOI Link to resource 10.2165/00002512-199915010-00005">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK1MXltVWltL4%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit11">D. E. Dolmans, D. Fukumura and R. K. Jain, <span class="italic">Nat. Rev. Cancer</span>, 2003, <span class="bold">3</span>, 380–387 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/nrc1071" title="DOI Link to resource 10.1038/nrc1071">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXjtlals74%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit12">F.-P. Montforts, B. Gerlach and F. Hoeper, <span class="italic">Chem. Rev.</span>, 1994, <span class="bold">94</span>, 327–347 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/cr00026a003" title="DOI Link to resource 10.1021/cr00026a003">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2cXitFOjs7o%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit13">H. Ali and J. E. Van Lier, <span class="italic">Chem. Rev.</span>, 1999, <span class="bold">99</span>, 2379–2450 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/cr980439y" title="DOI Link to resource 10.1021/cr980439y">CrossRef</a>.</span></li>
      <li><span id="cit14">I. Rosenthal, <span class="italic">Photochem. Photobiol.</span>, 1991, <span class="bold">53</span>, 859–870 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK3MXkt1Gjurw%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit15">D. Philips, <span class="italic">Progress in Reaction Kinetics</span>, 1997, <span class="bold">22</span>, 175–300 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Progress%20in%20Reaction%20Kinetics%5BJour%5D%20AND%2022%5Bvolume%5D%20AND%20175%5Bpage%5D%20and%201997%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit16">A. C. Tedesco, J. Rotta and C. G. Lunardi, <span class="italic">Curr. Org. Chem.</span>, 2003, <span class="bold">7</span>, 187–196 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXitlyqug%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit17">S. M. Ali and M. Olivo, <span class="italic">Int. J. Oncol.</span>, 2003, <span class="bold">22</span>, 1181–1191 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXksV2nsrs%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit18">D. Wöhrle, <span class="italic">Russ. Chem. Bull.</span>, 1998, <span class="bold">47</span>, 807–816 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Russ.%20Chem.%20Bull.%5BJour%5D%20AND%2047%5Bvolume%5D%20AND%20807%5Bpage%5D%20and%201998%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit19">K. Kalka, H. Merk and H. Mukhtar, <span class="italic">J. Am. Acad. Dermatol.</span>, 2000, <span class="bold">42</span>, 389–413 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0190-9622(00)90209-3" title="DOI Link to resource 10.1016/S0190-9622(00)90209-3">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD3c7ltlGltA%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit20">E. l. Taylor and S. B. Brown, <span class="italic">J. Dermatol. Treat.</span>, 2002, <span class="bold">13</span>, s3–S11 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD38Xmt1aisL8%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit21">C. J. Kelty, S. L. Marcus and R. Ackroyd, <span class="italic">Dis. Esophagus</span>, 2002, <span class="bold">15</span>, 137–144 <a target="_blank" class="DOILink" href="https://doi.org/10.1046/j.1442-2050.2002.00243.x" title="DOI Link to resource 10.1046/j.1442-2050.2002.00243.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD38vmtFylsQ%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit22">T. G. Sutedjia and P. E. Postmus, <span class="italic">J. Photochem. Photobiol., B</span>, 1996, <span class="bold">36</span>, 199–204 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S1011-1344(96)07372-1" title="DOI Link to resource 10.1016/S1011-1344(96)07372-1">CrossRef</a>.</span></li>
      <li><span id="cit23">H. Kostron, A. Obwegeser and R. Jakober, <span class="italic">J. Photochem. Photobiol., B</span>, 1996, <span class="bold">36</span>, 157–168 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S1011-1344(96)07364-2" title="DOI Link to resource 10.1016/S1011-1344(96)07364-2">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2sXntlSnsQ%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit24">J. Gahlen, R. L. Prosst and J. Stern, <span class="italic">Chirurg</span>, 2002, <span class="bold">73</span>, 122–131 <a target="_blank" class="DOILink" href="https://doi.org/10.1007/s00104-001-0371-7" title="DOI Link to resource 10.1007/s00104-001-0371-7">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD383jslCnuw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit25">N. L. Oleinick, R. L. Morris and I. Belichenko, <span class="italic">Photochem. Photobiol. Sci.</span>, 2002, <span class="bold">1</span>, 1 <a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=b108586g&amp;newsite=1" title="Link to RSC resource DOI:10.1039/b108586g">RSC</a>.</span></li>
      <li><span id="cit26">M. Otake, M. Nishiwaki, Y. Kobayashi, S. Baba, E. Kohno, T. Kawasaki, Y. Fujise and H. Nakamura, <span class="italic">Br. J. Cancer</span>, 2003, <span class="bold">89</span>, 730–736 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/sj.bjc.6601135" title="DOI Link to resource 10.1038/sj.bjc.6601135">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXmtFKqsb8%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit27">R. K. Pandey and C. K. Herman, <span class="italic">Chemistry &amp; Industry</span>, 1998, <span class="bold">21</span>, 739–743 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Chemistry%20&amp;%20Industry%5BJour%5D%20AND%2021%5Bvolume%5D%20AND%20739%5Bpage%5D%20and%201998%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit28">N. Brasseur, T. L. Nguyen, R. Langlois, R. Ouellet, S. Marengo, D. Houde and J. E. Van Lier, <span class="italic">J. Med. Chem.</span>, 1994, <span class="bold">37</span>, 415–420 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm00029a014" title="DOI Link to resource 10.1021/jm00029a014">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2cXhvVKhtr0%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit29">B. C. Wilson and M. S. Patterson, <span class="italic">Phys. Med. Biol.</span>, 2008, <span class="bold">53</span>, R61 <a target="_blank" class="DOILink" href="https://doi.org/10.1088/0031-9155/53/9/R01" title="DOI Link to resource 10.1088/0031-9155/53/9/R01">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1cXmvVSnu7w%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit30">C. M. Allen, W. M. Sharman and J. E. Van Lier, <span class="italic">J. Porphyrins Phthalocyanines</span>, 2001, <span class="bold">5</span>, 161–169 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/jpp.324" title="DOI Link to resource 10.1002/jpp.324">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXht1Sgtbo%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit31">J. L. Sessler, T. Murai, V. Lynch and M. Cyr, <span class="italic">J. Am. Chem. Soc.</span>, 1988, <span class="bold">110</span>, 5586–5588 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/ja00224a062" title="DOI Link to resource 10.1021/ja00224a062">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL1cXlt1Wmsb8%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit32">J. L. Sessler, T. Murai and V. Lynch, <span class="italic">Inorg. Chem.</span>, 1989, <span class="bold">28</span>, 1333–1341 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/ic00306a025" title="DOI Link to resource 10.1021/ic00306a025">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL1MXhsVKlsLk%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit33">B. G. Maiya, T. E. Mallouk, G. Hemmi and J. L. Sessler, <span class="italic">Inorg. Chem.</span>, 1990, <span class="bold">29</span>, 3738–3745 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/ic00344a021" title="DOI Link to resource 10.1021/ic00344a021">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK3cXls1Cns7g%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit34">J. L. Sessler, T. D. Mody, G. W. Hemmi and V. Lynch, <span class="italic">Inorg. Chem.</span>, 1993, <span class="bold">32</span>, 3175–3187 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/ic00066a032" title="DOI Link to resource 10.1021/ic00066a032">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK3sXltlSgs7c%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit35">S. W. Young, F. Qing, A. Harriman, J. L. Sessler, W. C. Dow, T. D. Mody, G. W. Hemmi, Y. Hao and R. A. Miller, <span class="italic">Proc. Natl. Acad. Sci. U. S. A.</span>, 1996, <span class="bold">93</span>, 6610–6615 <a target="_blank" class="DOILink" href="https://doi.org/10.1073/pnas.93.13.6610" title="DOI Link to resource 10.1073/pnas.93.13.6610">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK28XjvFeis7o%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit36">
          T. D. Mody and L. Fu, J. L. Sessler, in <span class="italic">Progress in Inorganic Chemistry</span>, ed. K. D. Karlin, John Wiley and Sons, Chichester,  2001, vol. 49, pp. 551–598 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Progress%20in%20Inorganic%20Chemistry%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202001%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit37">O. Rabb, <span class="italic">Z. Biol. (Munich)</span>, 1900, <span class="bold">39</span>, 524–546 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Z.%20Biol.%20(Munich)%5BJour%5D%20AND%2039%5Bvolume%5D%20AND%20524%5Bpage%5D%20and%201900%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit38">
          R. K. Pandey and G. Zheng, in <span class="italic">The Porphyrin Handbook</span>, ed. K. M. Kadish, K. M. Smith and R. Guilard, Academic Press, Boston,  2000, vol. 6, pp. 157–230 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=The%20Porphyrin%20Handbook%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202000%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit39">T. Tsuchida, G. Zheng, R. K. Pandey, W. R. Potter, D. A. Bellnier, B. W. Henderson, H. Kato and T. J. Dougherty, <span class="italic">Photochem. Photobiol.</span>, 1997, <span class="bold">66</span>, 224–228 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.1997.tb08647.x" title="DOI Link to resource 10.1111/j.1751-1097.1997.tb08647.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2sXlsVKkurc%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit40">R. K. Pandey, F.-Y. Shiau, T. J. Dougherty and K. M. Smith, <span class="italic">Tetrahedron</span>, 1991, <span class="bold">47</span>, 9571–9584 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0040-4020(01)91025-7" title="DOI Link to resource 10.1016/S0040-4020(01)91025-7">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK38XhsFWgu7c%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit41">T. J. Dougherty, J. E. Kaufman, A. Goldfarb, K. R. Weishaupt, D. Boyle and A. Mittleman, <span class="italic">Cancer Res.</span>, 1978, <span class="bold">38</span>, 2628–2635 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ACSeB3M3nvV0%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit42">
          T. J. Dougherty and J. G. Levy, in <span class="italic">Biomedical Photonics Handbook</span>, ed. T. Vo-Dinh, CRC Press, New York,  2003, pp. 38-1–38-16 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Biomedical%20Photonics%20Handbook%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202003%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit43">T. J. Dougherty, <span class="italic">Photochem. Photobiol.</span>, 1983, <span class="bold">38</span>, 377–379 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.1983.tb02687.x" title="DOI Link to resource 10.1111/j.1751-1097.1983.tb02687.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL3sXlsFCnurs%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit44">D. Kessel, P. Thompson, B. Musselman and C. K. Chang, <span class="italic">Photochem. Photobiol.</span>, 1987, <span class="bold">46</span>, 563–568 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.1987.tb04814.x" title="DOI Link to resource 10.1111/j.1751-1097.1987.tb04814.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL1cXntFCiug%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit45">I. K. Morris and A. D. Ward, <span class="italic">Tetrahedron Lett.</span>, 1988, <span class="bold">29</span>, 2501–2504 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0040-4039(00)87918-6" title="DOI Link to resource 10.1016/S0040-4039(00)87918-6">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL1MXhtFCmsLg%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit46">R. K. Pandey, T. J. Dougherty and K. M. Smith, <span class="italic">Tetrahedron Lett.</span>, 1988, <span class="bold">29</span>, 4657–4660 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0040-4039(00)80573-0" title="DOI Link to resource 10.1016/S0040-4039(00)80573-0">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL1MXkslOksL4%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit47">P. A. Scourides, R. M. Böhmer, A. H. Kaye and G. Morstyn, <span class="italic">Cancer Res.</span>, 1987, <span class="bold">47</span>, 3439–3445 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL2sXltFWru74%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit48">D. Kessel, P. Thompson, B. Musselman and C. K. Chang, <span class="italic">Cancer Res.</span>, 1987, <span class="bold">47</span>, 4642–4645 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL2sXlsFSnsbg%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit49">R. K. Pandey and T. J. Dougherty, <span class="italic">Cancer Res.</span>, 1989, <span class="bold">8</span>, 2042–2047.</span></li>
      <li><span id="cit50">R. K. Pandey, F.-Y. Shiau, C. J. Medforth, T. J. Dougherty and K. M. Smith, <span class="italic">Tetrahedron Lett.</span>, 1990, <span class="bold">31</span>, 7399–7402 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0040-4039(00)88499-3" title="DOI Link to resource 10.1016/S0040-4039(00)88499-3">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK3MXhtVWnurg%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit51">M. C. Berenbaum, R. Bonnett and P. A. Scourides, <span class="italic">Br. J. Cancer</span>, 1982, <span class="bold">45</span>, 571–581 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL38XltVKhu7k%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit52">C. J. Byrne, L. V. Marshallsay and A. D. Ward, <span class="italic">J. Photochem. Photobiol., B</span>, 1990, <span class="bold">6</span>, 13–27 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/1011-1344(90)85070-D" title="DOI Link to resource 10.1016/1011-1344(90)85070-D">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK3cXlslWkt7w%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit53">W. M. Sharman, C. M. Allen and J. E. Van Lier, <span class="italic">Methods Enzymol.</span>, 2000, <span class="bold">319</span>, 376–400 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3cXlsl2lurc%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit54">J. Moan and S. Sommer, <span class="italic">Cancer Res.</span>, 1985, <span class="bold">45</span>, 1608–1610 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaL2MXhvVWlsbY%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit55">J. D. Chapman, C. C. Stobbe, M. R. Arnfield, R. Santus, J. Lee and M. S. McPhee, <span class="italic">Radiat. Res.</span>, 1991, <span class="bold">126</span>, 73–79 <a target="_blank" class="DOILink" href="https://doi.org/10.2307/3578173" title="DOI Link to resource 10.2307/3578173">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK3MXit1Cltro%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit56">T. M. Busch, P. Wileyto, M. J. Emanuele, F. D. Piero, L. Marconato, E. Glatstein and C. J. Koch, <span class="italic">Cancer Res.</span>, 2002, <span class="bold">62</span>, 7273–7279 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXhtVyquw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit57">M. W. R. Reed, <span class="italic">Surgery</span>, 1989, <span class="bold">106</span>, 94–99 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ABiaB1Mfmt1A%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit58">B. C. Wilson, M. S. Patterson and L. Lilge, <span class="italic">Lasers Med. Sci.</span>, 1997, <span class="bold">12</span>, 182–199 <a target="_blank" class="DOILink" href="https://doi.org/10.1007/BF02765099" title="DOI Link to resource 10.1007/BF02765099">CrossRef</a>.</span></li>
      <li><span id="cit59">G. Schermann, R. Schmidt, A. Völcker, H.-D. Brauer, H. Mertes and B. Franck, <span class="italic">Photochem. Photobiol.</span>, 1990, <span class="bold">52</span>, 741–744.</span></li>
      <li><span id="cit60">B. Franck and A. Nonn, <span class="italic">Angew. Chem., Int. Ed. Engl.</span>, 1995, <span class="bold">34</span>, 1795–1811 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/anie.199517951" title="DOI Link to resource 10.1002/anie.199517951">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2MXotF2kur8%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit61">F. J. M. Hoeben, P. Johkheijm, E. W. Meijer and A. P. H. J. Schenning, <span class="italic">Chem. Rev.</span>, 2005, <span class="bold">105</span>, 1491–1546 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/cr030070z" title="DOI Link to resource 10.1021/cr030070z">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXitVyntrg%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit62">Y. Y. Tian, L. L. Wang and W. Wang, <span class="italic">Laser Phys.</span>, 2008, <span class="bold">18</span>, 1119–1123 <a target="_blank" class="DOILink" href="https://doi.org/10.1134/S1054660X08100010" title="DOI Link to resource 10.1134/S1054660X08100010">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKls7fJ" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit63">T. Sutedja, P. Baas, F. Stewart and N. van Zandwijk, <span class="italic">Eur. J. Cancer</span>, 1992, <span class="bold">28</span>, 1370–1373 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/0959-8049(92)90522-4" title="DOI Link to resource 10.1016/0959-8049(92)90522-4">CrossRef</a>.</span></li>
      <li><span id="cit64">R. Whelpton, A. T. Michael-Titus, S. S. Basra and M. Grahn, <span class="italic">Photochem. Photobiol.</span>, 1995, <span class="bold">61</span>, 397 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.1995.tb08629.x" title="DOI Link to resource 10.1111/j.1751-1097.1995.tb08629.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2MXkvVKjurc%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit65">T. R. Nathan, D. E. Whitelaw, S. C. Chang, W. R. Lees, P. M. Ripley, H. Payne, L. Jones, M. C. Parkinson, M. Emberton, A. R. Gillams, A. R. Mundy and S. G. Bown, <span class="italic">J. Urol.</span>, 2002, <span class="bold">168</span>, 1427–1432 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0022-5347(05)64466-7" title="DOI Link to resource 10.1016/S0022-5347(05)64466-7">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD38Xot1Sqsbc%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit66">C. M. Moore, T. R. Nathan, W. R. Lees, C. A. Mosse, A. Freeman, M. Emberton and S. G. Bown, <span class="italic">Lasers Surg. Med.</span>, 2006, <span class="bold">38</span>, 356–363 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/lsm.20275" title="DOI Link to resource 10.1002/lsm.20275">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD28zosFChtA%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit67">S. C. Chang, G. A. Buonaccorsi, A. J. MacRobert and S. G. Brown, <span class="italic">Int. J. Cancer</span>, 1996, <span class="bold">67</span>, 555–562 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/(SICI)1097-0215(19960807)67:4&lt;555::AID-IJC15&gt;3.0.CO;2-6" title="DOI Link to resource 10.1002/(SICI)1097-0215(19960807)67:4&lt;555::AID-IJC15&gt;3.0.CO;2-6">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK28Xlt1Cks7Y%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit68">P. Wyss, V. Schwarz, D. Dobler-Girdziunaite, R. Hornung, H. Walt, A. Degen and M. K. Fehr, <span class="italic">Int. J. Cancer</span>, 2001, <span class="bold">93</span>(5), 720–724 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/ijc.1400" title="DOI Link to resource 10.1002/ijc.1400">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXls1Wgt7o%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit69">A. K. D'Cruz, M. H. Robinson and M. A. Biel, <span class="italic">Head Neck</span>, 2004, <span class="bold">26</span>, 232–40 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/hed.10372" title="DOI Link to resource 10.1002/hed.10372">CrossRef</a>.</span></li>
      <li><span id="cit70">L. Ayaru, S. G. Bown and S. P. Pereira, <span class="italic">Int. J. Gastrointest. Cancer</span>, 2005, <span class="bold">35</span>, 1–14 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Int.%20J.%20Gastrointest.%20Cancer%5BJour%5D%20AND%2035%5Bvolume%5D%20AND%201%5Bpage%5D%20and%202005%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li>
      <li><span id="cit71">S. C. Chang, G. A. Buonaccorsi, A. J. MacRobert and S. G. Brown, <span class="italic">Prostate</span>, 1997, <span class="bold">32</span>, 89–98 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/(SICI)1097-0045(19970701)32:2&lt;89::AID-PROS3&gt;3.0.CO;2-A" title="DOI Link to resource 10.1002/(SICI)1097-0045(19970701)32:2&lt;89::AID-PROS3&gt;3.0.CO;2-A">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2sXkvVGjtbk%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit72">T. J. Dougherty, G. Lawrence, J. H. Kaufman, D. Boyle, K. R. Weishaupt and A. Goldfarb, <span class="italic">J. Natl. Cancer Inst.</span>, 1979, <span class="bold">62</span>, 231–237 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaE1M7ht1Gltw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit73">C. P. Lowdell, D. V. Ash, I. Driver and S. B. Brown, <span class="italic">Br. J. Cancer.</span>, 1993, <span class="bold">67</span>, 1398–403 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK3s3ptFSnsA%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit74">J. C. Kennedy and R. H. Pottier, <span class="italic">J. Photochem. Photobiol., B</span>, 1992, <span class="bold">14</span>, 275–292 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/1011-1344(92)85108-7" title="DOI Link to resource 10.1016/1011-1344(92)85108-7">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK38Xls1Klu70%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit75">D. J. Robinson, P. Collins, M. R. Stringer, D. I. Vernon, G. I. Stables, S. B. Brown and R. A. Sheehan-Dare, <span class="italic">Acta Derm.-Venereol.</span>, 1999, <span class="bold">79</span>, 451–455 <a target="_blank" class="DOILink" href="https://doi.org/10.1080/000155599750009898" title="DOI Link to resource 10.1080/000155599750009898">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3cXlt1yjurk%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit76">I. M. Stender, R. Na, H. Fogh, C. Gluud and H. C. Wulf, <span class="italic">Lancet</span>, 2000, <span class="bold">355</span>, 963–966 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0140-6736(00)90013-8" title="DOI Link to resource 10.1016/S0140-6736(00)90013-8">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3cXisFSnt7g%253D" title="Link to resource in CAS">CAS</a>.</span></li>
      <li><span id="cit77">W. Hongcharu, C. R. Taylor, Y. Chang, D. Aghassi, K. Suthamjariya and R. R. Anderson, <span class="italic">J. Invest. Dermatol.</span>, 2000, <span class="bold">115</span>, 183–192 <a target="_blank" class="DOILink" href="https://doi.org/10.1046/j.1523-1747.2000.00046.x" title="DOI Link to resource 10.1046/j.1523-1747.2000.00046.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3cXlvFOlt7o%253D" title="Link to resource in CAS">CAS</a>.</span></li>. <li><span id="cit78">I. M. Stender, J. Lock-Andersen and H. C. Wulf, <span class="italic">Clin. Exp. Dermatol.</span>, 1999, <span class="bold">24</span>, 154–159 <a target="_blank" class="DOILink" href="https://doi.org/10.1046/j.1365-2230.1999.00441.x" title="DOI Link to resource 10.1046/j.1365-2230.1999.00441.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK1MzjtVKhsw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit79">F. Cairnduff, M. R. Stringer, E. J. Hudson, D. V. Ash and S. B. Brown, <span class="italic">Br. J. Cancer</span>, 1994, <span class="bold">69</span>, 605–608 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3AByuC28fpslw%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit80">G. I. Stables, M. R. Stringer, D. J. Robinson and D. V. Ash, <span class="italic">Br. J. Dermatol.</span>, 1997, <span class="bold">136</span>, 957–960 <a target="_blank" class="DOILink" href="https://doi.org/10.1046/j.1365-2133.1997.01825.x" title="DOI Link to resource 10.1046/j.1365-2133.1997.01825.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3AByiA28%252Foslc%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit81">C. A. Morton, C. Whitehurst, J. H. McColl, J. V. Moore and R. M. MacKie, <span class="italic">Arch. Dermatol.</span>, 2001, <span class="bold">137</span>, 319–324 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXisVeqsrk%253D" title="Link to resource in CAS">CAS</a>.</span></li>. <li><span id="cit82">J. A. Leman, D. C. Dick and C. A. Morton, <span class="italic">Clin. Exp. Dermatol.</span>, 2002, <span class="bold">27</span>, 516–518 <a target="_blank" class="DOILink" href="https://doi.org/10.1046/j.1365-2230.2002.01119.x" title="DOI Link to resource 10.1046/j.1365-2230.2002.01119.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD38nhsFGjtQ%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit83">T. Horio, O. Horio, H. Miyauchi-Hashimoto, M. Ohnuki and T. Isei, <span class="italic">Br. J. Dermatol.</span>, 2003, <span class="bold">148</span>, 1274–1276 <a target="_blank" class="DOILink" href="https://doi.org/10.1046/j.1365-2133.2003.05360.x" title="DOI Link to resource 10.1046/j.1365-2133.2003.05360.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD3szgtFajtg%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit84">E. A. Coors and P. Von den Driesch, <span class="italic">J. Am. Acad. Dermatol.</span>, 2004, <span class="bold">50</span>, 363–367 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S0190-9622(03)00868-5" title="DOI Link to resource 10.1016/S0190-9622(03)00868-5">CrossRef</a>.</span></li><li><span id="cit85">M. H. Gold, V. L. Bradshaw, M. M. Boring, T. M. Bridges, J. A. Biron and T. L. Lewis, <span class="italic">J. Drugs Dermatol.</span>, 2004, <span class="bold">3</span>, S6–S9 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=J.%20Drugs%20Dermatol.%5BJour%5D%20AND%203%5Bvolume%5D%20AND%20S6%5Bpage%5D%20and%202004%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit86">A. R. Oseroff, S. Shieh, N. P. Frawley, R. Cheney, L. E. Blumenson, E. K. Pivnick and D. A. Bellnier, <span class="italic">Arch. Dermatol.</span>, 2005, <span class="bold">141</span>, 60–67.</span></li><li><span id="cit87">D. W. Hunt, Rostaporfin (Miravant Medical Technologies), <span class="italic">IDrugs</span>, 2002, <span class="bold">5</span>, 180–186 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=IDrugs%5BJour%5D%20AND%205%5Bvolume%5D%20AND%20180%5Bpage%5D%20and%202002%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit88">B. Krammer and K. Plaetzer, <span class="italic">Photochem. Photobiol. Sci.</span>, 2008, <span class="bold">7</span>, 283–9 <a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=b712847a&amp;newsite=1" title="Link to RSC resource DOI:10.1039/b712847a">RSC</a>.</span></li><li><span id="cit89">D. Zaak, R. Sroka, M. Höppner, W. Khoder, O. Reich, S. Tritschler, R. Muschter, R. Knüchel and A. Hofstetter, <span class="italic">Med. Laser Appl.</span>, 2003, <span class="bold">18</span>, 91–95 <a target="_blank" class="DOILink" href="https://doi.org/10.1078/1615-1615-00092" title="DOI Link to resource 10.1078/1615-1615-00092">CrossRef</a>.</span></li><li><span id="cit90">R. A. His, A. Kapatkin, J. Strandberg, T. Zhu, T. Vulcan, M. Solonenko, C. Rodriguez, J. Chang, M. Saunders, N. Mason and S. Hahn, <span class="italic">Clin. Cancer Res.</span>, 2001, <span class="bold">7</span>, 651–660 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXjtVOgu7g%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit91">J. H. Pinthus, A. Bogaards, R. Weersink, B. C. Wilson and J. Trachtenberg, <span class="italic">J. Urol.</span>, 2006, <span class="bold">175</span>, 1201–1207 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=J.%20Urol.%5BJour%5D%20AND%20175%5Bvolume%5D%20AND%201201%5Bpage%5D%20and%202006%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit92">K. Verigos, D. C. Stripp, R. Mick, T. C. Zhu, R. Whittington, D. Smith and A. Dimofte, <span class="italic">J. Environ Pathol. Toxicol. Oncol.</span>, 2006, <span class="bold">25</span>, 373–387 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=J.%20Environ%20Pathol.%20Toxicol.%20Oncol.%5BJour%5D%20AND%2025%5Bvolume%5D%20AND%20373%5Bpage%5D%20and%202006%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit93">H. Patel, R. Mick, J. Finlay, T. C. Zhu, E. Rickter, K. A. Cengel, S. B. Malkowicz, S. M. Hahn and T. M. Busch, <span class="italic">Clin. Cancer Res.</span>, 2008, <span class="bold">14</span>, 4869–4876 <a target="_blank" class="DOILink" href="https://doi.org/10.1158/1078-0432.CCR-08-0317" title="DOI Link to resource 10.1158/1078-0432.CCR-08-0317">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1cXpt1eju74%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit94">D. C. H. Stripp, R. Mick, T. C. Zhu, R. Whittington, D. Smith, A. Dimofte, J. Finlay, J. Miles, T. M. Busch, D. Shin1, A. Kachur, Z. A. Tochner, S. B. Malkowicz, E. Glatstein and S. M. Hahn, <span class="italic">Proc. of SPIE 5315</span>, 2004, 88–99 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Proc.%20of%20SPIE%205315%5BJour%5D%20AND%20%5Bvolume%5D%20AND%2088%5Bpage%5D%20and%202004%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit95">T. C. Zhu, A. Dimofte, J. C. Finlay, D. Stripp, T. Busch, J. Miles, R. Whittington, S. B. Malkowicz, Z. Tochner, E. Glatstein and S. M. Hahn, <span class="italic">Photochem. Photobiol.</span>, 2005, <span class="bold">81</span>, 96–105 <a target="_blank" class="DOILink" href="https://doi.org/10.1562/2004-06-25-RA-216.1" title="DOI Link to resource 10.1562/2004-06-25-RA-216.1">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXhvVequ7s%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit96">A. Dimofte, T. C. Zhou, S. M. Hahn and R. A. Lustig, <span class="italic">Lasers Surg. Med.</span>, 2002, <span class="bold">31</span>, 305–312 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/lsm.10115" title="DOI Link to resource 10.1002/lsm.10115">CrossRef</a>.</span></li><li><span id="cit97">J. I. Lim, <span class="italic">Ophthalmology Clinics of North America</span>, 2002, <span class="bold">15</span>, 473–478 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Ophthalmology%20Clinics%20of%20North%20America%5BJour%5D%20AND%2015%5Bvolume%5D%20AND%20473%5Bpage%5D%20and%202002%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit98">M. R. Gertner, A. Bogaards, R. A. Weersink, S. A. McCluskey, M. A. Haider, C. K. K. Yue, J. Savard, S. Simpson, P. H. Brun, P. Cohen, A. Scherz, Y. Salomon, A. G. Aprikian, M. M. Elhilali, B. C. Wilson and J. Trachtenberg, <span class="italic">Eur. Urol. Suppl.</span>, 2004, <span class="bold">3</span>, 212 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S1569-9056(04)90831-7" title="DOI Link to resource 10.1016/S1569-9056(04)90831-7">CrossRef</a>.</span></li><li><span id="cit99">N. E. Martin and S. M. Hahn, <span class="italic">Photodiag. Photodyn. Therapy 1</span>, 2004, 123–136 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Photodiag.%20Photodyn.%20Therapy%201%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20123%5Bpage%5D%20and%202004%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit100">R. A. Weersink, A. Bogaards, M. Gertner, S. R. H. Davidson, K. Zhang, G. Netchev, T. Trachtenberg and B. C. Wilson, <span class="italic">J. Photochem. Photobiol., B</span>, 2005, <span class="bold">79</span>(3), 211–222 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.jphotobiol.2005.01.008" title="DOI Link to resource 10.1016/j.jphotobiol.2005.01.008">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXkt1Ohsr4%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit101">M. Berdugo, R. A. Bejjani, F. Valamanesh, M. Savoldelli, J.-C. Jeanny, D. Blanc, H. Ficheux, A. Scherz, Y. Salomon, D. BenEzra and F. Behar-Cohen, <span class="italic">Invest. Ophthalmol. Visual Sci.</span>, 2008, <span class="bold">49</span>, 1633–1644 <a target="_blank" class="DOILink" href="https://doi.org/10.1167/iovs.07-0767" title="DOI Link to resource 10.1167/iovs.07-0767">CrossRef</a>.</span></li><li><span id="cit102">C. Moore, D. Huebler, T. Zimmermann, L. A. J. Heinemann, F. Saad and D. M. Thai, <span class="italic">Eur. Urol.</span>, 2004, <span class="bold">46</span>, 80–87 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.eururo.2004.01.009" title="DOI Link to resource 10.1016/j.eururo.2004.01.009">CrossRef</a>.</span></li><li><span id="cit103">O. Mazor, A. Brandis, V. Plaks, E. Neumark, V. Rosenbach-Belkin, Y. Salomon and A. Scherz, <span class="italic">Photochem. Photobiol.</span>, 2005, <span class="bold">81</span>, 342–351 <a target="_blank" class="DOILink" href="https://doi.org/10.1562/2004-06-14-RA-199.1" title="DOI Link to resource 10.1562/2004-06-14-RA-199.1">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXjslGmsbw%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit104">A. Ferrario, D. Kessel and C. J. Gomer, <span class="italic">Cancer Res.</span>, 1992, <span class="bold">52</span>, 2890–2893 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK38XktVens7c%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit105">L.-M. W. Song, K. K. Wang and A. R. Zinsmeister, <span class="italic">Cancer</span>, 1998, <span class="bold">82</span>, 421–427 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/1097-0142(19980115)82:2&lt;421::AID-CNCR25&gt;3.0.CO;2-O" title="DOI Link to resource 10.1002/1097-0142(19980115)82:2&lt;421::AID-CNCR25&gt;3.0.CO;2-O">CrossRef</a>.</span></li><li><span id="cit106">J. A. Hargus, F. R. Fronczek, M. G. Vicente and K. M. Smith, <span class="italic">Photochem. Photobiol.</span>, 2007, <span class="bold">83</span>, 1006–15 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.2007.00092.x" title="DOI Link to resource 10.1111/j.1751-1097.2007.00092.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGhurvF" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit107">A. Juzeniene, <span class="italic">Photodiagn. Photodyn. Ther.</span>, 2009, <span class="bold">6</span>(2), 94–96 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.pdpdt.2009.06.001" title="DOI Link to resource 10.1016/j.pdpdt.2009.06.001">CrossRef</a>.</span></li><li><span id="cit108">J. Jankun, L. Lilge, A. Douplik, R. W. Keck, M. Pestka, M. Szkudlarek, P. J. Stevens, R. J. Lee and S. H. Selman, <span class="italic">J. Urol.</span>, 2004, <span class="bold">172</span>, 739–743 <a target="_blank" class="DOILink" href="https://doi.org/10.1097/01.ju.0000135304.96496.20" title="DOI Link to resource 10.1097/01.ju.0000135304.96496.20">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2cXlsFelsbs%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit109">S. H. Selman and R. W. Keck, <span class="italic">J. Urol.</span>, 1994, <span class="bold">152</span>, 2129–2132 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=J.%20Urol.%5BJour%5D%20AND%20152%5Bvolume%5D%20AND%202129%5Bpage%5D%20and%201994%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit110">W. M. Sharman, C. M. Allen and J. E. van Lier, <span class="italic">Drug Discovery Today</span>, 1999, <span class="bold">4</span>, 507 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/S1359-6446(99)01412-9" title="DOI Link to resource 10.1016/S1359-6446(99)01412-9">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK1MXmvVKhsrY%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit111">A. E. O'Connor, W. M. Gallagher and A. T. Byrne, <span class="italic">Photochem. Photobiol.</span>, 2009, <span class="bold">85</span>, 1053–1074 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.2009.00585.x" title="DOI Link to resource 10.1111/j.1751-1097.2009.00585.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1MXht1amsbnL" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit112">S. J. Keam, L. J. Scott and M. P. Curran, <span class="italic">Drugs</span>, 2003, <span class="bold">63</span>, 2521–2554 <a target="_blank" class="DOILink" href="https://doi.org/10.2165/00003495-200363220-00016" title="DOI Link to resource 10.2165/00003495-200363220-00016">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXpvFShsLk%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit113">R. K. Pandey, A. B. Sumlin, W. R. Potter, D. A. Bellnier, B. W. Henderson, M. Aoudia, M. R. Rodgers, K. M. Smith and T. J. Dougherty, <span class="italic">Photochem. Photobiol.</span>, 1996, <span class="bold">64</span>, 194–205 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.1996.tb02442.x" title="DOI Link to resource 10.1111/j.1751-1097.1996.tb02442.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK28XjvF2js74%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit114">B. W. Henderson, D. A. Bellnier, W. R. Greco, A. Sharma, R. K. Pandey, L. A. Vaughan, K. R. Weishaupt and T. J. Dougherty, <span class="italic">Cancer Res.</span>, 1997, <span class="bold">57</span>, 4000 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2sXmtFehsLg%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit115">N. Rigual, <span class="italic">et al.</span>, unpublished results.</span></li><li><span id="cit116">G. M. Loewen, R. K. Pandey, D. Bellnier, B. W. Henderson and T. J. Dougherty, <span class="italic">Lasers Surg. Med.</span>, 2006, <span class="bold">38</span>, 364 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/lsm.20354" title="DOI Link to resource 10.1002/lsm.20354">CrossRef</a>.</span></li><li><span id="cit117">D. A. Bellnier, W. R. Greco, G. M. Loewen, H. Nava, A. R. Oseroff and T. J. Dougherty, <span class="italic">Lasers Surg. Med.</span>, 2006, <span class="bold">38</span>, 439 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/lsm.20340" title="DOI Link to resource 10.1002/lsm.20340">CrossRef</a>.</span></li><li><span id="cit118">D. A. Bellnier, W. R. Greco, G. M. Loewen, A. O. Oseroff and T. J. Dougherty, <span class="italic">Cancer Chemother. Pharmacol.</span>, 2006, <span class="bold">57</span>, 40 <a target="_blank" class="DOILink" href="https://doi.org/10.1007/s00280-005-0015-6" title="DOI Link to resource 10.1007/s00280-005-0015-6">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXht1CqtL%252FP" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit119">Y. Chen, R. Miclea, T. Srikrisnan, B. Balsubramanium, T. J. Dougherty and R. K. Pandey, <span class="italic">Bioorg. Med. Chem. Lett.</span>, 2005, <span class="bold">15</span>, 3189 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.bmcl.2005.05.019" title="DOI Link to resource 10.1016/j.bmcl.2005.05.019">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXltFSntbc%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit120">D. A. Bellnier, W. R. Greco, G. M. Loewen, H. Nava, A. Oseroff, R. K. Pandey and T. J. Dougherty, <span class="italic">Cancer Research</span>, 2003, <span class="bold">63</span>, 1806 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXivFyns7w%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit121">D. A. Bellnier, W. R. Greco, H. Nava, G. M. Loewen, A. R. Oseroff and T. J. Dougherty, <span class="italic">Cancer Chemother Pharmacol.</span>, 2004 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Cancer%20Chemother%20Pharmacol.%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202004%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit122">T. M. Anderson, T. J. Dougherty, D. F. Tan, A. Sumlin, J. M. Schlossin and P. M. Kanter, <span class="italic">Anticancer Research</span>, 2003, <span class="bold">23</span>, 3713 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2cXkvFag" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit123">J. Lobel, I. MacDonald, M. J. Ciesielski, T. Barone, W. R. Potter, J. Pollina, R. J. Plunkett, R. A. Fenstermaker and T. J. Dougherty, <span class="italic">Lasers Surg. Med.</span>, 2001, <span class="bold">29</span>, 397 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/lsm.10001" title="DOI Link to resource 10.1002/lsm.10001">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD387lslyntw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit124">T. J. Dougherty, R. K. Pandey, H. Nava, J. A. Smith, H. O. Douglass, S. B. Edge, D. A. Bellnier, L. O'Malley and M. Cooper, <span class="italic">Proc. SPIE</span>, 2000, <span class="bold">3909</span>, 25 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3cXjtFOqsrg%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit125">W. R. Potter, B. W. Henderson, D. A. Bellnier, R. K. Pandey, L. A. Vaughan, K. R. Weishaupt and T. J. Dougherty, <span class="italic">Photochem. Photobiol.</span>, 1999, <span class="bold">70</span>, 781 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK1MXnt12htb8%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit126">M. L. Magne, C. O. Rodriguez, A. A. Autry, B. F. Edwards, A. P. Theon and B. R. Madewell, <span class="italic">Lasers Surg. Med.</span>, 1997, <span class="bold">20</span>, 202 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/(SICI)1096-9101(1997)20:2&lt;202::AID-LSM12&gt;3.0.CO;2-H" title="DOI Link to resource 10.1002/(SICI)1096-9101(1997)20:2&lt;202::AID-LSM12&gt;3.0.CO;2-H">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK2s7pvFWquw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit127">K. Furukawa, D. H. Green, T. S. Mang, H. Kato and T. J. Dougherty, <span class="italic">Proc. SPIE</span>, 1994, <span class="bold">2133</span>, 170 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2MXhtlKgs7o%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit128">K. Furukawa, D. H. Green, T. S. Mang, H. Kato and T. J. Dougherty, <span class="italic">Proc. SPIE</span>, 1994, <span class="bold">2371</span>, 510.</span></li><li><span id="cit129">D. A. Bellnier, B. W. Henderson, R. K. Pandey, W. R. Potter and T. J. Dougherty, <span class="italic">J. Photochem. Photobiol., B</span>, 1993, <span class="bold">20</span>, 55 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/1011-1344(93)80131-R" title="DOI Link to resource 10.1016/1011-1344(93)80131-R">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK3sXmsVCmtrc%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit130">T. J. Dougherty and J. G. Levy, Photodynamic Therapy and Clinical Applications, in <span class="italic">Biomedical Photonics Handbook</span>, ed. T. Vo-Dinh, CRC Press, Boca Raton, ch. 38, pp. 1–16 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Biomedical%20Photonics%20Handbook%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%20%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit131">G. Zheng, W. R. Potter, S. H. Camacho, J. R. Missert, G. Wang, D. A. Bellnier, B. W. Henderson, M. A. J. Rodgers, T. J. Dougherty and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2001, <span class="bold">44</span>, 1540 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm0005510" title="DOI Link to resource 10.1021/jm0005510">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXjtFams7c%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit132">A. Gryshuk, A. Graham, R. K. Pandey, W. R. Potter, J. R. Missert, A. Oseroff, T. J. Dougherty and R. K. Pandey, <span class="italic">Photochem. Photobiol.</span>, 2002, <span class="bold">76</span>, 555 <a target="_blank" class="DOILink" href="https://doi.org/10.1562/0031-8655(2002)076&lt;0555:AFCSOP&gt;2.0.CO;2" title="DOI Link to resource 10.1562/0031-8655(2002)076&lt;0555:AFCSOP&gt;2.0.CO;2">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD38XovF2mtL0%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit133">Y. Chen, A. Graham, W. Potter, J. Morgan, L. Vaughan, D. A. Bellnier, B. W. Henderson, A. Oseroff, T. J. Dougherty and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2002, <span class="bold">45</span>, 255 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm010400c" title="DOI Link to resource 10.1021/jm010400c">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXptV2msr8%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit134">A. Gryshuk, Y. Chen, L. N. Goswami, S. K. Pandey, J. Missert, T. Ohulchanskyy, W. Potter, P. N. Prasad and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2007, <span class="bold">50</span>, 1754 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm061036q" title="DOI Link to resource 10.1021/jm061036q">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2sXjtFKksrk%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit135">R. K. Pandey, Synthetic Strategies in Designing Porphyrin-Based Photosensitizers for Photodynamic Therapy, in <span class="italic">Organic Photochemistry and Photobiology</span>, ed. W. Horspool and F. Lenci, CRC Press, Boca Raton, ch. 144, p. 1–21 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Organic%20Photochemistry%20and%20Photobiology%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%20%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit136">S. Mettath, M. Shibata, J. L. Alderfer, M. O. Senge, K. M. Smith, R. Rein, T. J. Dougherty and R. K. Pandey, <span class="italic">J. Org. Chem.</span>, 1998, <span class="bold">63</span>, 1646 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jo971968p" title="DOI Link to resource 10.1021/jo971968p">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK1cXhsFOqu7g%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit137">H. J. Callott, A. W. Johnson and A. J. Sweeny, <span class="italic">J. Chem. Soc., Perkin Trans. 1</span>, 1973, 1424 <a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=P19730001424&amp;newsite=1" title="Link to RSC resource DOI:10.1039/P19730001424">RSC</a>.</span></li><li><span id="cit138">R. K. Pandey, W. R. Potter, I. Meunier, A. B. Sumlin and K. M. Smith, <span class="italic">Photochem. Photobiol.</span>, 1995, <span class="bold">62</span>, 764 <a target="_blank" class="DOILink" href="https://doi.org/10.1111/j.1751-1097.1995.tb08727.x" title="DOI Link to resource 10.1111/j.1751-1097.1995.tb08727.x">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2MXovV2jsrc%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit139">G. Li, A. Graham, Y. Chen, M. P. Dobhal, J. Morgan, A. Oseroff, T. J. Dougherty and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2003, <span class="bold">46</span>, 5349 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm030341y" title="DOI Link to resource 10.1021/jm030341y">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXos1SlsLw%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit140">R. K. Pandey, M. Isaac, I. MacDonald, M. O. Senge, T. J. Dougherty and K. M. Smith, <span class="italic">J. Org. Chem.</span>, 1997, <span class="bold">62</span>, 1463 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jo960720h" title="DOI Link to resource 10.1021/jo960720h">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK2sXit1Knu70%253D" title="Link to resource in CAS">CAS</a>.</span></li>. <li><span id="cit141">C. Liu, M. P. Dobhal, M. Ethirajan, J. R. Missert and R. K. Pandey, <span class="italic">J. Am. Chem. Soc.</span>, 2008, <span class="bold">130</span>, 14311 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/ja8050298" title="DOI Link to resource 10.1021/ja8050298">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sjt77I" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit142">M. Ethirajan, N. J. Patel and R. K. Pandey, Porphyrin-based multifunctional agentsd for tumor-imaging and therapy, in <span class="italic">The Porphyrin Handbook</span>, ed. K. M. Kadish, K. M. Smith and R. Guilard, Academic Press, Boston,  2010, in press <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=The%20Porphyrin%20Handbook%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202010%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit143">X. Zheng, J. Morgan, S. K. Pandey, Y. Chen, E. Tracy, H. Baumann, J. R. Missert, C. Batt, J. Jackson, D. A. Bellnier, B. W. Henderson and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2009, <span class="bold">52</span>, 4306 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm9001617" title="DOI Link to resource 10.1021/jm9001617">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1MXntVSrsr0%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit144">A. Srivatsan, <span class="italic">et al.</span>, unpublished results.</span></li><li><span id="cit145">R. Weissleder and V. Ntziachristos, <span class="italic">Nat. Med.</span>, 2003, <span class="bold">9</span>, 123 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/nm0103-123" title="DOI Link to resource 10.1038/nm0103-123">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXivFOj" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit146">J. Chen, T. W. B. Liu, P. C. Lo, B. C. Wilson and G. Zheng, <span class="italic">Bioconjugate Chem.</span>, 2009, <span class="bold">20</span>, 1836 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/bc900207k" title="DOI Link to resource 10.1021/bc900207k">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1MXhtFagsL3O" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit147">T. Lammers, V. Subr, P. Peschke, R. Kühnlein, W. E. Hennink, K. Ulbrich, F. Kiessling, M. Heilmann, J. Debus, P. E. Huber and G. Storm, <span class="italic">Br. J. Cancer</span>, 2008, <span class="bold">99</span>, 900 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/sj.bjc.6604561" title="DOI Link to resource 10.1038/sj.bjc.6604561">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2jurrF" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit148">J. Culver, W. Akers and S. Achilefu, <span class="italic">J. Nucl. Med.</span>, 2008, <span class="bold">49</span>, 169 <a target="_blank" class="DOILink" href="https://doi.org/10.2967/jnumed.107.043331" title="DOI Link to resource 10.2967/jnumed.107.043331">CrossRef</a>.</span></li><li><span id="cit149">J. E. Bowsher, V. E. Johnson, T. G. Turkington, R. J. Jaszczak, C. E. Floyd Jr. and R. Edward Coleman, <span class="italic">IEEE Trans. Med. Imaging</span>, 1996, <span class="bold">15</span>, 673 <a target="_blank" class="DOILink" href="https://doi.org/10.1109/42.538945" title="DOI Link to resource 10.1109/42.538945">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD1c%252FmtlOqsA%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit150">C. Catana, D. Procissi, Y. Wu, M. S. Judenhofer, J. Qi, B. J. Pichler, R. E. Jacobs and S. R. Cherry, <span class="italic">Proc. Natl. Acad. Sci. U. S. A.</span>, 2008, <span class="bold">105</span>, 3705 <a target="_blank" class="DOILink" href="https://doi.org/10.1073/pnas.0711622105" title="DOI Link to resource 10.1073/pnas.0711622105">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Oit7Y%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit151">M. Rudin and R. Weissleder, <span class="italic">Nat. Rev. Drug Discovery</span>, 2003, <span class="bold">2</span>, 123 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/nrd1007" title="DOI Link to resource 10.1038/nrd1007">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXot12muw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit152">S. S. Gambhir, <span class="italic">Nat. Rev. Cancer</span>, 2002, <span class="bold">2</span>, 683 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/nrc882" title="DOI Link to resource 10.1038/nrc882">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD38Xmslanu7c%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit153">F. J. Bonte, T. S. Harris, L. S. Hynan, E. H. Bigio and C. L. White III, <span class="italic">Clin. Nucl. Med.</span>, 2006, <span class="bold">31</span>, 376 <a target="_blank" class="DOILink" href="https://doi.org/10.1097/01.rlu.0000222736.81365.63" title="DOI Link to resource 10.1097/01.rlu.0000222736.81365.63">CrossRef</a>.</span></li><li><span id="cit154">D. O. Cosgrove, H. B. Meire, A. Lim and R. J. Eckersley, in <span class="italic">Ultrasound: General Principles</span>, ed. R. G. Grainger and D. J. Allison, Diagnostic Radiology: A Textbook of Medical Imaging, Churchill Livingstone, New York,  2001, ch. 3 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Ultrasound:%20General%20Principles%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202001%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit155">A. Policard, <span class="italic">J. Soc. Biol.</span>, 1924, <span class="bold">91</span>, 1423 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=J.%20Soc.%20Biol.%5BJour%5D%20AND%2091%5Bvolume%5D%20AND%201423%5Bpage%5D%20and%201924%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit156">T. S. Mang, C. McGinnis, C. Liebow, U. O Nseyo, D. H. Crean and T. J. Dougherty, <span class="italic">Cancer</span>, 1993, <span class="bold">71</span>, 269 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/1097-0142(19930101)71:1&lt;269::AID-CNCR2820710141&gt;3.0.CO;2-R" title="DOI Link to resource 10.1002/1097-0142(19930101)71:1&lt;269::AID-CNCR2820710141&gt;3.0.CO;2-R">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK3s7gsFemuw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit157">R. K. Pandey, N. James, Y. Chen and M. P. Dobhal, Cyanine dye-based compounds for tumor imaging with and without photodynamic therapy, in <span class="italic">Heterocyclic Polymethine Dyes</span>, ed. L. Strekowski, Springer-Verlag, Berlin,  2008, p. 41 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Heterocyclic%20Polymethine%20Dyes%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202008%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit158">S. Achilefu, S. Bloch, M. A. Markiewicz, T. Zhong, Y. Ye, R. B. Dorshow, B. Chance and K. Liang, <span class="italic">Proc. Natl. Acad. Sci. U. S. A.</span>, 2005, <span class="bold">102</span>, 7976 <a target="_blank" class="DOILink" href="https://doi.org/10.1073/pnas.0503500102" title="DOI Link to resource 10.1073/pnas.0503500102">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2ju7c%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit159">D. Artemov, N. Mori, B. Okollie and Z. M. Bhujwalla, <span class="italic">Magn. Reson. Med.</span>, 2003, <span class="bold">49</span>, 403 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/mrm.10406" title="DOI Link to resource 10.1002/mrm.10406">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXisVGktL4%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit160">L. Josephson, U. Mahmood, P. Wunderbaldinger, Y. Tang and R. Weissleder, <span class="italic">Mol. Imaging</span>, 2003, <span class="bold">2</span>, 18 <a target="_blank" class="DOILink" href="https://doi.org/10.1162/153535003765276255" title="DOI Link to resource 10.1162/153535003765276255">CrossRef</a>.</span></li><li><span id="cit161">J. E. Bugaj, S. Achilefu, R. B. Dorshow and R. Rajagopalan, <span class="italic">J. Biomed. Opt.</span>, 2001, <span class="bold">6</span>, 122 <a target="_blank" class="DOILink" href="https://doi.org/10.1117/1.1352748" title="DOI Link to resource 10.1117/1.1352748">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXktF2nsb8%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit162">Z. Zhang and S. Achilefu, <span class="italic">Org. Lett.</span>, 2004, <span class="bold">6</span>, 2067 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/ol049258a" title="DOI Link to resource 10.1021/ol049258a">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2cXjvFKgtLw%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit163">J. H. Flanagan Jr., S. H. Khan, S. Menchen, S. A. Soper and R. P. Hammer, <span class="italic">Bioconjugate Chem.</span>, 1997, <span class="bold">8</span>, 751 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/bc970113g" title="DOI Link to resource 10.1021/bc970113g">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3AByiH28jpvFM%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit164">W. K. Moon, Y. Lin, T. O'Loughlin, Y. Tang, D. Kim, R. Weissleder and C. Tung, <span class="italic">Bioconjugate Chem.</span>, 2003, <span class="bold">14</span>, 539 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/bc0340114" title="DOI Link to resource 10.1021/bc0340114">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXjtlehtLs%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit165">V. Ntziachristos, J. Ripoll, L. V. Wang and R. Weissleder, <span class="italic">Nat. Biotechnol.</span>, 2005, <span class="bold">23</span>, 313 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/nbt1074" title="DOI Link to resource 10.1038/nbt1074">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7k%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit166">J. V. Frangioni, <span class="italic">Curr. Opin. Chem. Biol.</span>, 2003, <span class="bold">7</span>, 626 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.cbpa.2003.08.007" title="DOI Link to resource 10.1016/j.cbpa.2003.08.007">CrossRef</a>.</span></li><li><span id="cit167">Y. Chen, A. Gryshuk, S. Achilefu, T. Ohulchansky, W. Potter, T. Zhong, J. Morgan, B. Chance, P. N. Prasad, B. W. Henderson, A. Oseroff and R. K. Pandey, <span class="italic">Bioconjugate Chem.</span>, 2005, <span class="bold">16</span>, 1264 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/bc050177o" title="DOI Link to resource 10.1021/bc050177o">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXpsleqsb8%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit168">S. K. Pandey, Y. Chen, R. H. Zawada, A. Oseroff and R. K. Pandey, <span class="italic">Proceedings of SPIE 2006</span>, vol. 6139, p. 613905 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Proceedings%20of%20SPIE%202006%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%20%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit169">S. C. Davis, B. W. Pogue, H. Dehghani and K. D. Paulsen, <span class="italic">J. Biomed. Opt.</span>, 2005, <span class="bold">10</span>, 050501 <a target="_blank" class="DOILink" href="https://doi.org/10.1117/1.2114727" title="DOI Link to resource 10.1117/1.2114727">CrossRef</a>.</span></li><li><span id="cit170">R. W. Redmond, Photophysics and Photochemistry, in <span class="italic">Photodynamic Therapy in Advances in Photodynamic Therapy</span>, ed. M. R. Hamblin and P. Mroz, Artech House, Boston,  2008 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Photodynamic%20Therapy%20in%20Advances%20in%20Photodynamic%20Therapy%5BJour%5D%20AND%20%5Bvolume%5D%20AND%20%5Bpage%5D%20and%202008%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit171">D. Muffoletto, A. Gupta, Z. Xu, C. Mahrer, G. Bauer, S. Galas, R. K. Pandey and U. Sunar, <span class="italic">Proceedings of SPIE</span>, 2009, <span class="bold">7164</span>, 716409 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Proceedings%20of%20SPIE%5BJour%5D%20AND%207164%5Bvolume%5D%20AND%20716409%5Bpage%5D%20and%202009%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit172">Y. Ni, K. Adzamli, Y. Miao, E. Cresens, J. Yu, M. P. Periasamy, M. D. Adams and G. Marchal, <span class="italic">Invest. Radiol.</span>, 2001, <span class="bold">36</span>, 97 <a target="_blank" class="DOILink" href="https://doi.org/10.1097/00004424-200102000-00005" title="DOI Link to resource 10.1097/00004424-200102000-00005">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXhtl2itb8%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit173">J. Krzystek, J. Telser, L. A. Pardi, D. P. Goldberg, B. M. Hoffman and L. Brunel, <span class="italic">Inorg. Chem.</span>, 1999, <span class="bold">38</span>, 6121 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/ic9901970" title="DOI Link to resource 10.1021/ic9901970">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADyaK1MXnvVSltLo%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit174">G. Li, A. Slansky, M. P. Dobhal, L. N. Goswami, A. Graham, Y. Chen, P. Kanter, R. A. Alberico, J. Spernyak, J. Morgan, R. Mazurchuk, A. Oseroff, Z. Grossman and R. K. Pandey, <span class="italic">Bioconjugate Chem.</span>, 2005, <span class="bold">16</span>, 32 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/bc049807x" title="DOI Link to resource 10.1021/bc049807x">CrossRef</a>.</span></li><li><span id="cit175">B. Hofmann, A. Bogdanov Jr., E. Marecos, W. Ebert, W. Semmler and R. Weissleder, <span class="italic">J. Magn. Reson. Imaging</span>, 1999, <span class="bold">9</span>, 336 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/(SICI)1522-2586(199902)9:2&lt;336::AID-JMRI28&gt;3.0.CO;2-3" title="DOI Link to resource 10.1002/(SICI)1522-2586(199902)9:2&lt;336::AID-JMRI28&gt;3.0.CO;2-3">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK1M7nsVKmsA%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit176">R. K. Pandey, <span class="italic">et al.</span>, unpublished results.</span></li><li><span id="cit177">R. K. Pandey, <span class="italic">et al.</span>, unpublished results.</span></li><li><span id="cit178">R. K. Pandey, <span class="italic">et al.</span>, unpublished results.</span></li><li><span id="cit179">K. Licha and C. Olbrich, <span class="italic">Adv. Drug Delivery Rev.</span>, 2005, <span class="bold">57</span>, 1087 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.addr.2005.01.021" title="DOI Link to resource 10.1016/j.addr.2005.01.021">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXltVeisb0%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit180">X. Zhang, W. Cai, F. Cao, E. Schreibmann, Y. Wu, J. C. Wu, L. Xing and X. Chen, <span class="italic">J. Nucl. Med.</span>, 2006, <span class="bold">47</span>, 492 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD28Xlt1Kmsb4%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit181">T. Bury, A. Dowlati, P. Paulus, R. Hustinx, M. Radermecker and P. Rigo, <span class="italic">Eur. J. Nucl. Med. Mol. Imaging</span>, 1996, <span class="bold">23</span>, 204 <a target="_blank" class="DOILink" href="https://doi.org/10.1007/BF01731846" title="DOI Link to resource 10.1007/BF01731846">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK287ntFCnsg%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit182">L. P. Adler, H. F. Blair, J. T. Makley, R. P. Williams, M. J. Joyce, G. Leisure, N. Al-Kaisi and F. Miraldi, <span class="italic">J. Nucl. Med.</span>, 1991, <span class="bold">32</span>, 1508 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK3Mzjt1KqtA%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit183">P. Price and T. Jones, <span class="italic">European Journal of Cancer Part A: General Topics</span>, 1995, <span class="bold">31</span>, 1924 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=European%20Journal%20of%20Cancer%20Part%20A:%20General%20Topics%5BJour%5D%20AND%2031%5Bvolume%5D%20AND%201924%5Bpage%5D%20and%201995%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit184">J. Okada, H. Oonishi, K. Yoshikawa, J. Itami, K. Uno, K. Imaseki and N. Arimizu, <span class="italic">Ann. Nucl. Med.</span>, 1994, <span class="bold">8</span>, 187 <a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/sites/entrez?orig_db=PubMed&amp;db=pubmed&amp;cmd=Search&amp;term=Ann.%20Nucl.%20Med.%5BJour%5D%20AND%208%5Bvolume%5D%20AND%20187%5Bpage%5D%20and%201994%5Bpdat%5D" title="Search PubMed for this citation">Search PubMed</a>.</span></li><li><span id="cit185">B. Nakata, Y. Chung, S. Nishimura, T. Nishihara, Y. Sakurai, T. Sawada, T. Okamura, J. Kawabe, H. Ochi and M. Sowa, <span class="italic">Cancer</span>, 1997, <span class="bold">79</span>, 695 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/(SICI)1097-0142(19970215)79:4&lt;695::AID-CNCR6&gt;3.0.CO;2-D" title="DOI Link to resource 10.1002/(SICI)1097-0142(19970215)79:4&lt;695::AID-CNCR6&gt;3.0.CO;2-D">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK2s7nslWmtw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit186">M. Oshida, K. Uno, M. Suzuki, T. Nagashima, H. Hashimoto, H. Yagata, T. Shishikura, K. Imazeki and N. Nakajima, <span class="italic">Cancer</span>, 1998, <span class="bold">82</span>, 2227 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11&lt;2227::AID-CNCR18&gt;3.0.CO;2-W" title="DOI Link to resource 10.1002/(SICI)1097-0142(19980601)82:11&lt;2227::AID-CNCR18&gt;3.0.CO;2-W">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK1c3nt1agtg%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit187">T. M. Guerrero, E. J. Hoffman, M. Dahlbom, P. D. Cutler, R. A. Hawkins and M. E. Phelps, <span class="italic">IEEE Trans. Nucl. Sci.</span>, 1990, <span class="bold">37</span>, 676 <a target="_blank" class="DOILink" href="https://doi.org/10.1109/23.106697" title="DOI Link to resource 10.1109/23.106697">CrossRef</a>.</span></li><li><span id="cit188">P. S. Conti, D. L. Lilien, K. Hawley, J. Keppler, S. T. Grafton and J. R. Bading, <span class="italic">Nucl. Med. Biol.</span>, 1996, <span class="bold">23</span>, 717 <a target="_blank" class="DOILink" href="https://doi.org/10.1016/0969-8051(96)00074-1" title="DOI Link to resource 10.1016/0969-8051(96)00074-1">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK2s%252FpsFersw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit189">D. Delbeke, D. M. Rose, W. C. Chapman, C. W. Pinson, J. K. Wright, R. D. Beauchamp, Y. Shyr and S. D. Leach, <span class="italic">J. Nucl. Med.</span>, 1999, <span class="bold">40</span>, 1784 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD3c%252FivFGjsw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit190">M. E. Phelps, <span class="italic">Proc. Natl. Acad. Sci. U. S. A.</span>, 2000, <span class="bold">97</span>, 9226 <a target="_blank" class="DOILink" href="https://doi.org/10.1073/pnas.97.16.9226" title="DOI Link to resource 10.1073/pnas.97.16.9226">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3cXls12ksb8%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit191">I. Verel, G. W. M. Visser and G. A. Van Dongen, <span class="italic">J. Nucl. Med.</span>, 2005, <span class="bold">46</span>, 164S.</span></li><li><span id="cit192">K. S. Pentlow, M. C. Graham, R. M. Lambrecht, N. V. Cheung and S. M. Larson, <span class="italic">Med. Phys.</span>, 1991, <span class="bold">18</span>, 357 <a target="_blank" class="DOILink" href="https://doi.org/10.1118/1.596728" title="DOI Link to resource 10.1118/1.596728">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK3MzjtlCmsA%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit193">F. T. Lee, C. Hall, A. Rigopoulos, J. Zweit, K. Pathmaraj, G. J. O'Keefe, F. E. Smyth, S. Welt, L. J. Old and A. M. Scott, <span class="italic">J. Nucl. Med.</span>, 2001, <span class="bold">42</span>, 764 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BD3MvkvVGhtw%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit194">D. R. Collingridge, M. Glaser, S. Osman, H. Barthel, O. C. Hutchinson, S. K. Luthra, F. Brady, L. Bouchier-Hayes, S. J. Martin, P. Workman, P. Price and E. O. Aboagye, <span class="italic">Br. J. Cancer</span>, 2003, <span class="bold">89</span>, 1327 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/sj.bjc.6601262" title="DOI Link to resource 10.1038/sj.bjc.6601262">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXns1Cmu7o%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit195">P. Zanzonico, J. O'Donoghue, J. D. Chapman, R. Schneider, S. Cai, S. Larson, B. Wen, Y. Chen, R. Finn, S. Ruan, L. Gerweck, J. Humm and C. Ling, <span class="italic">Eur. J. Nucl. Med. Mol. Imaging</span>, 2004, <span class="bold">31</span>, 117 <a target="_blank" class="DOILink" href="https://doi.org/10.1007/s00259-003-1322-y" title="DOI Link to resource 10.1007/s00259-003-1322-y">CrossRef</a>.</span></li><li><span id="cit196">J. J. Bennett, J. Tjuvajev, P. Johnson, M. Doubrovin, T. Akhurst, S. Malholtra, T. Hackman, J. Balatoni, R. Finn, S. M. Larson, H. Federoff, R. Blasberg and Y. Fong, <span class="italic">Nat. Med.</span>, 2001, <span class="bold">7</span>, 859 <a target="_blank" class="DOILink" href="https://doi.org/10.1038/89991" title="DOI Link to resource 10.1038/89991">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3MXltVagtbs%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit197">J. V. Moore, M. L. Waller, S. Zhao, N. J. F. Dodd, P. D. Acton, A. P. Jeavons and D. L. Hastings, <span class="italic">Eur. J. Nucl. Med. Mol. Imaging</span>, 1998, <span class="bold">25</span>, 1248 <a target="_blank" class="DOILink" href="https://doi.org/10.1007/s002590050292" title="DOI Link to resource 10.1007/s002590050292">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK1czptFOitg%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit198">D. Dong, L. Dubeau, J. Bading, K. Nguyen, M. Luna, H. Yu, G. Gazit-Bornstein, E. M. Gordon, C. Gomer, F. L. Hall, S. S. Gambhir and A. S. Lee, <span class="italic">Hum. Gene Ther.</span>, 2004, <span class="bold">15</span>, 553 <a target="_blank" class="DOILink" href="https://doi.org/10.1089/104303404323142006" title="DOI Link to resource 10.1089/104303404323142006">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2cXkvVSqsL8%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit199">P. Westermann, T. Glanzmann, S. Anderjevic, D. R. Braichotte, M. Forrer, G. A. Wagnieres, P. Monnier, H. D. Van den Bergh, J. Mach and S. Folli, <span class="italic">Int. J. Cancer</span>, 1998, <span class="bold">76</span>, 842 <a target="_blank" class="DOILink" href="https://doi.org/10.1002/(SICI)1097-0215(19980610)76:6&lt;842::AID-IJC13&gt;3.0.CO;2-4" title="DOI Link to resource 10.1002/(SICI)1097-0215(19980610)76:6&lt;842::AID-IJC13&gt;3.0.CO;2-4">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADyaK1c3ovFKmsQ%253D%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit200">M. Sugiyama, H. Sakahara, K. Sato, N. Harada, D. Fukumoto, T. Kakiuchi, T. Hirano, E. Kohno and H. Tsukada, <span class="italic">J. Nucl. Med.</span>, 2004, <span class="bold">45</span>, 1754 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2cXpslCqsLw%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit201">B. Ma, G. Li, P. Kanter, D. Lamonica, Z. Grossman and R. K. Pandey, <span class="italic">J. Porphyrins Phthalocyanines</span>, 2003, <span class="bold">7</span>, 500 <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD3sXpsleit7c%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit202">Y. Chen, X. Zheng, M. P. Dobhal, A. Gryshuk, J. Morgan, T. J. Dougherty, A. Oseroff and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2005, <span class="bold">48</span>, 3692 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm050039k" title="DOI Link to resource 10.1021/jm050039k">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXjvFKjuro%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit203">R. K. Pandey, <span class="italic">et al.</span>, unpublished results.</span></li><li><span id="cit204">S. K. Pandey, A. L. Gryshuk, M. Sajjad, X. Zheng, Y. Chen, M. A. Abouzeid, J. Morgan, I. Charamisinau, H. A. Nabi, A. Oseroff and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2005, <span class="bold">48</span>, 6286 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm050427m" title="DOI Link to resource 10.1021/jm050427m">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD2MXpslWrsb0%253D" title="Link to resource in CAS">CAS</a>.</span></li><li><span id="cit205">S. K. Pandey, M. Sajjad, Y. Chen, X. Zheng, R. Yao, J. R. Missert, C. Batt, H. A. Nabi, A. R. Oseroff and R. K. Pandey, <span class="italic">J. Med. Chem.</span>, 2009, <span class="bold">52</span>, 445 <a target="_blank" class="DOILink" href="https://doi.org/10.1021/jm8012213" title="DOI Link to resource 10.1021/jm8012213">CrossRef</a> <a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BD1cXhsFaisrfO" title="Link to resource in CAS">CAS</a>.</span></li></ol>
    
    
    
    
  <table><tr><td><hr/></td></tr><tr><td><b>This journal is © The Royal Society of Chemistry 2011</b></td></tr></table></div></div></div></body><SaxonLicenceTest result="pass" message="Licenced Enterprise Edition [ EE 9.3.0.4 ]"/></html>